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1. INTRODUCTION 
 
   The Coordinated Research Project (CRP) entitled ‘Development and preclinical evaluations of therapeutic 
radiopharmaceuticals based on 177Lu and 90Y labelled monoclonal antibodies and peptides’ has been organized 
by IAEA with the major purpose of promoting the introduction in Member States of clinical applications based 
on radioimmunotherapy (RIT) and peptide receptor-based radionuclide therapy (PRRNT) for some important 
cancers. Targeted radionuclide therapy with labeled monoclonal antibodies (mAbs) and peptides has emerged as 
a complementary modality for the treatment of cancer. Several mAbs have been introduced for immunotherapy 
of various cancers. These include Rituximab® (for B-cell lymphomas), Trastuzumomab® (for breast cancer), 
Alemtuzumab® (for chronic lymphocytic leukemia), Cetuximab® (colorectal, head & neck cancers), and 
Bevacizumab® (for colorectal cancers). Two radiolabeled mAbs, Zevalin® (labeled with 90Y) and Bexxar® 
(labeled with 131I), have been approved for radioimmunotherapy (RIT) of B-cell lymphomas. Both these agents 
have demonstrated significant antitumour response following a single treatment in patients with B-cell 
lymphomas resulting in more than 40-70% complete responses (CR) lasting 3-7 years. Similarly, radiolabelled 
somatostatin-analog peptides have been extensively investigated as both diagnostic and therapeutic agents for 
neuroendocrine tumours, and some 177Lu and 90Y radiolabelled derivatives are currently under extensive clinical 
evaluation. 
 
   While RIT and PRRNT have been demonstrated to provide effective alternative treatments against some 
cancers, in developing countries, they do not yet constitute a firmly established therapeutic modality due to the 
high cost and low availability of some relevant radionuclides for routine clinical studies. This CRP was designed 
to develop technologies for the production of therapeutic radiopharmaceuticals based on monoclonal antibodies 
and peptides labeled with 177Lu and 90Y with the aim of promoting the clinical application of RIT and PRRNT. 
Recently, 177Lu has attracted much interest as therapeutic radionuclide due to its suitable physical characteristics. 
177Lu is emerging as a clear choice for therapy due to its easy production logistics, suitable physical 
characteristics, such as soft beta emission (Emax of 497, 384 and 172.KeV with 78.6, 9.1, and 12.2% abundance, 
respectively), and relatively longer half-life of 6.71 days). Unlike 90Y, 177Lu also has gamma emissions {113 
KeV (6.4%) and 208 KeV (11%)}, appropriate for imaging studies to document targeting and biodistribution 
studies for organ dosimetry calculations. The recent past activities of the IAEA through coordinated research 
projects have significantly contributed to enhancing the availability of both 90Y and 177Lu radionuclides. 
Yttrium-90 can be prepared in no-carrier added form from a 90Sr/90Y generator investigated through the CRP on 
‘Development of generator technologies for therapeutic radionuclides’ (2004-2007). A CRP on ‘Development of 
therapeutic radiopharmaceuticals based on 188Re and 90Y for radionuclide therapy’ (2008-2011) further evaluated 
the technology underlying 188W/188Re and 90Sr/90Y generators and validated the quality control procedures of 90Y 
and 188Re eluates obtained from these generators. An important result of the above CRPs was the technology 
transfer occurred among the participants’ groups that sharply enhanced the availability of clinical grade 90Y in 
several countries. The technology for the production of high specific activity 177Lu suitable for radiolabeling 
peptides and antibodies was demonstrated thorough the CRP on ‘Development of therapeutic 
radiopharmaceuticals based on 177Lu for radionuclide therapy’ (2006-2009). The availability of the radionuclides 
90Y and 177Lu in several member states might strongly enhance the applicability of targeted radionuclide therapy 
as an alternative approach for cancer treatment.   
 
   As mentioned above, among the various MAbs evaluated thus far, anti-CD20 mAbs specific for B-cell 
lymphomas have shown significant antitumor response and improved progression free survival either given 
alone or given as radioimmunoconjugates. Since Rituximab® will be available soon as a generic product, this 
CRP has been designed to focus on the preparation of either 177Lu or 90Y-labeled Rituximab as a therapeutic 
radiopharmaceutical for the treatment of lymphomas. Specifically, the development of a sterile kit formulation 
for Rituximab labelling was envisaged as a critical achievement because it could make possible the easy and safe 
in-house preparation of the radiolabeled MAb for RIT studies in patients. Similarly, the CRP was also expected 
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to facilitate the development of other 177Lu and 90Y therapeutic agents based on the labelling of peptides 
specifically targeting receptors expressed onto the surface of cancerous cells. 
 
   Participants of the consultant’s meeting on ‘Therapeutic radiopharmaceuticals for the treatment of cancers’, 
held in August 23-27, 2010 at IAEA headquarters, provided key inputs for the formulation of this CRP. The first 
research coordination meeting (RCM) was held in Vienna on May 9-13, 2011. This Report illustrates the results 
of the second RCM meeting, which was organized by the University of Stip, Republic of Macedonia on October 
01-05, 2012. 
 
 
2. REVIEW OF RESULTS ACHIEVED DURING THE FIRST PART OF THE CRP 
 
2.1. Monoclonal antibodies: Rituximab 
 
   Rituximab (formula, C6416H9874N1688O1987S44; molecular weight, 144 kD) is a chimeric anti-CD20 B-cell 
specific monoclonal antibody approved for the treatment of low-grade non-Hodgkin’s lymphoma. Therefore, 
Rituximab was almost exclusively employed by participants’groups for the development of a therapeutic agent 
for RIT labelled with 177Lu and 90Y. In the first part of this CRP, major efforts have been addressed to achieve a 
satisfactory optimization of techniques for conjugation of different bifunctional chelating agents (BFCA) to the 
monoclonal antibody (Moab), labelling conditions and quality control methods of the resulting conjugates. In 
particular, the following procedures have been extensively investigated to assess the most appropriate 
experimental conditions allowing the highest yield and degree of reproducibility. 
 
o Conjugation of the monoclonal antibody to a bifunctional chelating agent (BFCA). 
o Purification of the BFCA conjugated antibody (BFCA-MoAb). 
o Chemical characterization of the resulting BFCA-MoAb. 
o Labelling of the BFCA-MoAb with 177Lu and 90YY. 
o Determination of the radiochemical purity (RCP) of the resulting radiolabelled conjugate (M-BFCA-MoAb; 
M = 177Lu and 90YY). 
o Determination of the in-vitro stability of M-BFCA-MoAb (M = 177Lu and 90YY). 
 
   The chemical structures of the various BFCAs employed for the study are illustrated in Fig. 1 below. The 
compounds 1−4 were commercially available. Martin Brechbiel’s group at National Institute of Health (NIH) 
provided compound 5 to all groups. The two BFCAs 1 and 4 have been employed more extensively. 
 
7 
            
 
 
FIG. 1. The bifunctional chelating agents employed for conjugation to Rituximab. 
 
   Participants’groups presented results from their own studies obtained with the different chelating agents. These 
data have been extensively and carefully analyzed during the RCM with the purpose of identifying the most 
appropriate experimental protocol. The crucial issue was to clearly define a precise and detailed experimental 
procedure for all steps required to successfully conduct the preparation and quality control of the radiolabelled 
Rituximab. It was assumed that these standardized protocols have to be exactly followed by all research groups 
for conducting their subsequent studies on radiolabelled Rituximab during the second part of the CRP. The 
analysis of experimental data allowed drafting a number of protocols precisely describing each key step on the 
path for obtaining the high-yield labelling of the antibody including quality control methods. These procedures 
are reported here (see below) and all groups are strongly encouraged to be committed to following them closely 
in their future studies on the labelling of Rituximab. 
 
   The implementation of operational protocols for antibody conjugation and labelling has to be considered as a 
critical achievement of the CRP because it will allow for further progress towards the final objective of 
developing a kit formulation for routine clinical use. In fact, only the definition of exact protocols may permit to 
translate them into an easy-to-use kit-like procedure. Actually, the investigation to evaluate the most appropriate 
conditions for producing a lyophilized kit formulation for labelling Rituximab with 177Lu and 90Y has been 
already initiated by a few groups within the CRP. In particular, the group from Poland presented a preliminary 
kit formulation containing the conjugated MoAb, mannitol and sodium acetate in a freeze-dried form. Data 
reported by the same group showed that the kit formulation was sufficiently stable and afforded 177Lu-Rituximab 
in high radiochemical yields. Similarly, the group from Macedonia investigated the impact of different 
lyophilisation conditions on the formation of the microcrystalline structure of the conjugated antibody. These 
studies will provide a preliminary basis for the successful development of a suitable kit formulation. 
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2.2. Peptides: bombesin  
 
   In the first part of the CRP, some groups were also pursuing the goal to investigate the preparation of a new 
peptide-based therapeutic radiopharmaceutical labelled with 177Lu and 90Y. During the first RCM, the peptide 
called substance-P was proposed as a suitable candidate for developing a therapeutic agent for the treatment of 
malignant gliomas. Although a number of research groups have successfully conducted labelling studies of 
substance-P with 177Lu, it has been noticed that recent reports published on the scientific literature seriously 
questioned the potential utility of this peptide for targeting selectively brain tumours as receptors for substance-P 
are also expressed by a high number of healthy tissues. For this reason, participants’ groups agreed to switch the 
interest for a new peptide-receptor ligand from substance-P to bombesin. 
 
   Peptidic bombesin derivatives are particularly attractive for the development of tumour-specifc therapeutic 
agents. Bombesin (BBN), a 14-aminoacid peptide analog of human gastrin releasing peptide (GRP) and of the 
related neuromedin B (NMB) peptide, was originally isolated from the skin of the frog Bombina bombina in 
1970 [Anastasi, A., Erspamer, V., M. Bucci, M., Isolation and structure of bombesin and alytesin, two analogous 
active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 27 (1971) 166-167] 
(Fig. 2). 
 
 
 
FIG.2. Image of the frog Bombina bombina. 
 
   GRP and BBN share a common aminoacid sequence in the C-terminal region, which is necessary for 
exhibiting their biological activity. Four different bombesin receptor subtypes have been recognized in humans, 
namely the neuromedin B receptor (NMB-R), the gastrin-releasing peptide receptor (GRP-R), and the orphan 
bombesin subtype-3 receptor (BB3). These receptors can be distinguished by their different affinities for the 
mammalian peptides NMB and GRP, whereas a native ligand for the BB3 has not been identified yet 
[Varvarigou, A., et al., Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother 
Radiopharm, 19 (2004) 219-229]. The fourth BBN receptor (BB4) was isolated from the frog but has not been 
found in mammals yet. The interest in using radiolabeled bombesin derivatives as agents for radionuclide 
therapy of tumours has increased because of the observation that GRP-R are over-expressed in a variety of 
human tumor cells [Chen, J., et al., Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic 
radiotherapeutic agent for gastrin releasing peptide receptor positive tumors. Appl Radiat Isot 66 (2008) 497-
500]. GRP-R is not normally expressed by epithelial cells present in colon, lung, and prostate, but is expressed 
by non-neuroendocrine cells of the pancreas and breast and by most neuroendocrine cells of gastrointestinal 
tract, lung and prostate. However, GRP receptors are found in high density in a variety of primary and metastatic 
tumour tissues, such as breast, colon and prostate tumours. In the case of prostate cancer, it has been found a 
high density of GRP-R not only in the invasive prostatic carcinomas but also in the earliest phase of neoplastic 
transformation. GRP-R expression by prostate tumour cells seems to be closely related to the onset of the 
neoplastic condition and its activation regulates tumour cells morphology, differentiation and proliferation 
[Markwalder, R., Reubi, J. C., Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic 
transformation. Cancer Res 59 (1999) 1152-1159]. These findings encourage the search of bombesin derivatives, 
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which could be radiolabeled and used for imaging and/or delivering a cytotoxic radiation dose to prostate tumor 
cells. 
   A universal bombesin ligand, D-Tyr-Gln-Trp-Ala-Val-ß-Ala-His-Phe-Nle-NH2 (6–14), has been developed by 
Mantey et al. [Mantey, S. A., et al., Discovery of a high affinity radioligand for the human orphan receptor, 
bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other 
mammalian bombesin receptors. J Biol Chem 272 (1997) 26062-26071] and Pradhan et al. [Pradhan, T. K., et 
al., Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J 
Pharmacol 343 (1998) 275-287], which has high affinity to all of the bombesin receptor subtypes. Based on this 
universal ligand, Saudi Arabia has synthesized the new bombesin analogue DOTA-Glu-BNU (DOTA-Glu-Phe-
Glu-Trp-Ala-Val-ß-Ala-His-Phe-Nle-NH2). The sequence contains the spacer Glu-Phe-Glu. The rational of 
introducing negatively charged aminoacids in the sequence was to enhance the renal excretion and reduce 
abdominal uptake. The sequence has already been synthesized and will be distributed among the participating 
countries (Saudi Arabia, Argentina, Brazil, Syria, Macedonia, Poland, India, Austria, Hungary, Italy-Rome, 
Italy-Milano) for further evaluation during the second part of this CRP. 
 
 
3. SPECIFIC RESEARCH OBJECTIVES FOR THE SECOND PART OF THE CRP 
 
   The results presented by the various participant groups indicate that the primary objective of this CRP, which 
was aimed at developing an easy-to-use, freeze-dried, sterile kit formulation for labelling the antibody Rituximab 
with 177Lu and 90Y, might become feasible. The procedures for antibody’s conjugation and labelling have been 
precisely defined and this will pave the way for designing the final kit formulation. Hence, a major expected 
outcome for this CRP still remains the development of efficient technologies for producing pharmaceutical kit 
formulations for radiolabelling antibodies with trivalent therapeutic metallic radionuclides. 
 
   Similarly, the extension of methods employed for labelling somatostatin-derived peptides with 177Lu and 90Y to 
other peptides having potential application for cancer therapy continues to constitute another research elevant 
objective of the present project. In this respect, the development of a freeze-dried kit formulation is less 
challenging than for antibodies, the most critical issue being to find a peptide derivative having optimal 
properties for targeting specific cancer cells. 
 
 
4. WORKPLAN FOR THE SECOND PART OF THE CRP 
 
4.1. Rituximab 
 
   The protocols reported in the next paragraphs describe the detailed procedures that should be employed by all 
research groups for conducting studies on the labelling of Rituximab with 177Lu and 90Y. Since no significant 
differences have been found between the various bifunctional chelating agents 1-5, the compounds 1 and 2 
pictured in Fig. 1 have been selected for subsequent studies. The laboratory in Rome, Italy, will perform the 
chemical characterization of the resulting BFCA-MoAb conjugates as well as the determination of their 
imunoreactivities. Then, the various research groups will use these well-characterized antibody conjugates for 
labelling and stability studies. In a similar way, the Italian laboratory will determine the immunoreactivity of the 
resulting radiolabelled BFCA-MoAbs. Animal studies for assessing the biodistribution properties of the 
radiolabelled conjugates will be carried out by the laboratory in Hungary. The bulk of data collected from these 
studies will provide the experimental basis for the subsequent development of a convenient freeze-dried kit 
formulation according to the main objective of the CRP. 
 
4.2. Bombesin 
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4.2.1. Delivery of the peptide and radiolabelling 
 
   Saudi Arabia has synthesized a bulk of 15 mg of peptide and will initially send 1-2 mg to five participating 
countries (India, Brazil, Argentina, Italy-Rome, Italy-Milan). In a more advanced stage of the evaluation, the 
peptide will be delivered also to the other participating countries. Radiolabelling with high-specifc-activity 177Lu 
will be performed and the labelling conditions, in terms of peptide amount, labelling buffer, temperature, 
incubation and pH, will be optimized to obtain high labelling efficiency (India). It is expected that a standard 
radiolabelling protocol will be elaborated, which can be thereafter followed by all participating countries. 
 
4.2.2. Stability studies in vitro 
 
In three different centers, stability studies in solution and in serum will be performed with 177Lu-DOTA-Glu-
BNU ((DOTA-Glu-Phe-Glu-Trp-Ala-Val-ß-Ala-His-Phe-Nle-NH2 = DOTA-Glu-BNU). Results will 
provide some initial information on the stability of the radiolabel and against enzymatic degradation. 
 
4.2.3. Binding studies and cell uptake studies  
 
   Depending on the availability of different BBN receptor positive cell lines (PC-3 prostate cancer, MDA-MB-
231 or MCF-7 breast cancer) saturation assays will be perfomed with 177Lu-DOTA-Glu-BNU. Additionally, 
internalisation studies will be performed in the same cell lines to evaluate the receptor specific uptake into the 
cells. Brazil will perform these studies on 111In-labelled DOTA-Glu-BNU. In this way, the results can be 
compared with results available for other two bombesin analogues, BZH3 and BEYG5N, which have been 
previously evaluated. A complementary in vitro binding assay study will be performed by the laboratory in 
Rome, Italy, using the new ‘Ligand Tracer ‘ automated device. 
   Based on these experimental results, it will be possible to assess whether the selected bombesin peptide shows 
a promising biological profile for a further in vivo evaluation. Only after completing this initial evaluation, the 
peptide will be send also to the other participating countries (Syria, Macedonia, Poland, Austria, Hungary). 
 
4.2.4. In vivo biological studies  
 
   In vivo studies will be performed in normal mice, including also metabolite studies, as well as in a mouse 
xenograft model. The obtained results will be again compared with previous results obtained with BZH3 and 
BEYG5N. These in vivo investigations will definitely demonstrate if the new radiolabelled bombesin analogue 
exhibits lower abdominal uptake and higher renal excretion associated with high tumour uptake and prolonged 
retention. It is expected that these biodistribution studies will allow to draw clear conclusions on the clinical 
potential of the peptide DOTA-Glu-BNU. 
 
4.2.5. Development of a kit formulation 
 
   After completion of all evaluation steps, Macedonia will formulate a freeze-dried, sterile and pyrogen-free kit 
formulation to be conveneintly employed for subsequent investigational studies in human subjects. 
 
 
5. PROTOCOLS 
 
5.1 Conjugation of Rituximab to p-SCN-Bn-DOTA (1) and p-SCN-Bn-DTPA (4) 
 
5.1.1. Reagents 
11 
 
o Rituximab (10 mg/mL)  
o p-Isocyanatobenzyl-DOTA (p-SCN-Bn-DOTA, 1), p-isocyanatobenzyl-DTPA (p-SCN-Bn-DTPA, 2) 
(Macrocyclics) 
o PBS buffer (0.1 M, pH 8.5) 
o PBS (0.05 M)/NaCl (0.15 M) buffer (pH 7.2) 
o NH4OAc (0.5 M) 
o NH4OAc (0.05 M) 
o Sodium hydroxide (1.0 M) 
o Hydrochloric acid (1.0 M) 
o Metal-free water (typical resistance, 18 mΩ per cm) 
 
5.1.2. Equipment 
 
o Ultrafiltration device [i.e., Vivaspin, Amicon, (MWCO 30 kDa)] 
o Calibrated pH meter 
o Metal-free plastic test tubes 
o Refrigerated centrifuge 
o UV spectrophotometer 
o MALDI-TOF MS 
 
5.1.3. Reagent setup 
 
o PBS buffer (0.1 M, pH 8.2). Dissolve 17.9 g of Na2HPO4 × 12H2O in 500 mL of water (A). Dissolve 6.8 g of 
NaH2PO4 × H2O in 500 mL of water (B). Add 23.0 mL of solution B to solution A (resulting pH = 8.5). 
o Mixture of PBS (0.05 M)/NaCl (0.15 M). Dissolve 17.9 g of Na2HPO4 × 12H2O in approximately 1 liter 
(dm3) of water. Add 8 g of NaCl and 5 mL of HCl (2 M). Mix vigorously and check that the pH is between 
7.0 and 7.2. 
 
5.1.4. Preparation of Rituximab for conjugation 
 
{Caution! If Rituximab is not provided at a density of 10 mg/mL or it is not dissolved in a 0.1-M PBS 
buffer solution, please follow the steps given below.}  
 
(1) Pipette the required amount of protein solution (1.1 mL) into the ultrafiltration tube  
(2) Dilute to 2 mL with 0.1-M PBS buffer, pH 8.5. 
(3) Spin the tube in a centrifuge so that the protein solution volume is reduced by a factor of 2–3. 
(4) Discard the ultrafiltrate and repeat steps (2) and (3). 
(5) Spin the tube until the volume reduces to 1 mL or less (if you have less than 1 mL bring it up to 1 mL with 
PBS (0.1 M, pH 8.5). 
(6) Measure the absorbance of a protein sample at 280 nm in a UV spectrophotometer. Calculate the protein 
concentration (mg/mL) using the value of 1.4 (mg/mL)-1 for the molar extinction coefficient. 
 5.1.5. Conjugation reaction 
 
[1] Calculate the amount of BFCA required to give a 20-fold molar excess over the amount of Rituximab. 
[2] Dissolve a sufficient quantity of DOTA (1) (or DTPA, 2) bifunctional ligand in 0.1-M PBS (pH 8.5) to give 
a concentration of 10 mg/mL. Calculate the volume of the resulting solution required to fit with point [1] 
and add this to the protein solution.  
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[3] Adjust the pH with NaOH (1 M) and/or HCl (1 M) using a pH meter to a final pH of 8.5. Mix immediately 
and incubate at 4 ° C overnight with gentle shaking. 
5.1.6. Purification of the conjugate using ultrafiltration devices 
 
1) Rinse the ultrafiltration tube with ammonium acetate, pH 7 (0.05 M for storage or 0.5 M for immediately 
labelling). 
2) Pipette the reaction mixture into a tube. 
3) Dilute the mixture to 2.0 mL with 0.05-M or 0.5-M ammonium acetate, pH 7. 
4) Spin the tube in a centrifuge so that the protein solution volume is reduced by a factor of 2–3. 
5) Repeat steps 3) and 4) until the absorbance in the ultrafiltrate set at 280 nm is nearly zero (meaning that no 
more free chelating agent is being eliminated from the solution). 
6) Increase the volume to obtain a protein concentration of 5 mg/mL. 
7) Determine the concentration of the conjugate using some well-established method for measuring protein 
concentration (i.e., Bradford, BCA). 
5.1.7. HPLC analysis of the immunoconjugate 
 
   Immuconjugates should be characterized by SE-HPLC. Briefly, about 20 µL of the conjugate MAb is injected 
into a size-exclusion column using a mixture composed of NaCl (0.9%):NaN3 (0.05%) as mobile phase. The 
flow rate is maintained at 1 mL/min and the elution is monitored by UV spectrophotometer at 280 nm. The area 
under the immunoconjugate peak should span more than 95% of the total area. 
 
5.2. Labelling of the Rituximab conjugate 
 
5.2.1. Radiolabeling  
 
   An aliquot of the appropriate radionuclide (177Lu, 90Y; 1000 MBq in 10–15 µL) in HCl (0.05 M) is added to 
100 µL of NH4OAc buffer (0.5 M) at pH 7.0 followed by 200 µL (1 mg) of the corresponding immunoconjugate. 
Then, the reaction mixture is incubated at 42 °C for 1 h, or at room temperature for 30 min, when p-SCN-Bn-
DOTA (1) or p-SCN-Bn-DTPA (2) are used, respectively. 
 
5.2.2. Quality control 
 
   In order to scavenge any free radiometal for further quality control, a solution of DTPA or EDTA (0.01 M, pH 
= 6.0) corresponding to 1/10 of the sample volume withdrawn for the analysis, is added to the reaction vial and 
the mixture is incubated for 15 min at room temperature. Radiochemical purity is determined by thin-layer 
chromatography on SG-ITLC plates (Pall Corporation, USA), using 10% (w/v) ammonium acetate:methanol 
(1:1) as mobile phase. In these conditions, the radioimmunoconjugate remains at the origin and the radiometal-
DTPA (EDTA) complex migrates to the front. 
 
   SE-HPLC can be also employed using an instrument equipped with a size exclusion HPLC column and one 
online radio-detector, and following the same procedure described above for the immunoconjugate. 
   When required, radiolabeled conjugates are purified from unbound radiometal by ultracentrifugation.  
   The acceptance limit for RCP is ≥ 95%. 
 
5.3. Chemical characterization and immunoreactivity of BFCA-MoAb conjugates 
 
5.3.1. Protein characterisation by matrix-assisted laser desorption ionization time-of-flight (MALDI-ToF)  
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   Both characterization of the conjugated BFCA-MoAb and determination of the average number of BFCA 
attached to each antibody molecule can be performed by Matrix-Assisted Laser Desorption Ionization time-of-
flight (MALDI-ToF) mass spectrometry. A representative procedure can be outlined as follows. A volume (10 
µL) of the solution of the conjugated BFCA-MoAb is diluted (1:10) with a matrix solution of 3,5-dimethoxy-4-
hydroxycinnamic acid [10 mg/mL dissolved in a mixture of acetonitrile  (50%)/TFA (1%) (Sigma)] to a 
concentration of about 10 pmol/µL. An aliquot (1-2 µL) of the final solution is applied to the sample target prior 
to insertion into the high vacuum chamber of a mass spectrometer (Voyager-De MALDI-ToF, Applied 
Biosystems). Operational conditions for the MALDI-ToF apparatus are set as follows: Mode of operation, linear; 
Polarity, positive; Acceleration voltage, 20000 V; Delayed extraction time, 100 nsec; Acquisition mass range, 
140000-170000 Da. 
 
5.3.2. In vitro competitive binding assay  
 
   To test the in vitro binding affinity of radiolabelled Rituximab for specific receptors, a competitive binding 
assay can be performed on CD20-positive Burkitt lymphoma-derived cell lines, RAJI [Schaffland AO, 
Buchegger F, Kosinski M, Antonescu C, Paschoud C, Grannavel C, Pellikka R, Delaloye AB (2004) 131I-
rituximab: relationship between immunoreactivity and specific activity. J Nucl Med 45:1784–1790]. The cells 
are maintained in a RPMI 1640 culture medium (Sigma-Aldrich) supplemented with 10% heat-inactivated foetal 
calf serum (Gibco), 1% L-glutamine (Gibco), 1% antibiotics (penicillin and streptomycin, Gibco), in a 5% CO2 
humidified incubator at 37 °C. Cell viability and cell count are determined by trypan-blue assay using a 
haemocytometer. 
 
   For binding experiments, triplicate samples of the radiolabelled-Rituximab are incubated at increasing 
concentrations (from 0.05 to 50 nM) with 105 cells either alone or in the presence of a 100-fold molar excess of 
the unlabelled antibody to saturate the specific receptors on the cells. After 2 hours of incubation, cells are 
harvested by centrifugation (9,000g for 3 min) and washed two times with complete RPMI 1640 culture 
medium. Cells and supernatants are then collected in different vials and counted separately for radioactivity in a 
single-well gamma counter (Gammatom, Italy). The plot of specific binding is generated as the difference 
between total binding and nonspecific binding. A Scatchard analysis is finally performed using GraphPad Prism 
Version 5.00 Software (GraphPad Software, Inc.) to determine the dissociation constant (Kd). 
 
5.3.3. Automated in vitro binding assay 
 
   The in vitro binding assay illustrated above is usually performed manually. Since several methods are 
available, it is worthy only to recommend that experiments should be always carried out in triplicate or 
quadruplicate (both with and without displacement). Alternatively, these experiments can be performed 
automatically using a new instrument called ‘Ligand Tracer’, which has been designed to perform 
simultaneously several binding assays and to follow them in real time. The instrument is composed of a rotating 
device on which a Petri dish can be placed (Fig. 2). Cells are grown in a target area on the dish and then 
incubated with the radiopharmaceutical. The dish is then started to rotate and the activity associated with the 
target area measured by a detector. The device is connected to a computer in order to follow the binding assay in 
real time and to collect and plot data using dedicated software. This instrument allows performing a fast 
preliminary screening of different labelled compounds on different cell lines, in order to provide a preliminary 
evaluation of the pharmacokinetics and to give insights on the most promising radiopharmaceutical to be used 
for further experiments. The following tests can be performed with this device: (1) kinetic binding assay to 
determine the dissociation and association rate constants (off-rate and on-rate) of unlabeled compounds, (2) 
affinity assay to determine the strength of the ligand-receptor interaction (Kd), (3) competitive binding assay to 
determine the specificity of the ligand-receptor interaction (4) internalization assay to determine the internalized 
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fraction and the intracellular retention time. With this apparatus it is also possible to analyze the formation of 
metabolites in the supernatant. 
 
 
 
 
FIG. 2. Experimental setup for automated in vitro binding assay 
 
 
   Similar information can be also obtained by ex-vivo autoradiography on paraffin-embedded tissue samples 
incubated with the radiolabelled MoAb. 
 
5.3.4. Immunoreactive fraction assay  
 
   The assay for determination of the immunoreactive antibody’s fraction, carried out by linear extrapolation to 
conditions representing infinite antigen excess, has been adapted from the method described by Lindmo et al. 
[Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of 
radiolabelled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol 
Methods 72:77–89] with only slight modifications. The immunoreactive fraction assay is performed using a 
constant concentration of radiolabelled MoAb and serial dilutions of RAJI cells. The cells are washed three 
times in phosphate-buffered saline (PBS, pH 7.4) and suspended in a cold phosphate-buffered saline (PBS) 
containing 1% bovine serum albumin (BSA) solution. Radiolabelled MoAb, at a constant concentration of 50 
ng/mL in PBS with 1% BSA solution, is added to different amounts of cells (final concentration ranging from 
2.6 × 106 to 0.08 × 106 cells/mL). Cells are incubated for 2 hours at 4°C and then washed twice with 500 µL of 
cold PBS with 1% BSA solution. Then, cell-associated radioactivity is counted in a single-well gamma counter. 
Data are plotted as a double inverse plot of the applied radiolabelled antibody (Y axis = 1/cpm or nM of 
radiolabeled MAb) over the specific binding as a function of the inverse cell concentration X axis = 1/cells per 
mL). In this plot, the origin of the abscissa represents infinite cell concentration, i.e., conditions of infinite 
antigen excess. All experiments must be performed in triplicate [Malviya G, Anzola KL, Podestà E, Laganà B, 
Del Mastro C, Dierckx RA, Scopinaro F, Signore A (2012) 99mTc-labeled Rituximab for imaging B lymphocyte 
infiltration in inflammatory autoimmune disease patients. Mol Imaging Biol 14:637-646]. 
 
5.4. Animal studies on 177Lu/90Y-labelled Rituximab 
 
   To complement in vitro measurements on immunoreactivity, cell binding, saturation and dissociation assays, 
another crucial information is obtained by in vivo evaluation of the biodistribution of the radiolabelled antibody 
in tumour animal models. These xenograft models are usually produced by inoculation of the same cell lines 
(RAJI or equivalent) employed for in vitro studies. The preliminary verification of the presence of the target 
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CD20 antigen on the cell surface by immunohistochemistry or other methods is always considered an essential 
prerequisite before developing the tumour animal model. 
 
5.4.1. Biodistribution test in normal mice and in nude mice xenografts 
 
   Preliminary biodistribution studies in healthy mice (e.g., BALB/C mice) are primarily recommended, though 
other species  (e.g., rats, Guinea pigs, Syrian hamsters) are also feasible. A representative procedure is outlined 
here. The radiolabelled compound is injected intravenously (usually through a tail vein) into the animals (a 
minimum of 3 animals per group is always required), with injected activity ranging from 5 to 10 MBq (volume 
range from 0.1 to 0.2 mL) for each animal. For biodistribution studies with MoAbs, early (2 hours post injection) 
and late groups (24 hours post injection) are always required, but introduction of additional time points is 
strongly recommended. After administration, the animals are anaesthetized usually by narcotic gases (isofluran, 
aether, chloroform) or injectables [pentobarbital-Na (40 mg/bwkg ip), ketamine-HCl (10 mg//bwkg) + xylazine 
(2 mg/bwkg ip)], then euthanized using either an overdose of injectable narcotic (e.g., 400 mg/bwkgs 
pentobarbital-Na, ip) or registered veterinary drugs (T-61 inj AUV, Euthanyl inj). Organs, samples (tail, blood, 
heart, lungs, liver, kidneys, spleen, GI-tract, muscle, bone/femur, brain and tumor)  are then removed, washed, 
dried, scaled and radioactivity measured. Radiopharmaceutical uptake is calculated as percent of injected activity 
per whole organ or, alternatively, as injected activity per gram tissue. 
 
5.4.2. Imaging studies 
 
   Equipment specially designed for laboratory animal imaging (preferably a microSPECT/CT small-animal 
tomograph) is recommended for imaging studies with β-emitting radionuclides that also decay through γ-
emission (e.g., 177Lu), though rats and mice could be conveniently scanned using also conventional cameras for 
human studies. In this case, the use of a pinhole collimator is strongly recommended if available to achieve a 
better resolution in small laboratory animals. The imaging study is generally performed both in healthy and 
xenografted mouse models, but other rodents (e.g., Guinea pig, Syrian hamsters) are also acceptable alternatives. 
In those centers where imaging can be conducted on larger animals (e.g., healthy Beagle dogs, swines and 
referred B-cell lymphoma dogs) additional studies on these animal models are also recommended. A common 
procedure for imaging is to inject a solution (0.1−0.2 mL) of the radiolabelled compound (10–20 MBq) into a 
mouse. After anesthesia carried out using the methods mentioned above, the sleeping animal can be imaged. 
Different animals can be used if imaging is started at different time points after injection. A minimal imaging 
procedure requires collecting ventrodorsal whole body images at 3 and 24 hours post injection, but registration 
of additional serial images is strongly recommended. Though qualitative imaging provides a suitable picture of 
the in vivo biodistribution behaviour of the radiolabelled compound, quantitative scintigraphy (conducted by 
ROI or VOI analysis) should be carried-out whenever possible. 
 
5.5. Radiolabelling and biological evaluation of Bombesin-derived peptides 
 
5.5.1. Radiolabelling with Lu-177 
 
All buffers used for radiolabelling should be prepared with metal free water. Only high specific activity 177LuCl3 
will be used for radiolabelling. To ~ 20 µg DOTA-peptide 100-200 µL sodium acetate buffer (0.4 M, pH 4.5) or 
an alternative buffer will be added and the reaction mixture heated at 90° C for 30 minutes. For higher specific 
activity 177Lu-labelling, lower amounts of peptide can be used. 
 
5.5.2. Determination of radiochemical purity  
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Instant thin layer chromatography (ITLC-SG) can be applied to determine free lutetium-177, with citrate buffer 
(0.1 mol/L, pH 5.0) as solvent (Rf of labeled peptide is 0.0 and Rf of free lutetium is 0.9-1.0).  
Radiochemical purity (RCP) should also be determined by high performance liquid chromatography equipped 
with radioactivity detection, using a RP C18 column (4.0 x 150 mm, 5 µm), flow rate 1.0 mL/min using a 
water/acetonitrile/TFA gradient. 
 
5.5.3. Serum stability assay 
 
   Prior to incubation in the different test solutions the reaction solution is purified by solid phase extraction on a 
C-18 SepPak cartridge. The radiopeptide is then incubated at a concentration of ~1000-4000 pmol peptide/mL 
and incubated for up to 24 hours at RT of 37 °C. 
 
   The radiolabelled peptide is added to 1 mL of human or mouse/rat plasma and incubated for 15-30 minutes, 1, 
4 and 24 hours at 37 °C. After each time point, an aliquot of each sample is collected, the proteins precipitated 
with ethanol or ACN (1:1) followed by centrifugation to separate large proteins. The supernatant containing the 
radiolabelled peptide is diluted with water (1:1) and analysed by HPLC, and the percentage of intact 
radiolabelled peptide is determined (% intact peptide of each sample per time point). Similar studies have to be 
additionally perfomed in phosphated buffered saline or saline. 
 
5.5.4. Receptor binding assay 
 
   Saturation binding assays with the labelled peptide will be performed on whole adherent PC-3 cells or an 
alternative cell line. The cells should be seeded in 6-well plates (2.5 × 105/well) and grow in a 5% CO2 
atmosphere humidifying incubator at 37 °C for 24 h. Radiolabelling is performed to a standardized protocol 
followed by SepPak purification. The obtained solution will be diluted with PBS/1% BSA to give a 4,000 nM 
solution, followed by serial dilutions from 400 to 1 nM in PBS/1% BSA. The unlabeled peptide (10,000 nM in 
PBS/1% BSA) is used as the competitor. The cells are washed with culture medium (1% FBS) and culture 
medium containing 1% v/v FBS and 0.1% (w/v) sodium azide is added to minimize internalization. 
Subsequently, 150 µL of either PBS/1%BSA (to measure total binding) or 150 µL of competitor (to measure 
nonspecific binding) will be added. This is followed by the addition of increasing concentrations of radioligand 
(final concentration 0.1 – 40 nM). All samples will be repeated in triplicate. The plates are incubated at 20°C or 
RT for 1.5 h, and then washed twice with culture media containing 1 % v/v FBS and 0.1 % (w/v) sodium azide 
and lyzed with 1 mL of 1 M NaOH for 15 min and collected. Additionally, two washing steps are done with PBS 
and collected together with the cells. The protein content of three wells can determined using a Protein Assay kit 
(Biorad Laboratories). Dissociation constant (Kd) and maximum numbers of binding sites (Bmax) will be 
calculated with nonlinear regression using a dedicated software. Additionally, also cell internalization studies 
could be performed. 
 
   Additionally, an automated in vitro binding assay using the Ligand Tracer can be also performed in the 
laboratory in Rome, Italy, following the procedure described in section 5.3.3. Complementary information on the 
biodistribution behaviour can be also obtained by ex-vivo autoradiography on paraffin-embedded tissue samples 
incubated with the radiolabelled peptide. 
 
5.5.5. Biodistribution studies in tumour-xenograft mice 
 
   GRPR–positive xenografts are induced by subcutaneous injection in nude mice  of PC-3 cells (2 × 106/mouse), 
or any alternative receptor positive cell line, suspended in a 0.2-mL volume. Animals are used 15-21 days later 
when the tumors grow to around 5 mm in diameter.  
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   The radiolabelled peptide and SepPak purified peptide, diluted in saline solution, is injected intravenously into 
the tail vein of the tumour–bearing mice (n = 3 for each time point). At each selected time points, the mice are 
anesthetized, sacrificed and blood, tumour, pancreas, kidneys, heart, stomach, spleen, intestine, liver, lung, and 
muscle are sampled, weighed and counted in a γ-counter along with activity reference standards. The percentage 
of injected activity per gram of tissue is lastly calculated for each tissue type.  
 
5.6. Quality of 177Lu to be used for radiolabeling 
 
The following reccommendations have to be applied to the production of the 177Lu through neutron irradiation of 
176Lu targets to ensure a good quality for the final  177Lu labelling solution. 
 
1) Enrichment of the 176L target should be as high as possible (optimally > 82% enrichment in 176Lu). 
2) It is strongly recommended to perform dissolution of the irradiated target using suprapure grade 
hydrochloric acid. Similarly, suprapure or ultrapure quality water should be always employed. 
3) Specific activity should be as high as possible, but not lower than 16 mCi/µg. 
4) Recommended radioactive concentration is 1.0 mCi/µL. 
5) The amount of the radionuclidic impurity corresponding to the presence of 177mLu should be kept lower 
than 200 ppm at the time of production. 
6) Acceptable level of other non-radioactive metallic impurities should be set according to specifications for 
177Lu solutions reported in the Perkin-Elmer catalog. 
7) pH of 177LuCl3 solutions should fall into the range 1-4. 
8) Preferably sterile (by autoclaving) and pyrogen-free solutions should be supplied (this is mandatory for 
clinical studies). 
 
 
6. EXPECTED OUTPUTS 
 
o Freeze-dried, sterile and pyrogen-free kit formulation for labelling the anti-CD20 antibody Rituximab with 
177Lu and 90Y. 
o Freeze-dried, sterile and pyrogen-free kit formulation for labelling the peptide Bombesin with 177Lu and 90Y. 
 
 
7. COOPERATION AMONG PARTICIPANTS 
 
   Only a few number of cooperative research activities have been established during the first part of the CRP, 
mostly because all groups have been involved in protocol optimization and this work do not require extensive 
cross collaborations. Nonetheless, the following collaborations have been pursued. Austria and Argentina are 
collaborating on the development and biological evaluation of peptidic minigastrin-receptor targeting 
radiopharmaceuticals. So far, the A431 epidermoid carcinoma cell line stably transfected with the human CCK-2 
receptor has been established in Argentina and two minigastrin analogues are currently available for 
characterization in animal models. Italy (Rome) is actively cooperating with the laboratory in Hungary for 
conducting biological studies in large animals with new radiolabelled antibodies. India is supplying on demand 
reactor produced Lu-177 for labelling and biological studies. Saudi Arabia and Argentina will cooperate to 
investigate the labelling of a new HER2/neu receptor peptide with Lu-177. 
 
   According to the workplan, a sharp increase of research collaborations among the different laboratories is 
expected to occur during the second part of this CRP as requested by the need to share and compare 
experimental data for developing the final kit formulations. 
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8. RECOMMENDATIONS 
 
   It is envisaged that the following actions might further help the successful accomplishment of the relevant 
research work planned for this CRP. 
 
o Provide support and assistance for the purchase and distribution to the various groups of chemicals and 
biologically active compounds required for the preparation of the final radiopharmaceuticals. 
 
o Establish a research contract with a specialized laboratory for conducting both chemical and in vitro 
biological characterization of the resulting bifunctional ligands (BFCA-MoAbs and BFCA-peptides) and of 
the radiolabelled conjugates. 
 
 
9. CONCLUSIONS 
 
   The progress of the research work was accomplished according to the workplan proposed during the first RCM 
of this CRP and detailed in the first Report. Specifically, the rationale of the proposed program was to determine 
the most appropriate experimental conditions for conjugation and radiolabelling the antibody Rituximab. This 
information is essential for planning the final development of a lyophilized kit formulation for preparing this 
therapeutic radiopharmaceutical, which constitutes a key objective of this CRP. The various research groups 
have provided a sufficient amount of data that strongly support the feasibility of this product and, therefore, 
suggest that the research plan could be successfully completed during the second part of the CRP. 
 
   A parallel program was focused on the selection of a peptide derivative that might constitute a step forward on 
the route for the discovery of other useful peptide-based radiopharmaceuticals potentially having the same 
successful clinical applications as somatostatin-derived receptor targeting radiopharmaceuticals. After some 
initial emphasis on the peptide substance-P, it has been concluded that bombesin-related peptides might offer 
more advantages, particularly considering the recent development of many structurally related analogs. This 
conclusion will affect the second part of the CRP since more extensive studies will be devoted to this class of 
peptidic radiopharmaceuticals. 
 
 
10. SUMMARY OF COUNTRY PRESENTATIONS 
 
Argentina 
   In this summary we briefly describe the work carried out in the Radiopharmacy Division during the last year 
related with the scope of the CRP. The main focus was the conjugation of SCN-Bz-DTPA with Rituximab®, the 
radiolabelling of this conjugated with locally produced 177Lu and to perform HPLC studies to determine the 
radiochemical purity. In vitro stability test of the product were done using c-DTPA as a tranchelator at different 
molar ratios. 177Lu-DTPA-benzyl-Rituximab® biodistribution  were carried out  in normal mice at different time 
p.i. One freeze dried kit formulation for labelling with 177Lu were developed. High Specific Activity (H.S.A.) 
177Lu was obtained for the first time in Latinamerica in an experimental scale production using the direct method 
from an 82 % 176Lu enriched target. The level of 177mLu / 177Lu was determined by gamma spectrometry. 177Lu-
DOTA-Substance P biodistribution were carried out in normal mice with and without previous arginine infusion 
in order to quantify its renal protection effect. Internal dose assessment for quantification of this effect in normal 
mice and extrapolation to standar human patients were made in collaboration with the Dosimetric Group 
(Nuclear Regulatory Authority). Preliminar studies of 177Lu-DOTA-His2-MG11 in nude mice bearing A431 
CCK+ human cells were initiated. As a consecuence of a training period at the Nuclear Medicine Department of 
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the Insbruck University, one of our fellows participated in the synthesis of two new DOTA-Minigastrin 
analogues and acquired experience in internalization studies of radiolabelled DOTA-peptides. 
 
Austria 
   Beside the clinical use of 90Y-DOTA-TOC and 177Lu-DOTA-TATE for treatment of neuroendocrine tumours 
our department is continuously working on the development of novel radiopharmaceuticals based on other 
peptide analogues. Within the first year of this project we designed new minigastrin (MG) analogues based on 
DOTA-MG11, including collaborations with Turkey and Argentina. The new peptide derivatives contain 
unnatural amino acids in the peptide sequence with the aim to stabilize the peptide analogue against enzymatic 
degradation.  
 
   Another contribution of our department was the further optimization of the clinical preparation of Lu-177 and 
Y-90 labelled somatostatin analogues. In this respect we have evaluated the possibility to reduce radiolysis and 
elaborated procedures for the quantification of the total peptide amount in the final preparation. A future activity 
in this direction will be the optimization of the automated dispensing and infusion of the single dose to the 
patient. 
 
Brazil 
   In the field of radiolabelled molecules, substance P (SP), bombesin and Rituximab appear as promising 
molecules for radiopharmaceutical design, because they can target specifically to receptors present mainly in 
glioblastoma, prostate cancer and non-Hodgkin lymphoma, respectively. During this project, the DOTA and 
DTPA-peptides and Rituximab will be radiolabelled with 177Lu, applying our previous knowledge and a method 
for their 90Y-labelling will be developed. The radiolabelled molecules will be evaluated in preclinical studies in 
healthy and tumour mice. The radiopharmaceuticals with the best performance after these evaluations will be 
studied in order to develop a formulation, which should follow the requirements for clinical applications. 
 
China 
   In this report, the purification of mAb, the conjugation of mAb with CHX-A''-DTPA and p-SCN-Bn-DOTA, 
the measurement of chelator/mAb ratio in the conjugates using spectrophotometry were described. The factors, 
which influenced 177Lu labelling of conjugates were studied, and RCPs were analyzed with ITLC and HPLC. 
The RCPs of labelled conjugates were over 95% after purification with PD-10 column. The in-vitro stability of 
labelled conjugates in 10mm DTPA, saline, 5% HSA, 10% HSA was investigated. The preliminary 
biodistribution studies of labelled conjugates in normal mice were also carried out. 
 
Cuba 
   During the first period of this CRP we have been working in the final setting up of the technology of the 
90Sr/90Y electrochemical generator. The module and software are currently working properly. We followed 
different procedures to establish the best electrochemical parameters for 90Y separation (current or voltage 
values, time of electrolysis, washing agents, effects of carrier addition and number of electrolysis cycles for 
purification of 90Y). The mean yield for 90Y has been between 90 and 95%.  Nowadays we are establishing the 
best electrochemical conditions to reach the extremely low level of 90Sr breakthrough of 2 µCi in 1.0 Ci of 90Y. 
   Molecules of interest to bind to therapeutically useful radionuclides are still monoclonal antibodies and their 
fragments. In this regard, we continued working on DOTA-NHS conjugation of hR3 (Nimotuzumab) at different 
experimental conditions in order to obtain labeling efficiencies higher than 95% while keeping the highest 
degree of immunoreactivity. Special attention was devoted to biological models required to evaluate the 
radiolabelled conjugate, mainly by in vivo assessment of tumour uptake. Another antibody of interest is the anti 
CD20 (Rituximab), which was conjugated to DTPA-CHX also using different experimental conditions. We 
found that radiochemical purity higher than 95% was achieved at a molar ratio of 1:20. 
 
Hungary 
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   The major work carried-out in Hungary focused on in vivo testing of radiopharmaceutical applicant molecules. 
Elements of a complete biological evaluation system were published in earlier IAEA-coordinated projects. In 
this present period beyond the known normal and pathological animal distribution-, and radiotoxicological 
studies we established several double xenografted Nude mice models that are available to image and quantify the 
specific and non-specific binding of tumor-seeking radioligands. Spontaneously occurring canine tumors (eg.: 
canine insulinomas and B-cell lymphomas) were also selected and their usefulness proved in therapeutical 
radiopharmaceutical research.  Selection of the referred animal patients based on PET/CT or SPECT/CT whole 
body hybrid images (68Ga-DOTA-TATE, 99mTc-HYNIC-TATE, and FDG PET/CT) and immunohistochemical 
evaluation of biopsy specimens were carried-out. We also performed pilot studies for enhancing the 
radiopharmaceutical uptake in tumor xenografts by the use of locoregional electromagnetic hyperthermia 
(Oncothermia®). This complete animal testing method is capable to provide important preclinical data including 
safety-, kinetic-, excretion-, internal dosimetry-, and efficacy results that are assisting the decision making 
process for investigators. Hungary still offers its animal testing capacities for all other interesting participating 
countries. 
 
India 
   The objective of the present CRP is to develop 177Lu and 90Y-labeled radiotherapeutic agents based on 
monoclonal antibodies and peptides. Towards this, production of adequately high specific activity clinical grade 
177Lu has been augmented and suitable method to separate 90Y from 90Sr has been developed at our Institute. 
These two radionuclides have been utilized for the preparation of 177Lu/90Y-labeled Reditux® and 177Lu-labeled 
MabThera® (both Reditux® and MabThera® are commercially available anti-CD20 monoclonal antibody). A cold 
kit of DOTA-TATE, suitable for the preparation of therapeutic patient dose of 177Lu-DOTA-TATE, has also 
been developed and evaluated. 
 
Italy (Milan) 
   We focus on the optimization of the conjugation of three bifunctional chelating agents (BFC) to a monoclonal 
antibody such as hR3 and Rituximab.  
The following procedures were implemmented: 
 
- conjugation at molar ratios 1: 50 and 1:100, 
- purification of the conjugated molecules using PD-10 desalting column, 
- 111In- radiolabelling of immunoconjugates, 
- quality control analysis to calculate the radiochemical purity and also to determine the average number of 
chelates per antibody, 
- stability of labelled products using an excess of DTPA.  
   In summary, we have developed a conjugation procedure, optimized the QC of the immunoconjugates by 
checking the number of BFC per molecule of antibody, performed a successful labeling with 111In and checked 
the stability of the labeled products using an excess of challenging agent. 
 
   We conclude that we have become familiar with the basic techniques to obtain an immunoconjugate and we 
are ready to repeat these experiments for further evaluations by the member states. 
 
Italy (Rome) 
   In the framework of the CRP on “Development and preclinical evaluation of therapeutic radiopharmaceuticals 
based on 177Lu and 90Y labeled monoclonal antibodies and peptides” we proposed to participate as a specialized 
center for pre-clinical in vitro screening of kit formulations of 177Lu-labelled-mAb/peptides synthesized by other 
laboratories participating in this IAEA coordinated project. Over the past years we developed know-how on 
studying the biological properties of candidate radiopharmaceutical performing routinely different in vitro 
quality controls and binding assays. Therefore, we applied our experimental protocol to test HYNIC- and DTPA-
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conjugated Rituximab labeled with 99mTc in order to test its biological properties. We found that the Rituximab 
molecule can efficiently be conjugated to both bifunctional chelators and radiolabelled, retaining the dissociation 
constant of the native mAb. On the basis of the obtained results we propose again our center for centralized in 
vitro QC and small animal studies.  
 
   Moreover, we carried on our experiments on labeled superagonist rhTSH analogue TR1401 to develop an 
imaging and therapeutic radiopharmaceutical for thyroid cancer metastasis. We performed in vitro and in vivo 
binding studies on TSHR+ve and TSHR-ve cell lines that proved the specificity of labeled TR1401 for TSH 
receptor. We also imaged several mice with TSHr +ve tumors and, in collaboration with Dr Balogh from 
Hungary we also imaged cats with spontaneous tumors to verify the specificity of this new tracer. Next year we 
will continue our experiments in mice and cats and dogs. 
 
Macedonia 
   The purpose of this investigation was to introduce a technology for the production of ready-to-use cold kit 
formulations for the labelling of conjugated DOTA-Rituximab and peptide-based ligands (Substance-P) with Lu-
177 and Y-90, and to standardize the methods for synthesis and conjugation.  In a parallel study, the biological 
properties and pharmacokinetic behaviours of radiolabelled DOTA-Rituximab and Substance-P were 
investigated to compare and determine their toxicities and therapeutic efficacies using model systems comprising 
both isolated cell cultures and laboratory animals. 
 
   A preliminary study on Substance-P (SP) has been pursued with the aim to obtain a peptide derivative suitable 
for labelling with Tc-99m and Re-188. For this purpose, modified Substance-P peptides (Cys-Cys-SP/PCN for 
Tc-99m labeling and IsoCys-Cys-SP/PCN for Re-188 labelling) were prepared and labelled with Tc-99m and 
Re-188 and the resulting characteristics were examined including biodistribution studies in normal mice. 
 
   The other part of our work was devoted to establish an efficient freeze-drying procedure for developing a final 
kit formulation for simple antibody labelling. The procedure for freeze-drying should provide a stable ready-to-
use kit formulation, having the same labelling efficiency as established for the freshly prepared laboratory 
preparation. The freeze-dried formulation should preserve the same immunoreactivity of the antibody before and 
after conjugation as already observed for the liquid formulation. For this reason, we focused our study on the 
evaluation of the most important steps required to set up a sutable freeze-drying protocol and, in particular, to 
estimate the optimal time for lyophilization of the monoclonal antibody during each phase of the process, e.g., 
(a) pre-freezing, (b) primary drying and (c) secondary drying. 
 
Poland 
   DTPA- or DOTA-chelated antibodies have been proved to be effective in radioimmunotherapy of cancer after 
radiolabelling with beta-emitting radiometals. The standardization of methods for conjugation of suitable 
chelators to monoclonal antibodies and the further pharmaceutical development of these conjugates were 
planned within the framework of an IAEA coordinated research project aimed at developing 
radiopharmaceuticals labelled with 90Y or 177Lu. Therefore, our study was focused on the development of a 
freeze-dried kit formulation based on DOTA-anti-CD20 Rituximab for 177Lu labeling as potential 
radiopharmaceutical for radionuclide therapy. 
 
Saudi Arabia 
   The main purpose of this research project was to develop 90Y and 177Lu-labeled bioactive compounds 
(antibodies and peptides) for targeting of human cancers. A number of peptides have been prepared by solid-
phase peptide synthesis according to Fmoc/HBTU chemistry. After radiolabeling with 177Lu radionuclide, these 
compounds were evaluated for their potential as radiotherapeutic agents. The results of these evaluations are 
discussed. 
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Syria 
   The general scope of the CRP project is the development of peptide- and antibody-based radiopharmaceuticals 
labelled with 177Lu and 90Y to be applied to tumour treatment.  We defined many specific objectives such as: (a) 
preparation of 177Lu- or 90Y-labeled DOTA-Rituximab as therapeutic radiopharmaceutical for the treatment of  
non-Hodgkin’s lymphomas following two different conjugation approaches using as bifunctional chelating 
agents (BFCA) the ligands p-SCN-Bz-DTPA and p-SCN-Bz DOTA, and (b) optimization of labelling technique 
(incubation time, optimal pH, temperature, specific activity) of conjugated-MoAbs  and of protocols for 
developing a kit formulation for radiolabelling Rituximab with 177Lu and 90Y. 
 
 
  
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A 
 
 
 
Country reports 
 
 
 
  
24 
ARGENTINA 
 
Production of Lu-177 for labelling antibodys and peptides 
 
J.L. Crudo1, N.N. Nevares1, A.C. Lopez Bularte1, A.M. Zapata1, J.H. Perez1, A. Saretsky2, N. Puerta 
Yepes3, A. Rojo3. 
  
1. Basic and Applied Radiopharmacy Division, Ezeiza Atomic Center, National Atomic Energy Commission, 2 
High dosis dosimetry Division, Ezeiza Atomic Center, National Atomic Energy Commission, 3 Internal 
Dosimetry Division, Nuclear Regulatory Authority, Buenos Aires, Argentina. 
 
 
Abstract. In this report we briefly describe the work carried out in our laboratory during the first part of the Co-
ordinated Research Project (CRP). Its includes new results in the experimental production of High Specific 
Activity (H.S.A.) 177Lu, determination of 177mLu /177Lu level , conjugation of SCN-Bz-DTPA with Rituximab®, 
radiolabelling of DTPA-Rituximab with locally produced 177Lu, in vitro stability test of 177Lu- DTPA-Rituximab, 
challenge of 177Lu- DTPA-Rituximab with DTPA and preparation of  DTPA-Rituximab in a kit form. In 
reference to 177Lu-DOTA-peptides we evaluated the in vivo renal protecction effect of the arginine infusion in 
177Lu-DOTA-Substance P injected mice. Dosimetrical calculations and extrapolation to normal patients were 
done using the OLINDA program. Regarding to the other radiolabelled peptide, preliminary 177Lu-DOTA-His2-
MG11 biodistribution studies in nude mice with A431 CCK+ human cells were initiated. Collaboration with the 
Austrian counterpart was established through a training period at the Nuclear Medicine Department of the 
Insbruck University, in the field of new DOTA-Minigastrin analogues synthesis and internalization studies. 
 
1. Introduction 
 
   Radioimmunotherapy (RIT) and Peptide Receptor Radionuclide Therapy (PRRT) are two important fields of 
the Nuclear Medicine which require the development of new targeted radiotherapeutics particularly for the 
treatment of B-cell lymphomas, malignant brain tumour and neuroendocrine tumours. During the last 15 years 
we were working at the Radiopharmacy Division in the research and development of new radiopharmaceuticals 
for cancer radionuclide therapy based on different beta negative emitters. The recent local experimental 
production of H.S.A 177Lu, a low-energy β-emitter, allow us the possibility to obtain high radiochemical purity 
radiopharmaceuticals such us 177Lu-benzyl-DTPA-Rituximab, 177Lu-DOTA-Substance P and 177Lu-DOTA-His2-
MG11 for in vivo evaluation in mice. The collaboration with the austrian counterpart make possilbly to initiate 
177Lu-DOTA-His2-MG11 biodistribution studies in nude mice with A431 CCK+ human cells (gifted by the 
austrian group). 177Lu-DOTA-Substance P dosimetrical calculations and extrapolation to normal patients were 
done in order to quantify the arginine renal protecction effect. 
 
2. Objective 
 
   The main objective of the present work was to obtain 177Lu-Bz-DTPA-Rituximab and Bz-DTPA-Rituximab in 
a freeze-dried kit form for labelling with the local produced 177Lu. The second aim was to evaluate 177Lu-DOTA-
His2-MG11 in tumored nude mice and to quantify the arginine renal protecction effect in normal mice injected 
with 177Lu-DOTA-Substance P. 
 
3. Description of the work done during the first year of the CRP 
 
   Our activities during the first year were divided into eigth parts: 
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3.1. S.A. improvement in 177Lu experimental production. 
 
   During the period 2011 (2012), 7 (2) targets were irradiated. Total activity produced was 173.82 mCi at the 
end of bombardment (EOB). During the last part of 2011 and 2012 the irradiation time of the target was 
extended from 3 to 4 irradiation cycles in order to obtain a higher 177Lu S.A. than before [1]. The target 
irradiation was done at the RA-3 maximum thermal neutron flux (neutron trap position). The level of 177mLu / 
177Lu was 105 ppm for a 14.84-day irradiation. Calculated 177Lu S.A. obtained irradiating the enriched target 
82.0 % 176Lu (provided by the Agency) was approximately 24.1-27.88 Ci/mg at EOB. The highest S.A. obtained 
at the labelling time was 23.98 Ci/mg. This 177Lu S.A. was enough for radiolabelling biomolecules such as 
DOTA-SP and monoclonal antibodies with high radiochemical yield.  
 
3.2. Conjugation of SCN-Bz-DTPA chelator to MoAb anti CD20 
 
   The conjugation of p-SCN-Bz-DTPA (Macrocyclics, USA) to 10 mg of Rituximab (c= 10 mg/mL) (Roche, 
Argentina) were carried out  at a molar ratio 20:1 (pH 9, 37 ºC) during 1 h.  
The product was purified by centrifugation using a Vivaspin 4 filter (Sartorius, Argentina). The preparation of a 
freeze-dried kit of Bz-DTPA-Rituximab for instant labeling with 177Lu was described in reference [2].  
 
3.3. Labelling of DTPA-Rituximab using 177Lu locally produced 
 
1 mg of Bz-DTPA-Rituximab (+ 150 µl of ammonium acetate 1M pH 7) was radiolabelled with 2,0-2,5 mCi of 
177LuCl3 (S.A. = 15.7-18,3 mCi/µg of Lu-176). The incubation conditions were 30 min. at 37 ºC. The 
radiochemical purity of the 177Lu-Bz-DTPA-Rituximab determined by HPLC-Gel Permeation was 99.5 % and 
the S.A. was 2 mCi/mg of protein. .  
   In the case of the freeze-dried kit of Bz-DTPA-Rituximab labelled with 177Lu (S.A. = 9.21 mCi/µg), the 
radiochemical purity was between 95-99 %. 
 
3.4. In vitro stability of 177Lu-Bz-DTPA-Rituximab   
 
   The radiolabelled product was challenged with c-DTPA using a molar ratio from 1:1 up to 1:1000, and 
measuring radiochemical purity at 1 and 24 h. The percentages of 177Lu transchelation for each molar ratio were 
5 % and 2% at 1 h, and 8 % and 5 % at 24 h, respectively. 
   The results of 177Lu transchelated corrresponding to the product obtained from the frezee-dried kit were 9.1 % 
and 17.2% at 1 h respectively and 69.4 % and 99.9 % at 24 h respectively. 
 
3.5. In vivo stability of 177Lu-Bz-DTPA-Rituximab  
 
   Biodistribution in normal mice for the 177Lu-Bz-DTPA-Rituximab are listed in Table 1.  
 
 
TABLE 1. Biodistribution of 177Lu-Bz-DTPA-Rituximab expressed as % of Injected activity/ per gram of tissue 
(% I.A./g). 
__________________________________________________ 
Time p.i.            2h                        24h                   48h 
__________________________________________________ 
Blood         24,25  ± 3,22   14,26 ± 3,20 12,25 ± 2,29 
Liver             4,35  ± 0,68   5,44 ± 0,33   5,24 ± 1,76 
Spleen           3,16  ± 0,30   2,85 ± 0,32   2,54 ± 0,22 
Kidney          4,77  ± 0,41   3,57 ± 0,41   3,33 ± 0,55 
26 
Stomach        0,92  ± 0,16   1,22 ± 0,13   0,58 ± 0,11 
Intestine        0,89  ± 0,20   0,65 ± 0,11   0,49 ± 0,18 
Lungs            6,00  ± 0,70   4,11 ± 0,38   3,42 ± 0,26 
Fémur rigth   1,54  ± 0,06   1,83 ± 0,21   1,77 ± 0,28 
Fémur left     1,57 ±  0,08   1,86 ± 0,15   1,74 ± 0,27 
___________________________________________________ 
 
   The results showed a low accumulation in fémur (less than 2 % I.A./g) at 48 h p.i. It means that the product do 
not present in vivo unstability by 177Lu transchelation. 
 
3.6. Preliminary results of 177Lu-DOTA-His2-MG11 biodistribution in a nude mouse with and without A431 
CCK+ human cells at 1 h p.i. 
 
   DOTA-His2-MG was labelled with 177Lu locally produced  (S.A. 14.5 mCi/µg) by the well-established 
technique. One nude mouse was inoculated subcutaneously with 10^6 A431 cells CCK+. After 10 days the 
tumored mouse and a normal mouse were injected with 20 µCi of 177Lu-DOTA-His2-MG11. Biodistribution 
were carried out at 1 h p.i. and the results expressed as % of injected activity (Fig.1) as a consecuence of a 
relative big tumor mass (2.46 g). The accumulation in the tumor at 1 h was as 3.38 % I.A. 
 
 
 
 
FIG.1. Biodistribution of  177Lu-DOTA-His2-MG11 in a normal nude mouse (red bars) and in a nude mouse 
bearing A431 CCK+ cells (blue bars) at 1 h p.i.   
 
 
3.7. Biodistribution 177Lu-DOTA-SP in normal mice with and without arginine infusion 
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   In a previous work [3], 177Lu-DOTA-Substance P was evaluated in normal mice and dosimetrical calculations 
were done in order to extrapolate the dose to patients. 
   The renal protection effect of arginine in normal mice injected with 177Lu-DOTA-Substance P was studied. 
Statistical comparison between treated and non treated mice were done [4]. There was statistically significant 
difference in the average 177Lu-DOTA-SP renal accumulation beetween the two groups without and with 
arginine (Fig. 2) at 30 and 120 min. p.i. 
 
 
 
FIG.2. 177Lu-DOTA-SP  renal accumulation: comparison between non treated (left box) and arginine treated 
mice (rigth box) at 30 and 120 min p.i respectively. 
 
 
   However, there was not statistically significant difference beetween the average of two groups (Fig.3) at 360 
min. p.i. 
 
 
FIG.3. 177Lu-DOTA-SP renal accumulation: comparison between non treated (left box) and arginine treated 
mice (rigth box) at 360  min p.i. 
 
 
3.8. Internal dose assessment in 177Lu-DOTA-SP injected mice with and without arginine  and extrapolation 
to standar human patients 
 
   Absorbed dose from 177Lu-DOTA-SP per unit of I.A. for two conditions, with and without prior administration 
of arginine, in organs of the NIH mouse, adult female (56,9 kg ) and adult male (76,7 kg ) is showed in Table 2. 
All this work were made in collaboration with the Dosimetric Group (Nuclear Regulatory Authority) [5]. 
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TABLE 2. Absorbed dose from 177Lu-DOTA-SP per unit of I.A (mGy/MBq) for NIH mouse with and without 
arginine and extrapolation to standard women and man. 
 
Organs 
Absorbed Dose (mGy/MBq) 
with Arginine without Arginine 
Mouse Woman Man Mouse Woman Man 
Kidneys 115.07 1.04 1.16 139.9 1.15 1.59 
Liver 8.47 0.06 0.06 4.61 0.02 0.03 
Lungs 17.05 0.02 0.02 14.57 0.06 0.05 
Stomach 5.64 0.01 0.01 9.67 0.05 0.05 
Spleen 27.70 0.09 0.07 14.85 0.05 0.05 
Intestine 1.81 0.10 0.10 4.66 0.22 0.22 
Bone Marrow 0.57 0.01 0.01 0.51 0.01 0.01 
 
 
   The Maximum tolerated activity (MAT) is the calculated maximum activity of 177Lu-DOTA-SP that can be 
administered to patients (Table 3) without exceeding the tolerance dose of the kidneys (20 Gy). 
 
TABLE 3. Maximum tolerated activity (MBq/kg) of 177Lu-DOTA-SP for women and man with and without 
arginine. 
 
MAT for case with Arginine MAT for case without Arginine 
Woman 
(MBq/kg) 
Man 
(MBq/kg) 
Woman 
(MBq/kg) 
Man 
(MBq/kg) 
338 234 306 170 
 
 
4. Description of the work proposal for the rest of the CRP 
 
4.1. Conjugation of SCN-Bz-DOTA and 1B4M-DTPA (2-(4-iso-tio-ciano-bencil)-6-metil-DTPA) to MoAb anti 
CD20 
 
   This study will be conducted according to the established protocols and compared with the results obtaine by 
the other participating groups. 
 
4.2. Preparation of a freeze-dried kit of DOTA-Rituximab and 6-CH3-DTPA-Rituximab for instant labelling 
with 177Lu and 90Y 
 
   Freeze-dried kit formulations for antobody’s labelling will be checked for stability and labelling efficiency. 
 
4.3. In vitro binding studies of the different radiolabelled products 
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   The in vitro binding studies of the products will be performed, in order to determine its biological activity after 
the labelling procedure. In the case of radiolabelled Rituximab the target will be, B-cells from human 
leucopheresis and Raji cells from Burkit`s lymphoma. 
 
4.4. Biodistribution and dosimetrical studies of the different radiolabelled products 
 
   Biodistribution and dosimetrical studies will be carried out in normal mice and in tumored nude mice (if 
available) for 90Y-SCN-Bz-DTPA-Rituximab, 177Lu(90Y)-SCN-Bz-DOTA-Rituximab [6] and 177Lu(90Y)-1B4M-
DTPA-Rituximab. We will extend the research to other potential candidates as a monoclonal antibodies and new 
universal bombesine-DOTA labelled with 177Lu depending on its availability. 
 
4.5. Biodistribution and dosimetrical studies of the 177Lu(90Y)-DOTA-Minigastrin analogues 
 
   In the near future we expect to radiolabel two new DOTA-Minigastrin analogues (gifted by the Austrian 
counterpart) with 177Lu and 90Y, to carry out internalization studies in A431 CCK+ cells and in vivo evaluation 
studies in tumored nude mice bearing A431 CCK+ cells. If the result were successfull we will initiate 
dosimetrical pre-clinical studies. 
 
5. Collaboration among participants 
 
   Collaboration with the Austrian counterpart was established through a training period at the Nuclear Medicine 
Department of the Insbruck University, in the field of new DOTA-Minigastrin analogues synthesis and 
internalization studies.  
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1. Introduction 
 
   The use of radiolabelled antibodies and peptides for targeted radionuclide therapy of cancer is an established 
procedure in nuclear medicine. Beside the clinical use of 90Y-DOTA-TOC and 177Lu-DOTA-TATE for treatment 
of neuroendocrine tumours our department is continuously working on the development of novel 
radiopharmaceuticals based on other peptide analogues. 
Within the first year of this project we designed new minigastrin (MG) analogues based on DOTA-MG11. The 
new peptide derivatives contain unnatural amino acids in the peptide sequence with the aim to stabilize the 
peptide analogue against enzymatic degradation. The new derivatives have been radiolabelled with In-111 for a 
first preclinical evaluation in vitro. 
Another contribution of our department was the further optimization of the clinical preparation of Lu-177 and Y-
90 labelled radiopeptides. In this respect we evaluated the possibility to reduce radiolysis and elaborated 
procedures for the quantification of the total peptide amount in the final preparation.  
 
2. New minigastrin analogues based on DOTA-MG11 
 
   Under the premise that the radiolabelled MG analogues developed so far are not suitable for clinical 
application, we have investigated new derivatization strategies. Our current research efforts are focused on the 
development of alternative peptide analogues with improved pharmacokinetics and targeting properties. Native 
MG contains a methionine residue in the C-terminal receptor specific sequence –Trp-Met-Asp-Phe-NH2. This 
poses the risk of oxidation when a heating step is involved in the radiolabelling step. We have shown that 
oxidation of methionine results in loss of receptor affinity (1). For the substitution of methionine with other 
amino acids we found a retained cell internalization and tumour uptake for substitution with norleucine, whereas 
substitution with isoleucine again resulted in loss of receptor affinity (1,2). It is known that linear peptide 
analogues are rapidly metabolized by peptidases in vivo. Classical strategies to improve the stability of peptides 
are d-amino acid substitutions, modification of N- and C-terminus (N-acetylation and C-amidation), replacement 
of labile amino acids and cyclization. Cyclization was already successfully used for the metabolic stabilization of 
radiolabelled somatostatin (3) and RGD (=Arg-Gly-Asp) (4) analogues. With a cyclic MG analogue based on 
MG11 we were however able to obtain only a partial stabilization against degradation (5). In collaboration with 
Turkey we have determined the enzymatic cleavage sites for a number of MG analogues analyzing the 
metabolites formed after incubation in serum using MALDI-TOF mass spectrometry (6). Based on the obtained 
results we were able to design new alternative stabilization strategies (see Figure 1). 
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FIG. 1. Cleavage site of different MG analogues characterized by MALDI-TOF MS. 
 
   As at the C-terminal receptor binding sequence we found a major cleavage site between Asp and Phe-NH2 we 
focused on the modification in this particular region of the peptide sequence. Additionally, we have investigated 
substitution possibilities for Met which is sensitive to oxidation in heating steps required for radiolabelling. We 
initially synthesized two peptide analogues, DOTA-MGS2 where Phe in position 8 was substituted with (N-
Me)Phe and DOTA-MGS4 where Met in position 6 was additionally substituted with (N-Me)Nle. 
   The radiolabelling conditions were investigated using three different buffer systems: 1) the Polatom kit 
containing 50 mg ascorbic acid pH 4.5, 2) 0.4 M ammonium acetate pH 5.5, 3) 0.2 M 2-(N-
morpholino)ethanesulfonic acid (MES) pH 5.5. The best radiolabelling yield was obtained by using 100 µl MES 
buffer together with 30 µg peptide and 50 µl 111In-chloride solution and heating at 95°C for 25 min. Met-
oxidation was avoided by addition of 4 mg seleno-methionine. For in vitro characterization experiments the 
radiolabelling mixture was subjected to solid phase extraction on a SepPak Light cartridge (Waters, Milford, 
USA). 
   The determination of the distribution coefficient at pH 7.4 in a 1:1 mixture of phosphate buffered saline and 
octanol showed a similar log D value for 111In-DOTA-MG11 (-3.55 ± 0.23; n=6) and 111In-DOTA-MGS2 (-3.46 
± 0.19; n=6), while 111In-DOTA-MGS4 (-2.49 ± 0.06; n=6) showed a somewhat higher lipophilicity. The protein 
binding as determined by incubation in fresh human serum at 37°C and Sephadex G-50 size-exclusion 
chromatography (MicroSpin, GE-Healthcare Life Sciences, Vienna, Austria) up to 24 h after incubation resulted 
to be higher for both 111In-DOTA-MGS2 and 111In-DOTA-MGS4 in comparison with 111In-DOTA-MG11 (see 
Figure 2). 
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FIG. 2. Protein binding of 111In-DOTA-MGS2 and 111In-DOTA-MGS4 in comparison with 111In-DOTA-MG11. 
 
 
   The stability of the radiolabelled peptides was investigated by incubation in fresh human serum at a 
concentration of 4000 pmol peptide/mL at 37°C for up to 24 h. Degradation of the radioligands was assessed by 
radio-HPLC after precipitation with ACN and centrifugation at 2000 g for 2 min (centrifuge 5424, Eppendorf 
AG, Germany). 
   As shown in figure 3, 111In-DOTA-MGS2 and 111In-DOTA-MGS4 showed a much higher resistance against 
enzymatic degradation in comparison with 111In-DOTA-MG11. Even 24 h after incubation still more than 80% 
of the intact radiopeptide was present, whereas for 111In-DOTA-MG11 this value was only 12% confirming the 
low stability of this peptide analogue.  
   In competitive receptor binding assays on AR42J cells and A431 cells transfected with the human CCK-2 
receptor (A431-CCK+), using [125I]Tyr12-Gastrin I and increasing concentrations of DOTA-peptide, DOTA-
MGS2 (IC50 25-45 nM) showed an impaired binding affinity in comparison with DOTA-MG11 (IC50 2.5-5.5 
nM), whereas DOTA-MGS4 again showed a good binding affinity (IC50 5.0-5.5 nM). In accordance with the 
results of the binding affinity experiments, 111In-DOTA-MGS4 showed a cell uptake of >10% of the total 
radioactivity added in both cell lines which was comparable with 111In-DOTA-MG11, while 111In-DOTA-MGS2 
showed a much lower uptake of less than 5%. 
 
 
33 
 
 
FIG. 3. Stability in human serum of 111In-DOTA-MGS2 and 111In-DOTA-MGS4 in comparison with 111In-DOTA-
MG11 (dotted line: radiochemical purity after preparation; solid line: radiochromatogram after 24 h incubation 
in human serum). 
 
   In collaboration with Argentina two other peptide derivatives were synthesized. DOTA-MGS6 beside 
substitution in position 8 shows the substitution with the respective D-amino acid of Trp in position 5, and 
DOTA-MGS7 shows an additional D-amino acid substitution of Tyr in position 3. Unfortunately, DOTA-MGS6 
according to MALDI-TOF MS after the purification at the end of synthesis resulted to be completely oxidized, 
only the mass corresponding to the Met-sulfoxide was detected. The peptide analogue has to be subjected to 
reduction of Met-sulfoxide before performing a further characterization in vitro. DOTA-MGS7 labelled with In-
111 showed a very good stability against enzymatic degradation. However, in cell uptake studies performed with 
both cell lines no specific uptake could be obtained. The reason for this might be the conformational changes 
introduced by the two D-amino acid substitutions resulting in loss of receptor affinity. 
 
3. Optimization of clinical formulations  
 
The preparation of 90Y-DOTA-TOC and 177Lu-DOTA-TATE is routinely performed in an automated cassette 
based synthesis module (Eckert&Ziegler, Berlin, Germany). After the reaction the solution is subjected to solid 
phase extraction on a SepPak tC18-cartridge (Waters, Milford, USA) and sterile filtration. The final solution 
contains 8-24 GBq Lu-177 or 4-10 GBq Y-90, ~200-600 µg DOTA-peptide, 2-3% ethanol and 0.9% sodium 
chloride solution to obtain a total volume of 20 ml. The original reaction solution contains ascorbic acid which is 
stabilizing the solution against radiolysis. As the final solution does not contain a stabilizing agent we performed 
stability studies at room temperature, 5°C and -20°C on the final preparation showing that in these conditions the 
final formulation was stable only for 4 h. After 1 day storage only 70% of the intact radiopeptide was present 
and after 3 days the stability dropped to 16-32%. To see if we are able to stabilize the final formulation against 
radiolysis we added a stabilization buffer containing ascorbic acid and sodium chloride, adjusted to pH 5. The 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 33 min
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 33 min
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storage at the different storage conditions was tested for up to 3 weeks and the obtained results are summarized 
in Table 1.  
 
TABLE 1. Stability of 177Lu-DOTA-TATE in stabilization buffer at different storage conditions 
Storage at 1 day 3 days 7 days 15 days 21 days 
RT 94.2 88.9 86.0 74.9 yellow solution 
5°C 94.6 91.7 93.1 91.3 81.6 
-20°C 94.3 94.7 93.5 93.2 87.2 
      
 
 
 
 
FIG. 4. Radiochromatograms of 177Lu-DOTA-TATE in stabilization buffer at different storage conditions: A) 
room temperature 24 h, B) +5°C 2 weeks, C) -20°C 2 weeks. 
 
 
   By adding the stabilization buffer we were able to stabilize the final formulation at room temperature for 24 h 
and for 2 weeks when the product was stored at +5°C or -20°C. In figure 4 the radiochromatograms are shown 
for the different storage conditions at these time points.  
For the determination of the radiochemical purity we are using a combination of HPLC and TLC. The HPLC-
gradient is based on a gradient system of acetonitrile/water/TFA and was optimized to allow the identification of 
different DOTA-peptides radiolabelled with different radiometals. Beside identification also the quantification of 
the total DOTA-peptide amount in the final preparation is an important parameter in the quality control. The 
problem in this regard is that for the HPLC analysis only a very small aliquot containing less than 1 µg DOTA-
peptide is used. Based on a UV standard curve using a range of 0.1 to 0.8 µg DOTA-peptide we calculated the 
peptide amount of different preparations of 90Y-DOTA-TOC and 177Lu-DOTA-TATE. All found UV-peaks 
corresponding to the unlabelled und labelled peptide were included in the calculation. When comparing the total 
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peptide amount used for the radiolabelling and the peptide amount calculated from the UV-HPLC analysis we 
found a deviation of ±20-30% allowing only a rough estimation of the peptide amount in the final formulation. 
 
4. Conclusions 
 
Within the first year of the CRP we have proceeded in developing new stabilized MG analogues showing 
promising results in vitro supporting further studies. Furthermore, we continuously improve our technology for 
the preparation and application of 177Lu- and 90Y-labelled peptides for targeted radionuclide therapy, focussing 
on the automation of the radiolabelling process and optimization of the quality assurance. A future activity in 
this direction will be the optimization of the automated dispensing and infusion of the single dose to the patient. 
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1. Introduction 
 
   The Radiopharmacy Department of the Nuclear and Energy Research Institute in São Paulo, Brazil (IPEN-
CNEN) produces radiopharmaceuticals for Nuclear Medicine including 99Mo-99mTc generators, lyophilized kits 
for labelling with technetium-99m, iodine-131 (solution and capsules), iodine-123, gallium citrate (67Ga), 
thallium chloride (201Tl), and some labelled molecules, including 131/123I-MIBG, 131I-lipiodol, 153Sm-EDTMP, 
153/90Y-Hydroxiapatate, 177Lu-DOTATATE, 111In-DTPA-Octreotide and 18F-FDG.  
   The success in the area of somatostatin receptor-positive tumor targeting with diagnostic and therapeutic 
radionuclides [1] has stimulated research toward radionuclide targeting of alternative receptor systems 
overexpressed in tumors. Considering this, promising results have been obtained by IPEN group in the field of 
development of novel peptides for tumor radionuclide therapy (bombesin and substance P) and methods for 
antibody conjugation to chelating group and labelling with 177Lu. Further investigations should be done applying 
the peptides and antibody labelled with 177Lu and 90Y.  
   In designing radiometal-based radiopharmaceuticals for cancer treatment, important factors to consider are 
half-life, mode of decay, cost and availability of the radionuclide and the chemical and biological properties of 
the labelled molecule. In the field of radiolabelled molecules, substance P (SP), bombesin and Rituximab appear 
as promising molecules for radiopharmaceutical design, because they can target specifically to receptors present 
mainly in glioblastoma, prostate cancer and non-Hodgkin lymphoma, respectively.  
We have developed 177Lu-labelling protocols for DOTA-SP [2] and DOTA- bombesin derivatives [3,4] and 
procedures for Rituximab conjugation to DOTA chelators followed by 177Lu-labelling. High radiochemical 
purity radiopeptides were obtained and high stability under storage at 4° C was observed, especially when 
stabilizers were applied.  
   During this project, the DOTA and DTPA-peptides and Rituximab will be radiolabelled with 177Lu, applying 
our previous knowledge and a method for their 90Y-labelling will be developed. The radiolabelled molecules will 
be evaluated in preclinical studies in healthy and tumour mice and also in in vitro tumor cells binding assays. 
The radiopharmaceuticals with the best performance after these evaluations will be studied in order to develop a 
formulation, which should follow the requirements for clinical applications. 
 
2. Objective 
 
   The general scope of this project is the development of peptides and antibody-based radiopharmaceuticals 
labelled with 177Lu and 90Y to be applied in tumour treatment.  
   The specific objectives of the project are: (I) Development of a radiopharmaceutical based on Substance P for 
brain tumours radionuclide therapy; (II) development of a radiopharmaceutical based on Anti-CD20 for non-
Hodgkin lymphoma radionuclide therapy; (III) development of a radiopharmaceutical based on Bombesin for 
prostate and breast tumours radionuclide therapy. 
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3. Methods and Results 
 
3.1. Development of a radiopharmaceutical based on Substance P for brain tumours radionuclide therapy 
 
   We have studied the 177Lu-radiolabelling and stability of DOTA-Substance P-Met11 (DOTA-SP-Met11) [2]. 
Preliminary studies were done in order to establish the ideal labelling conditions for obtaining the highest yield 
of labelled DOTA-SP-Met11.  All reagents of these experiments were prepared with Chelex 100 treated free 
metal water. DOTA-SP, 0.4 M sodium acetate buffer (0.2 mL, pH 4.5) and 177LuCl3 in 0.05N HCl (specific 
activity 871 – 920 GBq/mg; IDB, Holland) were heated at different temperatures (70 – 90° C) for different time 
intervals (15 - 30 minutes). Good results were obtained (RP ≥ 99%) at 80oC for 30 minutes or 90oC for 15 to 30 
minutes. Radiochemical purity was also superior than 99% when 92.5 to 185.0 MBq of 177LuCl3 reacted with 10 
µg of DOTA-SP-Met11and decreases progressively from 96.8 to 74.7%, when using higher specific activities, 
25.9 and 40.7 MBq/µg, respectively. 
   During the first period of this CRP, this labelling protocol was applied to compare DOTA-SP-Met11with 
DOTA-SP-Nle11, a derivative of DOTA-Substance P in which the last amino acid (methionine) was replaced by 
Norleucine (Nle), especially in the field of stability under oxidation during labelling. DOTA-SP-Nle11labelled 
with 177Lu was submitted to preclinical evaluations in mice and cell binding studies.  
Additionally, DOTA-SP-Met11 and DOTA-SP-Nle11 were labelled with itrium-90 and the stability of the 
preparations was evaluated, using gentisic acid as stabilizer. 
 
 3.1.1 Study of reaction parameters for labelling DOTA-SP-Nle11 with 177Lu and analysis of oxidation during 
labelling 
 
   The following labelling parameters of DOTA-SP-Nle11 were evaluated: time reaction, temperature, mass of 
peptide and activity. The parameters defined as standard condition were 10µg of peptide; 74 MBq (2.0 mCi) of 
177Lu; 90°C; 30 min; 350 rpm. 
   To analyse the oxidation during labelling, DOTA-SP-Nle11 was radiolabelled with 177Lu using the standard 
condition. The amino acid methionine was also introduced in the labeling reaction (6mg/mL), in order to 
investigate the influence in the oxidation of the labelled peptide in comparison with the labeling of SP (Met11) 
with 177Lu.  
   Figure 1 shows the HPLC profile of 177Lu-labelled DOTA-SP-Met11 (A) and DOTA-SP-Nle11 (B) and the 
influence of the Methionine in the reaction medium in oxidation and stability of the preparations. 
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FIG. 1. HPLC profile of 177Lu-labelled DOTA-SP-Met11 (A) and DOTA-SP-Nle11 (B) with and without methionine 
(Met) in the reaction medium. A1: SP(Met11) without Met in reaction; B1: SP(Nle11) without Met in reaction; 
A2: SP(Met11) with Met in reaction; B2: SP(Nle11) with Met in reaction. 
 
   The labelling of DOTA-SP-Met11 with and without methionine in the reaction medium, resulted in different 
radiochemical species, as demonstrated in HPLC profile A (RT 10.3 and 11.05 minutes), probably related to the 
oxidised and non-oxidised form of the labelled peptide, respectively, considering the oxidation of the Met11 
residue in the protein. When DOTA-SP-Nle11 was labelled with 177Lu, the influence of methionine in the reaction 
was not observed and only one radiochemical form was observed in HPLC profiles (B). As expected, the 
substitution of Met11 for Nle11 prevented the oxidation of the labelled peptide.  
 
3.1.2 Study of stability of  177Lu –DOTA-SP-Nle11 in human serum and after storing under freezing and 
refrigeration and in the absence or presence of stabilizers 
 
   Stability studies were performed after labelling 100 µg de DOTA-SP-Nle11 with 1480 MBq (40 mCi) of 177Lu 
at 90°C, 30 min; 350 rpm and final volume of 130 µL. Aliquots of 3 mCi of the preparation were incubated in 
human serum at 37oC for 1, 4 and 24 hrs. The remaining activity was divided in two aliquots and incubated in 
freezer (-20oC) and refrigerator (2-8oC) for 48 and 168 hours, respectively. Radiochemical purity was 
determinated by TLC (Table 1) and also by HPLC to the samples stored in refrigerator and freezer.  
   Stability studies were also performed after labelling 20 µg de DOTA-SP(Nle11) with 333 MBq (9 mCi) of 177Lu 
at 90°C, 30 min; 350 rpm, and 130µL of final volume,  with the addition of ascorbic acid or gentisic acid as 
stabilizers (6mg/mL) immediately after labelling. An aliquot of  88.8 MBq (2.4 mCi) of the preparation was 
incubated in human serum for 1, 4 and 24 hrs and the remaining activity was divided equally and stored under 
refrigeration or freezer. Radiochemical purity was determinate by TLC (Table 1) and also by HPLC to the 
samples stored in freezer and refrigerator. 
 
TABLE 1. Stability of 177Lu –DOTA-SP-Nle11 under different conditions and stabilizers: % RCP determined by 
TLC. 
STABILITY - % RCP DETERMINED BY TLC 
TIME SERUM (37oC) 
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(min) Without 
stabilizer With Ascorbic Acid With gentisic acid 
0 97.9 ± 0.6 98.8 ± 0.3 98.2 ± 0.1 
1 96.6 ± 0.2 97.9 ± 0.5 98.8 ± 0.1 
4 98.5 ± 0.4 98.4 ± 0.1 98.8 ± 0.1 
24 98.0 ± 0.1 98.0 ± 0.1 97.8 ± 0.3 
TIME 
(min) 
FREEZER (-20oC) 
Without 
stabilizer With Ascorbic Acid With gentisic acid 
0 97.9 ± 0.6 98.8 ± 0.3 98.2 ± 0.1 
24 96.1 ± 0.1 97.0 ± 0.8 97.3 ± 0.7 
TIME 
(min) 
REFRIGERATOR (2-8oC) 
Without 
stabilizer With Ascorbic Acid With gentisic acid 
0 97. 9 ± 0.6 98.8 ± 0.3 98.2 ± 0.1 
24 77.5 ± 2.5 89.3 ± 0.1 92.9 ± 0.2 
48 73.9 ± 0.2 86.6 ± 0.5 91.2 ± 1.4 
96 57.3 ± 0.2 88.6 ± 0.7 92.1 ± 0.7 
120 58.6 ± 0.5 85.7 ± 0.5 89.5 ± 0.7 
 
 
3.1.3 Biodistribution of   177Lu –DOTA-SP-Nle11 in Balb-c mice 
 
   Biodistribution studies were performed in Balb-c healthy mice, after intravenous administration of 1.67 MBq 
(45 µCi)/100µL of the labelled peptide (3 animals for each time). The animals were sacrificed at 1, 4 and 24 
hours after administration and the organs were removed, weighted and the radioactivity determined in an 
automated gamma counter. Blood samples were collected for each time. The results were expressed as percent of 
injected activity (%IA) per gram of organ (Table 2).  
 
 
TABLE 2. Biodistribution of 177Lu –DOTA-SP-Nle11 in Balb-c mice in %IA/g 
 
% IA/g  (n=3) 
ORGAN 1 Hour 4 Hours 24 Hours 
Blood 0.294 ± 0.018 0.047 ± 0.025 0.012 ± 0.003 
Heart 0.187 ± 0.053 0.014 ± 0.005 0.008 ± 0.003 
Lungs 0.360 ± 0.070 0.080 ± 0.005 0.021 ± 0.006 
Pancreas 0.136 ± 0.030 0.49 ± 0.016 0.011 ± 0.002 
Spleen 0.305 ± 0.069 0.092 ± 0.015 0.035 ± 0.010 
Stomach 0.207 ± 0.070 0.073 ± 0.016 0.033 ± 0.010 
Liver 0.129 ± 0.040 0.197 ± 0.033 0.061 ± 0.013 
Kidneys 3.031 ± 0.547 1.391 ± 0.270 0.605 ± 0.138 
Intestines 0.479 ± 0.089 0.356 ± 0.075 0.173 ± 0.027 
40 
Muscle 0.110 ± 0.025 0.011 ± 0.002 0.004 ± 0.001 
Bone 0.655 ± 0.139 0.291 ± 0.088 0.524 ± 0.121 
Brain 0.022 ± 0.002 0.005 ± 0.001 0.005 ± 0.001 
 
 
3.1.4 Labelling of DOTA-SP-Nle11 with 90Y and stability studies 
 
   DOTA-SP Nle11 was labelled with Y-90 (Nordion, Canada), using similar conditions employed for 177Lu. The 
stability of the preparations were evaluated after 24 and 48 hours under freezing and in the presence of gentisic 
acid by TLC and HPLC.  
 
 
TABLE 3. Labelling of DOTA-SP-Nle11 with 90Y: 50 ug of peptide, 370 MBq (10 mCi) of 90YCl3; 30 minutes, 
90oC; 350 rpm – stability study with gentisic acid (n = 2). 
 
Labelling conditions 
Radiochemical Purity (%) 
Immediately 24 hours 48 hours 
With gentisic acid as stabilizer 
(6mg/mL) 97.4  ± 0.3 98.7  ± 0.7 98.1 ± 1.1 
 
 
   Figure 2 shows the HPLC profile of 90Y-DOTA-SP-Nle11 48 hours after labelling represented in the last table. 
 
 
 
FIG. 2. HPLC profile of 90Y-DOTA-SP-Nle11 48 hours after labelling, with gentisic acid as stabilizer (6 mg/mL) 
and stored under freezing. 
 
 
3.2. Development of a radiopharmaceutical based on Anti-CD20 for non-Hodgkin lymphoma radionuclide 
therapy 
 
   We have been studied the DOTA conjugation to Anti-CD20 (Rituximab) antibody and the 177Lu-radiolabelling 
as a part of the last CRP and the general methods employed are summarized as following. 
The pre-purification of the Rituximab solution was studied with Sephadex G-50 columns, dialysis and 
ultrafiltration tube (Vivaspin, MWCO 30,000, Pharmacia Biotech) using phosphate buffer pH 8.0. 
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   Three different chelators (p-SCN-Bn-DOTA, DOTA-NHS-ester and p- SCN-Bn-DTPA) were conjugated to 
Anti-CD20 antibody based on procedures previously described, [6-11], using 5-10 mg of antibody previously 
purified by ultrafiltration device. The reaction was conducted for 1 hour in phosphate buffer pH 8.0, and gently 
mixing at room temperature and remained for 24 to 48 hours under refrigeration. The molar Ab:chelator ratio 
employed were 1:50, 1:20; 1:10 and 1:5. Two aliquots of the reaction mixture (about 239 pmol of Ab) were 
separated to determine the average number of chelators per Ab as previously described [12]. 
   After conjugation, the sample was purified by Sephadex G50 column (1.5 x 20 cm) or ultrafiltration to change 
buffers (0.2 M acetate buffer pH 5.5) and remove the excess of chelator.  
177LuCl3  (111-148 MBq) was added to the conjugated Ab (0.25 to 5 mg) in 0.2 M acetate buffer pH 5.5 and the 
resultant solution was heated for 1 or 3 hours at 37oC or 43oC in a termomixer (Eppendorf). An aliquot of 10 
mM DTPA was added and allowed to react for 15 minutes at room temperature to bind any free radiometal. 
HPLC was performed with molecular exclusion column (BioSep SEC-S 3000) and 0.2M sodium phosphate 
buffer pH 7.0, flux of 1 mL/min for 25 minutes. 
   During the first period of this CRP, the conjugation parameters was studied, specially Ab:chelator molar ratio 
and the labelling parameters of this antibody with 177Lu to achieve a standard protocol for preparation of this 
new radiopharmaceutical. In vitro studies with CD20 positive tumor cells (RAJI) was developed in order to 
investigate the influence of conjugation and labelling conditions in the immunoreactivity of the antibody. 
Preclinical studies with the labelled antibody were performed in healthy animals. 
 
3.2.1 Conjugation of Anti-CD 20 antibody using DOTA-NHS-ester  
 
A) Study of the purification method 
   The purification of the Ab after conjugation with the chelating group is an important step in the preparation of 
an immunoconjugate. The presence of residual chelating groups in the preparation decreases the labelling of the 
radionuclide to the immunoconjugate. We studied different methods for purification of the immunoconjugate 
and ultrafiltration tube (Vivaspin, MWCO 30,000, Pharmacia Biotech) presented better results to remove the 
excess of chelator and also to reduce the final volume to a protein concentration of about 10 mg/mL (that is 
important to achieve good results in the labelling procedure). The ultrafiltration system significantly saves 
purification time and has high recovery efficiency when compared to Sephadex gel column purification. 
   To determine the number of centrifugations cycles using the ultrafiltration tube, necessary to remove the 
excess of chelator, the absorbance of the ultrafiltrated was determined (280 nm) after each centrifugation cycle 
(Figure  3). The experiment was repeated for each Ab:chelator molar ratio employed (1:5, 1:10, 1:20 and 1:50). 
At least seven cycles of centrifugation were necessary to remove all the excess of chelator after conjugation 
reactions. 
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FIG. 3. Absorbance of the ultrafiltrate (280 nm) in each cycle of centriugation (3000 g, 27 minutes under 
refrigeration).  
 
   Figure 4 shows the HPLC profiles of each ultrafiltrate fraction when 10 mg of Ab was conjugated to DOTA 
using a molar ratio of 1:50. The chromatograms show that the absorbance was reduced to half of value at each 
cycle of centrifugation and reached almost zero after the last centrifugation cycle. 
 
 
FIG. 4. HPLC profile of ultrafiltrate obtained at each cycle of centrifugation (1st to 7th) in the purification 
process of the Antibody conjugated with DOTA-NHS. 
 
 
   Another purification protocol was studied in order to reduce the number centrifugation cycles that can damage 
the antibody structure. This method used a previous purification of the conjugated antibody with Sephadex G25 
column, 10 cm (PD-10, Pharmacia) column, followed by two or three cycles of centrifugation. Eighth fractions 
of 1.0 mL were collected from P-10 column and analyzed by HPLC, so it was possible to identify the fractions 
corresponding to the conjugated antibody, which corresponds to the first three fractions (not shown). 
 
B) Conjugation using different Ab:DOTA-NHS molar ratios 
   The conjugation of DOTA-NHS to the Rituximab was performed as previously described, using different 
Ab:chelator molar ratios (1:5, 1:10, 1:20, 1:50 and 1:100). The final objective was to determine the influence of 
the number of chelating groups per antibody in the immunoreactivity and stability of the immunoconjugate. The 
conjugated obtained were analyzed by HPLC after purification by ultracentrifugation. 
   As expected, the conjugation of chelating groups to Rituximab, increases the molar weight of the antibody and 
decreases the retention time in the HPLC system employed (using a column of molecular exclusion) (Table 4). 
The HPLC profiles after purification show only one peak and confirm the efficiency of ultrafiltration as 
purification method. 
 
 
TABLE 4. HPLC retention time (RT) for Rituximab, DOTA-NHS-ester e Rituximab-DOTA (conjugated at 
diferente Ab:chelator molar ratios). 
 
Species Retention Time (minutes) in HPLC 
Rituximab 8.04 
43 
DOTA-NHS-éster 10.78 
Rituximab-DOTA (1:5) 7.95 
Rituximab-DOTA (1:10) 7.93 
Rituximab-DOTA (1:20) 7.88 
Rituximab-DOTA (1:50) 7.86 
Rituximab-DOTA (1:100) 7.80 
 
 
3.2.2 Labelling of  DOTA-NHS-Rituximab with 177Lu 
 
   The labelling of DOTA-Rituximab with 177Lu was performed with 1 mg of DOTA-rituximab, 148 MBq (4 
mCi) of 177LuCl3, 1 hour at 43° C and 350 rpm (Figure 5). 
 
 
 
FIG. 5. Radiochemical purity of 177Lu-DOTA-rituximab before and after purification by PD-10 column (n ≥ 3). 
 
 
   The labelled antibody can be purified using Sephadex G-25 column (PD10, Pharmacia), when radiochemical 
purity is inferior to 90%. The HPLC profile of purified labelled antibody are showed in the Figure 6. 
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FIG. 6. HPLC profile of 177Lu-DOTA-rituximab after purificaton in Sephadex colum (PD-10 Pharmacia). 
 
 
   The antibody conjugated in the most promising molar ratio (1:50), was radiolabelled with high activity (1480 
MBq / 40 mCi) of 177LuCl3 (Table 5). 
TABLE 5. Radiochemical purity of DOTA-Rituximab labelled with high activity of 177LuCl3: 5 mg of DOTA-
rituximab, 1480 MBq (40 mCi), 1 hour at 43° C and 350 rpm (n = 2). 
 
Molar ratio Radiochemical purity (%) 
1:50 80.56±0.08 
 
 
   The labelling of DOTA-Rituximab with 177LuCl3 was comparatively investigated using the isotope from 
different suppliers: IBD (870 - 920 MBq/mg) and ITG (non-carrier added) (Table 6).  
 
 
TABLE 6. 177Lu-DOTA-rituximab labelled with 177LuCl3 from IBD and ITG and storage at 2-8 °C. Labelling 
conditions: 1 mg, 37 MBq (1 mCi) of 177LuCl3, 1 hour at 43 °C, 350 rpm  (n = 1). 
 
Molar ratio 
177Lu- IBD 177Lu- ITG 
Immediately 24 hs after radiolabelling Immediately 
24 hs after 
radiolabelling 
1:20 77.61±0.004 53.15±0.15 92.80±0.013 91.70±0.004 
1:50 91.00±0.062 - 95.33±0.002 94.37±0.005 
 
 
3.2.3 Biodistribution of 177Lu-DOTA-NHS-Rituximab in Swiss mice 
 
   Biodistribution of 177Lu-DOTA-NHS-Rituximab was performed in healthy Swiss mice, after intravenous 
administration of 0.185MBq/0.1mL of the labelled antibody in the tail vein. Aliquots of blood was collected at 
different time intervals after dose administration and the animals were sacrificed, the organs removed, weighted 
and the radioactive determined in a gamma counter. The results were expressed as percent injected activity 
(%IA) per organ or per gram of organ, as following. 
 
 
TABLE 7. Biodistribution of 177Lu-DOTA-Rituximab (0.185 MBq) in healthy Swiss mice (n = 4). 
 
Organ 
Time after administration 
1 hour 4 hours 24 hours 48 hours 
% IA % IA /g % IA % IA /g % IA % IA /g % IA % IA/g 
Heart 0.90±0.1 7.98±1.2 1.01±0.1 9.09±4.4 0.56±0.1 4.52±0.7 0.64±0.0 5.63±1.3 
Lungs 1.61±0.3 8.23±3.0 1.54±0.3 7.01±3.0 1.38±0.1 5.77±1.1 1.47±0.4 5.86±2.1 
45 
Pancreas 0.54±0.1 2.81±0.4 0.97±0.2 3.86±1.3 0.54±0.1 2.92±0.4 0.45±0.1 2.09±0.4 
Spleen 0.61±0.1 7.51±2.6 0.51±0.1 4.92±2.4 1.58±0.4 8.45±3.2 0.75±0.2 6.74±2.8 
Stomach 0.86±0.2 1.18±0.2 1.21±0.1 1.12±0.3 1.28±0.3 1.80±0.3 0.93±0.1 1.06±0.5 
Liver 17.32±2.3 13.56±4.0 15.56±1.5 10.09±3.6 19.01±1.4 10.84±2.8 15.54±2.7 10.64±4.6 
Kidneys 3.12±0.3 7.47±0.8 3.49±0.4 8.20±0.9 2.66±0.2 5.65±1.3 2.23±0.2 5.19±1.1 
Intestines 4.40±0.4 1.51±0.3 6.44±0.3 1.96±0.8 4.97±0.4 1.47±0.3 4.10±0.3 1.29±0.3 
Muscle   0.23±0.1  1.09±0.4  0.11±0.0  0.52±0.4  0.30±0.0  1.27±0.2  0.25±0.0  1.16±0.3 
Bone  0.27±0.0  3.71±1.0  0.24±0.0  2.53±0.9  0.20±0.0  2.37±0.9  0.21±0.0  2.60±0.4 
Brain   0.31±0.1  0.78±0.5  0.40±0.0  0.87±0.1  0.30±0.1  0.68±0.3  0.42±0.0  1.00±0.2 
 
 
3.2.4 In vitro cell binding of  177Lu-DOTA-NHS-Rituximab  
 
   Specific binding assays were conducted for the antibody conjugated at molar ratios with higher radiochemical 
purity: 1:20, 1:50 and 1:100. The radiolabelled and purified antibody was diluted in medium with 1% of FBS 
(v/v) with a radioactive concentration of 400 cpm/µL. The non-radiolabeled antibody (4 µM in medium with 1% 
of FBS v/v) was used as a competitor. The assay was performed by adding different amounts of cells (0.125, 
0.25, 0.5 e 1.0 x 106 cells, in 0.5 mL of culture medium with 1% of FBS v/v) at conical tubes of 2 mL, followed 
by addition of 250 µL of medium (1 % FBS) (total binding) or 250 µL of competitor solution (non-specific 
binding) and 250 µL of diluted radiolabed antibody solution. The conical tubes were incubated by 1.5 hour at 
room temperature, centrifuged at 5000 g by 5 minutes, washed twice with 1 mL of medium with 1 % FBS and 
analized by gamma counter. The curves of the percentage of total binding, specific binding and non-specific 
binding, in relation to the number of cells, were constructed using the statistical program GraphPad Prism ® 
5.00. The experiment was performed in triplicate. 
 
 
 
 
FIG. 7. Specific binding of 177Lu-DOTA-Rituximab to Raji cell – conjugated prepared at different molar ratios 
(1:20, 1:50 and 1:100)  (n = 3). 
 
 
3.2.5 Conjugation of Anti-CD 20 antibody using 1B4M-DTPA chelating group and preliminary binding results  
 
   The antibody was conjugated with 1B4M-DTPA chelating group, gently provided by Dr. Zalutsky, at molar 
ratio 1:50. The purification after conjugation and labelling procedure were performed as described to DOTA-
NHS chelating group. The result are expressed in the following table. 
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TABLE 8. Radiochemical purity of 1B4M-DTPA-Rituximab labelled with 177LuCl3.  Labelling conditions: 1 mg, 
37 MBq (1 mCi) of 177LuCl3, 1 hour at 43 °C, 350 rpm  (n = 1). 
 
Molar ratio Before purification After purification 
1:50 32,99±0,007 92.56±0.001 
 
   Figure 8 shows the results of specific binding assay  of 177Lu-1B4M-DTPA-Rituximab to Raji cells. 
 
 
 
 
FIG. 8. Specific binding of 177Lu-1B4M-Rituximab to Raji cell (n = 1). 
 
 
 
3.2.6 Conjugation of Anti-CD 20 antibody using p-SCN-Bn-DOTA and p-SCN-Bn-DTPA 
 
   Preliminary conjugation and labelling studies were performed using p-SCN-Bn-DOTA and p-SCN-Bn-DTPA 
as chelators. The procedures for conjugation of the chelating group to the Ab and purification were the same 
employed for DOTA-NHS chelator, previously described. The labelling procedures were developed using 3.7 
MBq (1.0 mCi) of 177Lu and reaction conditions as previously described. The results are expressed on Table 9. 
 
 
TABLE 9. Radiochemical purity of 177Lu-DOTA-rituximab conjugated to two different chelators. Labelling 
conditions: 1 mg, 37 MBq (1 mCi) of 177LuCl3, 1 hour at 43 °C, 350 rpm  (n = 5). 
 
 Radiochemical purity (%) 
Ab:chelator molar ratio p-SCN-Bn-DOTA. p-SCN-Bn-DTPA. 
1:5 79.71 ± 1.40 - 
1:10 88.04 ± 1.08 - 
1:20 82.10 ± 0.32 76.68 ± 14.63 
1:50 - 59.49 ±  9.10 
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3.3 Development of a radiopharmaceutical based on Bombesin for prostate and breast tumors radionuclide 
therapy 
 
   We have recently developed and described the properties of novel radiopharmaceuticals based on bombesin 
(BBN) structure and radiolabeled with Lutetium-177 – 177Lu-DOTA-Phe-(Gly)1-5-BBN(6-14) – for application in 
prostate tumor detection and treatment and we have obtained promising results. The derivative 177Lu-DOTA-
Phe-(Gly)5-BBN(6-14) showed fast blood clearance (T½ = 10 minutes), rapid renal excretion, low abdominal 
accumulation, short effective half-life and specifically target to human prostate tumor (PC-3) cells in mice [3]. 
We describe now, in this phase of the work, the toxicological aspects of this bombesin derivative in rats, in order 
to determine if it is safe for evaluation in clinical studies in humans. The toxicological studies analyze the 
adverse effects inherent to the administration of a pharmaceutical and are demanded by National Agency of 
Sanitary Surveillance (ANVISA) for radiopharmaceutical registration in Brazil. 
   Acute and chronic intravenous toxicity were evaluated by injecting 60 µg (150 µL of sterile saline) of the cold 
peptide DOTA-Phe-(Gly)5-BBN(6-14) in rats (adults, male, 250 g) tail vein. The total mass injected was 10 
times higher the mass that would be administrated to humans per kg, considering an adult of 70 kg, for 
radionuclide therapy. Rats’ behavior was evaluated for two hours post injection and water and food intake as 
well as body weight were assessed daily. Moreover, after 24 hours and 7 days p.i., the animals were sacrificed in 
groups of five, the blood was collected for hematology and serum biochemistry and organs were dissected for 
histological evaluation. 
   Neither mortality nor changes in animals’ behavior were observed during all times analyzed. Food and water 
intake, body weight, hematological (Fig. 28) and biochemical (Fig. 29 and 30) variables did not show differences 
of toxicological and/or statistical relevance between the experimental and control groups. In addition, 
microscopic examination of organs did not demonstrate any alterations and there were no histological findings of 
toxicological significance (Fig. 31). These results suggested that the bombesin derivative studied can be 
considered potentially safe for human use in clinical studies. 
 
4. Future studies 
 
4.1. Substance P 
 
• Conclude in vitro cell binding assays with different tumor cells lines. 
• Conclude biodistribution studies in Nude mice with tumor. 
•  
4.2. Anti CD-20 antibody (Rituximab) 
 
• Determination of number of chelating groups per antibody using mass spectrometry; 
• Prepare a lyophilized formulation for labelling the conjugated antibody with 177Lu – study of ideal 
formulation and stability of preparation; 
• Conclude cell binding studies for the antibody conjugated with different chelators and study the 
influence of specific activity of the labelled antibody in tumor cell binding; 
• Conclude biodistribution studies with the Ab prepared with different chelators and using different  
Ab:chelator molar ratios. 
 
4.3. Bombesin 
 
• Study new BBN derivatives: labelling conditions, biodistribution studies, cell binding assays – 
comparative study with the BBN derivative previously studied. 
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5. Published works during the related period 
 
   Full length articles 
   Pujatti, P.B., J.S. Santos, R.M. Couto, L.T. Melero, M.F. Suzuki, C.R. Soares, S.R. Grallert, J. Mengatti, and 
E.B. De Araujo. Novel series of (177)Lu-labeled bombesin derivatives with amino acidic spacers for selective 
targeting of human PC-3 prostate tumor cells. Q J Nucl Med Mol Imaging. 55:310-323, 2011. 
 
   Abstracts in events 
   Priscilla B. Pujatti, Jair Mengatti, Elaine Bortoleti de Araújo,  Comparision of in vitro serum stability and in 
vivo properties of spacer-modified-bombesin conjugates with methionine and norleucine as C-terminal amino 
acids. 24th Annual Congress of the European association of Nuclear Medicine – EANM’11, October 15-19, 
2011, Birmingham, UK. Eur. J. Nucl. Med. Mol. Imaging 38 (Suppl 2): S93-S228, OP378. 
   Priscilla B. Pujatti, Nathanael Gomes, Akin G. Akanji, Jair Mengatti, Elaine Bortoleti de Araújo. Preclinical 
evaluation of a radiopharmaceutical for refractory prostate tumor radionuclide therapy. Alasbimn Journal Year 
14, Number 54, October 2011 / Año 14, Nº 54, Octubre 2011, XXIII Congreso de ALASBIMN: Resúmenes. 
   Clarice M. de Lima, Priscilla B. Pujatti, Maria T. Colturato, Jair Mengatti, Elaine Bortoleti de Araújo 
Evaluation of methionine oxidation on  177Lu-DOTA-Substance P on in viro binding to glioma cells. Alasbimn 
Journal Year 14, Number 54, October 2011 / Año 14, Nº 54, Octubre 2011, XXIII Congreso de ALASBIMN: 
Resúmenes. 
   Adriana V. F. Massicano, Priscila B. Pujatti, Jair Mengatti, Elaine Bortoleti de Araújo  Mass influence of 
DOTA-Rituximab in the radiolabelling with Lu-177. Alasbimn Journal Year 14, Number 54, October 2011 / 
Año 14, Nº 54, Octubre 2011, XXIII Congreso de ALASBIMN: Resúmenes. 
   Massicano, A.V.F.; Alcarde, L.F.; Mengatti, J.; Araújo, E.B. Labelling of Rituximab with 177Lu: specific cell 
binding assays. Brazilian Congress of Nuclear Medicine, Salvador, Bahia, October, 10-14, 2012 – Accepted for 
poster presentation. 
   Oliveira, R.S; Pujatti, P.B; Massicano, A.V.F.; Mengatti, J.; Araújo, E.B. Determination of standard condition 
for labelling Bombesin derivative with 111In. Brazilian Congress of Nuclear Medicine, Salvador, Bahia, October, 
10-14, 2012 – Accepted for poster presentation. 
   Priscilla B. Pujatti; Jane K. Sosabowski; Julie M. Foster; Ciara Finucane; Chantelle D. Hudson; Jerome C. 
Burnet; Jair Mengatti; Stephen J. Mather, and Elaine B. de Araújo. Comparative biodistribution and 
nanoSPECT/CT imaging of a new [In-111]-DOTA-bombesin derivative in low and high GRPr expressing 
prostate tumor cells. Brazilian Congress of Nuclear Medicine, Salvador, Bahia, October, 10-14, 2012 – Accepted 
for oral presentation. 
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1. Introduction 
 
   The overall objective of this CRP is to promote the clinical application of radioimmunotherapy and peptide 
receptor-based radionuclide therapy for the most important cancers in developing countries. 
   This report summarized the ongoing activities of our group within the first half of this CRP. 
 
2. Production of 177Lu 
 
   Smaller quartz glass tubes (φ, 5 × 5 mm) were used to improve the discovery rate of 177Lu in the chemical 
process. 1mg of 176Lu2O3 (82.8% enriched) was dissolved in 6 mol/L HCl and 30% H2O2 (V/V = 1:1) and the 
clear solution was dispersed in quartz glass tubes (φ, 5 × 5 mm) and then evaporated to dryness. After irradiated 
for one cycle (9-11 days) under the neutron flux of 2-4×1013, the target was directly dissolved in 0.2 mol/L HCl. 
The radionuclidic purity in all circumstances was over 99.9%. 
   Lu content was determined using ARS III spectrophotometry. Briefly, standard Lu solution, sample solution, 
1.0 mL 0.5% ARS III and 0.5mL 1mol/L HCl were mixed together, and after 5 min of color reaction, the 
absorbance was measured at 655 nm. The obtained specific activity of 177Lu was 2.5-2.9 Ci/mg. 
 
 
TABLE 1. The production of 177Lu (some examples) 
 
EOB 
(date) 
176Lu2O3 
(µg) 
Chemical 
processing 
(date) 
177Lu(mCi)a 
177Lu 
(mCi/mL)b 
Yield 
(%)c 
S.A. 
（mCi/mgLu）d 
20111013 20 20111020 29 15/0.3mL 51.7 2900/1450 
20120314 60 20120316 151 141/0.9mL 93.4 2517/2275 
20120412 60 20120413 170 147/0.9mL 86.5 2833/2577 
20120517 60 20120518 174 150/0.55mL 86.2 2900/2639 
20120712 60 20120713 127 110/0.5mL 86.6 2117/1926 
20120816 60 20120817 174 143/0.55mL 82.2 2900/2640 
a Radioactivity before chemical process. b Radioactivity after chemical process. c Recovery rate. d Specific 
activity after chemical process / specific activity when labelling started. 
 
 
3. Conjugation of Nimotuzumab with CHX-A''-DTPA and p-SCN-Bn-DOTA 
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3.1. Purification of Nimotuzumab 
 
   1.0 mL of Nimotuzumab（5 mg/mL）was purified with ultrafiltration centrifugal tube (Vivaspin 2, MWCO 
30,000, Sartorius). After incubated with 0.5 mL of 40 mM DTPA (in 0.25 M sodium acetate buffer, pH = 6.5-
7.0) at 4 °C for 30 min, the solution was centrifuged at 4000rpm/min and washed with 6 × 1mL of 0.1 M 
carbonate buffer (pH = 8.3-9.0). After purification, the concentration of antibody was determined using UV 
spectrophotometry at 280 nm, and the recovery rate was around 70%. 
 
3.2 Conjugation of Nimotuzumab with chelators 
 
3.2.1. Conjugation of Nimotuzumab with CHX-A''-DTPA 
 
   Purified Nimotuzumab was mixed with 10～250 folds molar excess of CHX-A''-DTPA (15 mg/mL) in 50 mM 
bicarbonate buffer (pH = 8.3-9.0). After incubated at 4 °C for 17h, the reaction mixture was transferred in 
Vivaspin 2 tube and centrifuged at 4000 rpm/min, then 10 × 0.5 mL acetate buffer (20 mM，pH = 6.5-7.0) was 
added to change medium. The conjugate solution was stored at 4°C. 
 
3.2.2. Conjugation of Nimotuzumab with p-SCN-Bn-DOTA 
 
   Purified Nimotuzumab was mixed with 30～350 folds molar excess of p-SCN-Bn-DOTA (1mg/mL) in 50 mM 
bicarbonate buffer (pH = 8.3-9.0). After incubated at 4 °C for 42 h, the reaction mixture was transferred in 
Vivaspin 2 tube and centrifuged at 4000 rpm/min, then 10 × 0.5ml acetate buffer (20 mM，pH = 6.5~7.0) was 
added to change medium. The conjugate solution was stored at 4°C. 
 
3.3. Measurement of chelator to antibody ratio 
 
3.3.1. Measurement of the concentration of antibody in mAb conjugate 
 
   The concentration of antibody was measured by BCA protein assay kit. 
   Standard antibody solutions were made by dissolving purified Nimotuzumab in sodium acetate buffer (20 
mM，pH = 6.5-7.0), and final concertration of antibody was 1000, 500, 250, 125, 62.5 µg/mL. 
   Each of above antibody solution was tested by microplate reader (MK3, Thermo-Fisher SCIENTIFIC). 
Briefly, 25 µL of standard antibody solutions were mixed with 200 µL of BCA solution in 96-well plate (Brand 
plates, immunograde) and tested at 570 nm after 2 h of color reaction, and acetate buffer was used as reference 
solution. The standard concentration- absorbance curve was shown in Figure 1. 
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Fit type:  Linear regression (SVD): y = a+b*x 
Parameters: a b   
  0.154 0.002   
Corr. coeff. R2: 0.996    
 
FIG. 1. The standard curve for measurement of antibody in mAb conjugates. 
 
   Then 25 µL of conjugate sample was tested in the same way described above, and the concentration of 
Nimotuzumab in mAb conjugate was about 2.5437 mg/mL, 1.696 × 10-5M according to the standard curve.  
 
3.3.2. Measurement of the concentration of DTPA in mAb conjugate 
 
   The density of DTPA in mAb conjugate was determined according to the literature method [1]. 
 
3.3.2.1. Preparation of Y-ARSIII solution 
 
   Arsenazo III (ARS III) 4.2 mg and YCl3·6H2O 6.7 mg were dissoveled in 100 mL acetate buffer (0.2 M, pH = 
4), respectively. 10mL of ARS III solution and 1mL of YCl3 solution were mixed in 100 mL acetate buffer to get 
Y-ARSIII color solution. 
 
3.3.2.2. Preparation of standard cuver 
 
   Standard DTPA chelator solutions were made by dissolving 4.8 mg of CHX-A''-DTPA  in 100 mL acetate 
buffer(0.2 M,  pH = 4), and final concertration of chelator was 48, 24, 12, 6, 3, 1.5 µg/mL.  
   30 µL of standard chelator solutions were mixed with 270 µL of Y-ARSIII solution and tested at 650nm after 5 
min of color reaction, and acetate buffer (pH = 4, 0.2 M) was used as reference solution. The standard 
concentration- absorbance curve was shown in Figure 2. 
   30 µL of conjugate sample was tested, and the concentration of DTPA in the conjugate was about 10.92 
µg/mL, 1.838 × 10-5M according to the standard curve. 
   Therefore, the ratio of CHX-A''-DTPA to mAb was 1.08:1. 
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Corr. coeff. R2: 0.997   
 
FIG. 2. The standard curve for measurement of DTPA in mAb conjugates. 
 
 
3.3.3. Measurement of the concentration of DOTA in mAb conjugate 
 
   The density of DOTA in mAb conjugate was determined according to the literature method [2]. 
 
3.3.3.1. Preparation of ARS-Cu solution 
 
   Arsenazo III (ARS III) 0.16 mg was dissoveled in 20 mL ammonium acetate buffer (0.2M, pH = 4) and mixed 
with 6.4 µL Cu standard solution (Cu: 1 mg/mL) to get stock solution. 
 
3.3.3.2. Preparation of standard cuver 
 
   Standard DOTA chelator solutions were made by dissolving p-SCN-Bn-DOTA 0.46 mg in 2 mL ammonium 
acetate buffer (0.2M,  pH = 6.5), and final concertration of chelator was 230, 115, 57.5, 28.8, 14.4, 7.2 µg/mL.  
   20 µL of standard chelator solutions were mixed with 180 µL of stock solution and tested at 630 nm after 20 
min of color reaction, and acetate buffer was used as reference solution. The standard concentration-absorbance 
curve was shown in Figure 3. 
 
 
 
Fit type:  Linear regression (SVD): y = a+b*x 
Parameters: a b   
  0.080 -0.177   
Corr. coeff. R2: 0.995    
 
FIG. 3. The standard curve for measurement of DOTA in mAb conjugates. 
 
3.4. Discussion 
 
1) Conjugation should be carried out under alkaline condition (bicarbonate buffer (pH = 8.3-9.0)). There 
seemed to be no coupling under neutral condition in our experiments.  
2) It takes longer for DOTA conjugation than for DTPA conjugation. 
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3) Measurement of DOTA concentration in the conjugate using spectrophotometry was not successful. We will 
try the method of radiolabelling [6]. 
4) Though the inlets of chelator to mAb were quite different, but the ratio of chelator/mAb of the conjugate 
didn’t show much difference (see Table 2).  
 
4. 177Lu labeling of mAb conjugates 
 
4.1. Preparation and purification of 177Lu mAb conjugates  
 
Typical labelling procedure: Mab conjugate(200ug) was mixed with 177LuCl3 (2.0 mCi/10µL) in sodium acetate 
buffer (pH = 6.5-7.0). After vortex, the mixture was incubated at 37℃ (for DTPA conjugates) or at 40℃ 
(mainly for DOTA conjugates) with shaking speed of 650rpm for 60min then the reaction was quenched by 
adding 50 µL of 10 mM DTPA. The results are shown in Table 2-5. 
 
TABLE 2. 177Lu labelling of DTPA-Nimotuzumab 
 
DTPA/mAb 
inlet 
DTPA/mAb 
detected Lu/mAb pH 
RCP（%） 
200:1 1.08:1 3:1 7 52.7 
200:1 1.08:1 1.4:1 7 57.7 
144:1 -- 10:1 7 99.6 
144:1 -- 0.3:1 7 98.6 
55.5:1 -- 2:1 7 97.3 
55.5:1 -- 1:1 7 92.3 
55.5:1 -- 0.5:1 7 91.7 
50:1 -- 3:1 7 21.6 
50:1 -- 1.4:1 7 70.6 
12.5:1 1.07:1 3:1 7 32.2 
12.5:1 1.07:1 1.4:1 7 90.2 
 
 
TABLE 3. 177Lu labelling of DTPA-Rituximab 
 
DTPA/mAb Lu/mAb pH RCP（%） 
240:1 2:1 7 69.8 
240:1 1:1 7 66.1 
240:1 0.5:1 7 58.5 
 
 
TABLE 4. 177Lu labelling of DOTA-Nimotuzumab 
 
DOTA/mAb Lu/mAb pH RCP（%） 
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340:1 3:1 7.5 84.9 
340:1 3:1 5.5 96.5 
340:1 3:1 4.8 98.4 
200:1 5:1 7 67.8 
50:1 2.4:1 7 99.4 
50:1 1.5:1 7 99.0 
46:1 2:1 7 95.2 
46:1 1.1：1 7 97.7 
 
 
TABLE 5. 177Lu labelling of DOTA-Rituximab 
 
DOTA/mAb Lu/mAb pH RCP（%） 
30:1 2.3:1 7 96.9 
30:1 1.1:1 7 96.9 
30:1 0.5:1 7 98.7 
 
 
   The labelled mAb was purified using PD-10 column eluted with PBS, and the typical eluting curve was shown 
in Figure 4. 
 
 
 
FIG. 4. The eluting curve of purification of labelled mAb conjugates with PD-10 
 
   Lu-177 labelled mAb conjugates were mainly in 3.0 mL~5.0 mLof elution solution. The labeling yield was 
over 90%, and RCP could reach 99% after purified with PD-10 column. 
   This conjugated mAb was, and the concentration of mAb was 2.37 mg/ml as we checked before labelling. But 
mainly because of the low S.A of 177Lu, which was 1.5 Ci/mg when we did the labelling, the labelling yield was 
quite low.  
   The labelled mAb was purified using PD-10 column (pre-treated with 0.5% human serum albumin) eluted with 
saline. 
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4.2. Influence of pH and reation time 
 
   DOTA-Nimotuzumab (180ug) was mixed with 177LuCl3 (1.5 mCi/6µL) in sodium acetate buffer, and pH was 
adjusted to 7.5, 5.5, 4.7 respectively with 36% acetic acid.  The results are showed in Table 6. 
 
 
TABLE 6. The influence of pH to the labelling reaction 
 
pH 7.76 5.25 4.53 
Labelling yield (%) 84.9 96.5 98.4 
 
   During labelling, the samples were taken for RCP analysis, and the results showed that from 30 min to 60 min, 
the RCP increased from 85.2% to 90.2%. 
 
4.3. Discussion 
 
1) Though most of labelling experiments were done in neutral condition, acid condition seemed to be more 
favorable. 
2) Labelling yield could be increased when reaction time was prolonged or Lu/mAb ratio was increased. 
3) During PD-10 purification, labelled conjugate mainly in eluate 3-5mL, but 3-4mL seemed to be purer.  
 
5. Analysis of RCP 
 
5.1. ITLC analysis 
 
Using ITLC-SG as support, the samples were analysized in following different developing solvents, and based 
on the results, EtOH:NH4OH:H2O(2:1:5) and 10mM DTPA were chosen to be main developing solvents. 
 
 
TABLE 7. The Rf in differant systems 
 
Conditions 
Rf 
177Lu-mAb conjugate 177Lu-chelator Free 177Lu 
10%NH4OAc:CH3OH (1:1) 0.0-0.2 0.8-1.0 0.0-0.5 
EtOH:NH4OH:H2O (2:1:5) 0.0-0.2 0.8-1.0 0.0-0.2 
14%NaOAc 0.0-0.2 0.3-0.5 0.0-0.2 
0.1M Sodium citrate 0.0-0.2 -- 0.9-1.0 
10mM DTPA 0.0-0.1 0.9-1.0 0.9-1.0 
Acetone:saline = 1:1 0.0-0.2 0.0-0.2 0.0-0.2 
 
 
5.2.  HPLC analysis 
 
   HPLC was performed on size exclusion column using 0.9% NaCl/0.05%NaN3 as eluting solvent. The results 
were shown in Figure 5.  
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A          B            C 
 
                      D                               E 
FIG. 5. HPLC profoles. A: Nimotuzumab, Rt = 8.05min; B: DTPA-Nimotuzumab, Rt = 7.73min; C: 177Lu-DTPA-
Nimotuzumab, Rt = 7.74min; D: DOTA-Nimotuzumab, Rt = 7.39min; E: 177Lu-DOTA- Nimotuzumab, Rt = 
7.48min 
 
6. In-vitro stability 
 
   Lu-177 labelled Nimotuzumab conjugates were incubated in 0.9%NaCl, 10mM DTPA, 5%HSA and 10%HSA 
at 37℃, and samples were taken at 24h, 48h, 72h and 96h for ITLC analysis. The results were shown in Figure 
6. 
   The results showed that 177Lu labelled mAb conjugates were relatively stable in 0.9% NaCl and 10-mM DTPA, 
but not stable in 5%HSA and 10%HSA.  
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FIG. 6. In-vitro stability. A: 177Lu-DTPA-Nimotuzumab; B: 177Lu-DOTA- Nimotuzumab. 
 
 
7. Biodistribution study in normal mice 
 
   A typical procedure was as follows. normal Kunming mice (18-22g) were injected with 0.37 MBq/0.1 mL of 
177Lu labelled Nimotuzumab conjugates via tail vein. Animals were killed at 24hr and 48hr p.i. and samples of 
different organs were dissected and counted. The uptake in terms of %ID/g was calculated. Table 8 and Figure 7 
showed the biodistribution of 177Lu-DTPA-Nimotuzumab in Kunming mice (N=5). Table 9 and Figure 8 showed 
the biodistribution of 177Lu-DOTA-Nimotuzumab in Kunming mice (N=5). 
 
 
TABLE 8. The biodistribution of 177Lu-DTPA-Nimotuzumab in Kunming mice (N = 5) 
 
Organs 24 h p.i. 48 h p.i. 
Heart 1.84±0.58% 2.11±0.35% 
Liver 5.58±1.33% 4.79±0.64% 
Spleen 3.71±1.16% 4.50±0.91% 
Lung 2.78±0.60% 2.43±0.38% 
Kidney 9.23±1.84% 9.32±0.77% 
Stomach 1.07±0.52% 1.34±0.74% 
Small Intestine 0.96±0.18% 0.98±0.07% 
Muscle 0.58±0.09% 0.82±0.09% 
Bone 3.68±1.04% 4.47±0.43% 
Blood 5.61±1.18% 4.64±0.30% 
 
 
TABLE 9. The biodistribution of 177Lu-DOTA-Nimotuzumab in Kunming mice (N = 5) 
 
Organs 24 h p.i. 48 h p.i. 
Heart 1.42±0.26% 0.39±0.20% 
Liver 14.44±1.47% 3.85±0.64% 
Spleen 11.06±2.16% 3.58±0.46% 
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Lung 1.19±0.24% 0.36±0.2% 
Kidney 10.78±1.27% 2.96±0.24% 
Stomach 0.72±0.15% 0.23±0.12% 
Small Intestine 0.78±0.16% 0.27±0.16% 
Muscle 0.50±0.13% 0.07±0.06% 
Bone 4.73±0.53% 1.91±0.40% 
Blood 1.45±0.18% 0.31±0.10% 
 
 
 
 
FIG. 7. The biodistribution of 177Lu-DTPA-Nimotuzumab in Kunming mice 
 
 
 
 
FIG.8. The biodistribution of 177Lu-DTPA-Nimotuzumab in Kunming mice 
 
   Rapid blood clearance and high kidney uptake showed that 177Lu-DOTA-Nimotuzumab may be degraded in-
vivo which was consistent with its in-vitro instability. 177Lu-DTPA-Nimotuzumab also showed high kidney 
uptake besides high uptake in liver and blood. Further data from HPLC was needed to confirm the results from 
stability studies.  
 
8. Future work plan 
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1) Radioimmunoassay of Nimotuzumab will be performed using LoVo colorectal cells. 
2) More experiments on Rituximab and new chelators will be carried out. 
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1. Description of research work 
 
1. Experiments and adjustment of labelling procedures for Rituximab with 90Y.   
2. Determination of the conditions under which DOTA and DTPA immunoconjugates can be labeled with 90Y 
in high yield. 
3. Quality Controls and binding assay of conjugated antibodies. 
 
2. Results 
 
   The main contribution of our group in this period was focused in conditions for conjugation of rituximab with 
DTPA and DOTA chelators. 
 
2.1. DOTA conjugation 
 
   Rituximab (15mg/mL) was incubated overnight at room temperature with HHS-DOTA in 0.1M PBS pH 8.5 at 
different molar ratios (160:1, 80:1, and 40:1). Then, a purification step by exclusion chromatography in 
Sephadex column (PD10, Pharmacia) was performed. 
 
2.2. DTPA conjugation 
 
   Rituximab (10 mg/mL) was incubated overnight at room temperature with CHX-DTPA in NaHCO3 Buffer 0.1 
M, pH 8.5, at different molar ratios (30:1, 20:1, 10:1, and 5:1). Then, a purification step by exclusion 
chromatography in Sephadex column (PD10, Pharmacia) was performed. 
   Conjugated antibodies were concentrated by mean of spin concentration and fractions of 10mg of conjugated 
antibody were stored in a fridge in 1mL eppendorff test vials until use. 
 
2.3. Binding experiments of conjugated antibodies to Ramos cells 
 
   2 × 105 cells were incubated for 30 min with 10 µg/mL of conjugated antibody. Then, cells were washed with 
physiological saline and centrifuged at 2000 rpm for 2 min. After a second incubation step with a rabbit anti 
human IgG (Fcγ) coupled to FITC (fluorescein iso-thiocyanate, Dako, Denmark) in ice for 30 min, a flow 
cytometry analysis was performed (FACScan, Becton Dickinson, USA). 
   Binding capacity was evaluated at different Ab/DOTA molar ratios. As can be observed in Figure 1, binding of 
conjugated antibody decreases with respect to free Rituximab when molar ratio increases, which is more evident 
at 80:1 and 160:1 molar ratios.  
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FIG. 1. CD20 recognition in Ramos cells of DOTA conjugated Rituxan (numbers represent fluorescence 
intensity and percentage of CD20 expressing cells). 
 
 
FIG. 2. CD20 recognition in Ramos cells of DTPA conjugated Rituxan (numbers represent fluorescence 
intensity). 
 
   FITC conjugated antibody, is Fcγ specific. So, a binding decreasement can be due to poor CD20 recognition or 
Fc fragment damage. Nonetheless, both factors are very important in “in vivo” behavior of radiolabeled 
antibodies. 
 
2.4. 90Y radiolabeling and quality control of conjugated Rituximab 
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   In the case of DOTA conjugated Rituximab, radiolabeling was carried out at 42oC, acetate buffer 0.25 M, pH 
7.0, for 90 minutes.  
   In the case of DTPA conjugated Rituximab, radiolabeling was carried out at room temperature in acetate buffer 
0.25 M, pH 5.5, during 15 minutes. 
   Quality control of radiolabeling was performed by paper chromatography and ITLC. 
 
 
TABLE 1. Chromatographic method for quality control of radiolabeled Abs 
 
System Mobile phase 
Paper, Whatman 3MM NH4Ac 0.1 M pH 5.5-6.0, EDTA 50 mM 
ITLC MeOH:NH3 10% (1:1) 
 
 
TABLE 2. Radiochemical purity of radiolabeled MAbs 
 
DOTA-Ab DTPA-Ab 
Molar ratio RP Molar ratio RP 
160:1 97-99 % 30:1 96-98 % 
80:1 90-95 % 20:1 96-98 % 
40:1 ∼ 80 % 10:1 96-98 % 
  5:1 10-12 % 
 
   Final radiochemical purity of DTPA conjugated antibody was initially superior to radiochemical purity 
obtained with DOTA conjugated antibody. Better results, more than 90% of radiochemical purity, were further 
obtained with DOTA conjugated at lower molar ratio (20:1). 
 
2.5. Cell binding assay of 90Y-DTPA-Rituximab 
 
   Ramos cell line (CRL-1596, ATCC) was used for binding experiments. Cells were grown, 37ºC in 5% CO2, in 
RPMI 1640 (Gibco, UK) media supplemented with penicilline (100 U/mL), streptomicine (100 µg/mL) and fetal 
calf serum 10%. For binding experiments cells were centrifuged and washed in isotonic PBS/BSA pH 7.4 and 
resuspended in the same buffer at different concentrations (2.4, 1.2, 0.6, 0.3, 0.15 and 0.075 x106 cell/mL).  The 
conjugate DTPA-Rituximab obtained at 20:1 molar ratio was used for cell binding experiments after labeling. 
   By duplicate, 10µL of a conveniently diluted radiolabeled antibody (5000cpm) was added to 1mL of each cell 
dilution. 
   Cell binding was processed following the variable antigen concentration approach according to already 
described procedures (Konishi, et al, 2004). Conventional and Lindmo plot (Lindmo et al, 1984) are depicted in 
Figure 3. 
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FIG. 3. Results of binding experiment. A: conventional plot, B: Lidmo plot. 
 
The value of immunoreactive fraction (r) of 0.96, as estimated by both procedures, is an excellent result. So, we 
may consider that conjugation procedures did not affect binding capacity of Rituximab. 
 
 
 
3. Conclusions 
 
1. Rituximab conjugated with DOTA and DTPA shows a good binding capacity to Ramos cells in vitro. 
DOTA-rituximab at 40:1 molar ratio and DTPA-Rituximab at 20:1 molar ratio as demonstrated by flow 
cytometry. 
2. 90Y labeled DOTA-Rituximab and DTPA-Rituximab were obtained with more than 90% of radiocemical 
purity. 
3. 90Y labeled DTPA-Rituximab showed a good receptor recognition in Ramos cells as demonstrated by 
binding experiments. 
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1. Introduction 
 
   The investigation of target-specific radiopharmaceuticals based on monoclonal antibodies (mAb), their 
fragments and peptides for therapy and molecular imaging is increasing due to the availability of new 
radioisotopes and biomolecules with improved characteristics. Unfortunately, the success of 
radioimmunotherapy (RIT) in hematologic disease has not been translated to solid tumours yet. Nevertheless, 
treatment of minimal residual disease, locoregional applications and pretargeted RIT has shown some advances 
[1].  
   The epidermal growth factor receptor (EGFR) is a rational target of anticancer therapies due to their 
overexpression in a variety of malignant epithelial tumours and its correlation with a poor prognosis[2]. One of 
the approaches most widely studied to inhibit the EGFR oncogenic expression is the use of monoclonal 
antibodies which bind the extracellular domain of this receptor inhibiting dimerization and autophosporylation 
[3]. Trastuzumab was the first mAb approved by FDA for the treatment of HER-2 positive breast cancer. Later, 
cetuximab (Erbitux) was approved for treatment of metastatic colorectal cancer and squamous cell carcinoma. 
Relatively news mAbs against EGFRs such as Panitumumab, Matuzumab, MDX-447, Nimotuzumab and 
mAb806 are currently under preclinical and clinical evaluation [2, 4]. Tc-99m-h-R3 has been used for 
radioimmunoscintigraphy of nodal metastatic disease, but poor correlation between EGFR expression and 
positive tumour imaging was observed [5]. However, encouraging results have been obtained in RIT (phase I 
clinical trial) of recurrent high-grade glioma after intracavitary administration of h-R3 labelled with 188Re [6].  
Residualizing radionuclides, such as 90Y and 177Lu, are potentially more suitable for RIT [7]. Y-90 is of 
particular interest for radiotherapy due to its high-energy pure β-particle emission8. 90Y form very stable 
complex with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate acid (DOTA) derivatives in vivo, hence it is 
well suited for receptor-based therapeutic radiopharmaceuticals 177Lu (t1/2 = 6.7 days, Eγ = 0.208 MeV, β¯= 
0.497 MeV, max range in tissue penetration = 2.0 mm) is being strongly considered for RIT since it combines 
the advantages of both 90Y and 131I. In addition, 177Lu emits two low energy γ lines with energy of 113 and 208 
keV that are suitable for imaging and assessment of delivered doses.  
   Hereby, we describe the radiochemistry and preclinical evaluation for the successful preparation of 
radioimmunoconjugates formed by 90Y/177Lu and monoclonal antibodies with intermediate affinity to EGFR 
(Nimotuzumab) and HER2/neu (Trastuzumab). In addition, Rituximab was modified with p-SCN-Bn-DOTA and 
1B4M-DTPA and radiolabeled with 90Y. Part of the following results has been published [7-11].  
 
2. Materials and methods 
 
2.1. Conjugation of monoclonal antibodies  
 
   Modification of Nimotuzumab and Trastuzumab with DOTA-NHS, p-SCN-Bn-DOTA and p-SCN-Bn-DTPA 
(Macrocyclics (Dallas, TX, USA) were performed as previously described [9-11]. Monoclonal antibodies were 
mixed with 10, 20, 50,100 and 150-fold molar excess of the selected bifunctional chelating agent. Rituximab was 
66 
modified with 20-fold molar excess of p-SCN-Bn-DOTA and 1B4MDTPA. The reaction mixture was incubated 
overnight at 4 °C. The immunoconjugates were purified by ultrafiltration on Vivaspin 6 until the absorbance in 
the ultrafiltrate at 280 nm was nearly zero. Protein concentration was determined by Bradford assay. Conjugates 
were stored at 4°C for further use.  
 
2.2. Characterization  
 
   Immunoconjugates were characterized by SE-HPLC to verify conjugate integrity. About 20 µL of conjugates 
was injected onto a TSK-Gel SW 3000 (7.5× 300 mm, 10 µm, TosoHass) column using NaCl (0.9%)/NaN3 
(0.05%) as the mobile phase. The flow rate was maintained at 1 mL/min and the elution was monitored by UV at 
280 nm. Immunoconjugates were also analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS–PAGE) under reducing and nonreducing conditions using NuPAGE® minigels 4-12 % Bis-Tris (10 mm × 
10 well). The electrophoresis running was carried out in an Amershan Biosciences electrophoretical systems 
using NuPAGE® running buffer. The proteins in the gel were visualized with Coomassie Blue R-250 (BioRad, 
CA, USA) solutions.  
 
2.3. Determination of average number of chelates linked to an antibody molecule  
 
   The average number of chelates linked to an antibody molecule was determined using 90Y by a radioactive 
method previously described [12]. Briefly, 49 µg (10 µL) of the conjugates were added to 30-50 µL of NH4OAc 
0.5 mol/L, pH 7.0. Afterward, 10 -30 µL (3.33 X 10-4 mol/L) of a standardized YCl3 spiked with 90Y solution 
were added.  
 
2.4. F(ab')2 antibody fragments generation  
 
   Monoclonal antibodies were digested with 6.5% (w/w) of immobilized pepsin for 4 – 48 hours at 37ºC in 
0.02M sodium acetate buffer, pH 4.1. The F(ab')2 fragments were purified by protein A column chromatography 
followed by elution with PBS 0.05M pH – 7.1. The F(ab')2 where concentrated by ultracentrifugation using 
Vivaspin 6 (MWCO = 30 kDa) as described above. The digestion and purity of F(ab')2 preparation was 
evaluated by SDS-PAGE under nonreducing conditions and SE-HPLC. The HPLC procedure was carried out 
using TSK-Gel SW 3000 and Bio Rad SEC 250 columns in series to increase the resolution. The F(ab')2 were 
modified with p-SCN-Bn-DOTA using the same procedure as described above for the intact monoclonal 
antibodies.  
 
2.5. Radiolabeling 
 
   Lu-177 no-carrier added (n.c.a in 0.05 mol/L HCl), produced indirectly via the 176Yb(n,γ)177Yb→(β−)→177Lu 
reaction, was generously donated by Isotope Technologies Garching (ITG, Garching GmbH). In-house-produced  
177Lu or purchased from PelkinElmer was also used for the experiments. Aliquots of 177LuCl3 (15 – 400 MBq, 2 
– 48 µL) was mixed with 0.5 mol/L NH4OAc buffer at pH 7.0, followed by 20 – 50 µL (0.050-0.200 mg) of the 
conjugates. 90YCl3 (555 MBq in 22 µL of 0.05 M HCl) was purchased from PerkinElmer. Aliquots of 90YCl3 (28 
– 56 MBq, 1-2 µL) were added to 20 -40 µL of 0.5 mol/L NH4OAc buffer at pH 7.0, followed by 20 – 50 µL 
(0.050-0.200 mg) of conjugates. Afterward the reaction mixture was incubated at RT or 42 °C for 30 or 60 min 
for DTPA and DOTA derivatives, respectively.  
 
2.6. Quality control  
 
   For stopping the reaction and binding of free radiometal, 1/10 of the total radiolabeling reaction volume of 
DTPA 0.01 mol/L, pH 6.0, was added and the mixture was incubated for 15 min at room temperature. 
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Radiometal labelling efficiency and radiochemical purity were determined by thin-layer chromatography 
performed on SG-ITLC plates (Pall Corporation, USA), using 10% (w/v) ammonium acetate: methanol (1:1) as 
the mobile phase. SE-HPLC was also employed using TSK-Gel SW 3000 (7.5 × 300 mm, 10 µm, TosoHass) 
column, with an isocratic mobile phase of NaCl 0.9%/NaN3 0.05% and a flow rate of 1.0 mL/min. When needed, 
radiolabeled conjugates were purified from unbound radiometal by size exclusion chromatography on PD-10 
column eluted with phosphate buffered saline at 0.05 mol/L.  
 
2.7. Cell Culture  
 
   The human cell lines from squamous carcinoma (A431 and SCC25), colorectal carcinoma (SNU-C2B), 
glioblastoma-astrocytoma (U373 MG), prostate carcinoma (DU145) and the mama carcinomas (HCC 1419 and 
SK-BR 3) were used in the in vitro experiments. In addition, the human skin fibroblast cell line BJ was used as a 
control. A431, SK-BR 3 and SCC25 cell line was cultured in DMEM high glucose medium. U373 MG, SNU-
C2B, DU145 and BJ cell lines were cultured in RPMI 1640. All media were supplemented with 10% fetal calf 
serum and Penicilin/Streptomycin (penicillin 100 IU/mL and streptomycin 100 µg/mL). During cell culture and 
cell experiments (unless otherwise stated), cells were grown at 37°C in incubators with humidified air, 
equilibrated with 5% CO2.  
 
2.8. Binding saturation and competitive assays 
 
   For saturation binding and competitive experiments A431, SNU-C2B, HCC 1419 and SK-BR 3 cells were 
cultured ~2 × 105cells/well on 12-well-plates (BD Falcon™, Becton-Dickinson, UK) in 1 mL of medium for 24 
h prior to the studies. Cells were treated with solutions of different concentrations (100 µL/well, 2.7–120.0 
nmol/L) of radiolabeled conjugates for the saturation-binding assay. For the competitive binding assay cells were 
incubated with 100 µL/well (50 ng, ~75000 cpm/well) of radioimmunoconjugates in cell culture medium and 
incresing concentrations of unmodified mAbs. After incubating the cells for 3 hours at 4 ºC or 37 ºC, the 
medium was discarded and cells were washed with ice-cold phosphate buffer solution (PBS). Cells were lysed 
using 0.5 mL of 0.5 M NaOH containing 5% SDS and radioactivity was measured in an automatic γ or β-
counter. The nonspecific binding was studied by adding a 100 times excess of native Nimotuzumab or 
Trastuzumab to some wells. Triplicate cell dishes were used for each measuring point. For cell counting, a 
representative parallel sample from the experiments was trypsinized for about 15 min and the cells were counted 
using a fully automated cell analyzing system (CASY TT, Roche Innovatis AG, Germany). The mean was used 
as a cell number for all wells. Dissociation constants (Kd), half maximal inhibitory concentration (IC50) and 
maximal binding sites (Bmax) were estimated from the non-linear fitted curves using GraphPad Prism software 
(GraphPad Software, Inc., California, USA). The immunoreactivity fraction of the radioimmunoconjugates was 
determined using the method described by Konishi et. al., based on competitive binding assay using fixed cell 
concentration.  
 
2.9. Cytotoxicity study  
 
   For cytotoxic study A431, SNU-C2B, SCC25, HCC 1419, U373 MG, PC-3 and SK-BR 3 cells were cultured 
(~2 × 105 cells/well) on 12-well-plates for 48 h. Cells were treated with 90Y-DOTA-Bn-hR3/Herc with different 
DOTA-Bn/mAb molar ratios, Theraloc®, HerceptinTM and 90YCl3 for 10 days and cell proliferation was then 
assessed. At corresponding time point cells were trypsinazed and living cells were counted using CASY TT. The 
increase in cell number was compared with control samples. 
 
2.10. In vivo studies  
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   As reported previously, animal experiments were performed according to the Animals Ethics Committees of 
the Faculty of Pharmacy (Charles University, Hradec Kralove, Czech Republic) or Institute of Nuclear Research 
(Husinec-Rez, Czech Republic).  
 
2.11. Biodistribution of 177Lu-nimotuzumab in mice bearing SNU-C2B xenograft  
 
   The in vivo studies of 177Lu-DOTA-Bn-h-R3 in tumour model was conducted in female SNU-C2B engraft 
bearing athymic mice. The mice were injected subcutaneously with SNU-C2B tumour cells (~6 to 8 million cells 
per tumour in 100 µL of cell culture medium). The tumours were allowed to grow for two weeks before the 
experiments were performed. Mice were tail vein injected with approximately 100 kBq (50 µL, 10 µg) of 177Lu-
DOTA-Bn-h-R3. Preparation with 50-fold excess of p-SCN-Bn-DOTA to modify Nimotuzumab was used. 
Groups of three animals were anesthetized, bled, sacrificed and dissected at 3, 24, 48, 72 and 144 h after 
injection. In addition to the tumours, blood, liver, kidney, muscle, stomach and skin were collected, weighed, 
and measured in a γ-counter. The percentage of injected dose per gram tissue was determined.  
 
2.12. Biodistribution of 177Lu-nimotuzumab in mice bearing A431 xenograft  
 
   Mice bearing A431 human epithelial carcinoma xenogratfs were injected intravenously via tail vein with 
approximately 100 to 280 kBq (100 µL, 10 µg) of 177Lu-DOTA-Bn-h-R3. Groups of three to four animals were 
anesthetized, euthanized by cervical dislocation, and dissected at 24, 72, 96, 168, 216 and 264 h after injection. 
In addition, 177Lu-DOTA-Bn-h-R3 conjugate was applied directly into the volume of the tumour tissue for a 
second group of mice, to study the in vivo behavior of loco regional applied radioimmunoconjugate. Groups of 
four animals were anesthetized, euthanized by cervical dislocation, and dissected at 24, 72 and 96 h after 
injection. At the selected time points for each experiment, blood was collected by cardiac puncture and tumours 
and main organs were collected, weighed, and measured in an automatic γ-counter. The percent of injected dose 
per gram of tissue were determined using standards representing the injected dose per animal and tumour-to-non 
tumour (T/nT) tissue ratios were also calculated.  
 
2.13. Statistical analysis  
 
   Statistical analysis was performed to compare the results from radiolabeling, in vitro studies and the 
differences in tissue uptakes among the conjugates using Student’s t-test (P < 0.05) or analysis of variance (One 
or Two-way ANOVA test) by the software package GraphPad Prism. The ANOVA test was followed by 
Bonferroni’s multiple comparison test (P < 0.05). The same approach was used to determine the differences 
between intravenously and locoregional application.  
 
3. Results and discussion  
 
3.1. Anitbodies modification and radiochemistry  
 
   Conjugates with high purity and low-grade aggregation were obtained (Figure 1). The concentration of 
conjugates ranged from 5.5 – 8.0 mg/mL as determined by Bradford assay. Conjugation reaction gave final 
chelate to mAbs ratios of 2-4, 9, 12 and 15 for 20:1, 50:1, 100:1 and 150:1 chelate/mAb molar ratios, 
respectively. For rituximab the conjugation reaction gave 2 – 3 1B4M-DTPA group per mAb molecule. 
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FIG. 1. HPLC profiles of DOTA-mAbs conjugate. 
 
 
   Since 90Yand 177Lu is used for endoradiotherapeutic purpose, this study was undertaken to obtain 
radioimmunoconjugates with high specific activities. Radiolabeling yield higher than 90% were obtained. 
Radioimmuconjugates with high radiochemical purity (> 98%) and specific activity up to 2 GBq/mg (Figure 2) 
were obtained. The quality of the radionuclide and the volume of radiolabeling mixture influenced the 
radiolabeling efficiency [9]. The radiolabeling yields and specific activities achieved are suitable for 
radiopharmaceutical preparation. It seems to be that the radioactive concentration, not only in the radionuclide 
preparation but also in the final reaction mixture, plays an important role in the labelling of mAbs with 
radiometals. 
 
 
     
(a)                                                                                  (b) 
 
0.5 GBq/mg 1.0 GBq/mg 
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(b)                                                                                       (c) 
  
FIG. 2. Radio HPLC profiles of the radiolabeled conjugates where the uppper part corresponds to UV profile 
where the main peak (left) and the second peak (right) corresponds to the radioimmunoconjugate and DTPA 
added for the quality control, respectively: a) 177Lu-DOTA-hR3, SA 0.5 GBq/mg. b) 177Lu-DOTA-hR3, SA 1 
GBq/mg. c) 177Lu-DOTAhR3, SA 2 GBq/mg. d) 90Y-14BM-Rituximab. 
 
 
3.2. In vitro studies 
 
   Radioimmunoconjugates without significant loss of biological activity were obtained. The binding of the 
radioimmunoconjugate to the cell lines was receptor specific estimated for the ability to compete with native 
unmodified mAbs [9-12]. The immunoreactivity fraction of labelled mAbs was higher than 90%. The results 
showed that the conjugation and radiolabeling did not significantly affect the specifity and affinity of the 
conjugate.  
   The results from the cell proliferation assay with 90Y-mAbs conjugates, unmodified mAbs and 90Y showed that 
90Y-mAbs conjugates increased cell growth proliferation compared with unmodified mAbs and 90Y (Figure 3). 
The cell proliferation study shows that 90Y-DOTA-Bn-h-R3 conjugates, like nimotuzumab, selectively binding 
to cells which moderate to high EGFR expression due to the necessity of bivalent binding in order to have stable 
attachment to the cell surface [13]. The increased cell proliferation inhibition of 90Y-DOTA-Bn-conjugates over 
unmodified mAbs or 90Y alone in treated cells might be explained as due to the crossfire effect of the 90Y 
radiation and its residualization. 
 
2.0 GBq/mg 
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FIG. 3. Cell growth inhibition assay 
 
 
   In a previous study [14], Trastuzumab labeled with 111In showed 1.2 fold higher toxicity in cultured SKBR3 
cells than unlabeled trastuzumab whereas in a recent study15 Trastuzumab labelled with 177Lu showed 4.5-fold 
higher toxicity in cultured SKBR3 cells than unlabeled trastuzumab. In this study, it was observed that 90Y-
(DOTA-NHS)8-9-Herceptin and 90Y-(DOTA-Bn)8-9-Herceptin showed 3.0 and 1.7-fold higher toxicity, 
respectively, than unlabeled trastuzumab. Consequently, target RIT with 90Y (h-R3 or Trastuzumab) could be a 
promising approach to increase the apoptotic effect of h-R3 and Trastuzumab in cells with intermediate to high 
EGFR expression. Due to energy and maximal tissue penetration of the beta particles emitted by 90Y and the 
results of the citotoxicity studies, 90Y-hR3/Herc might be suitable for treatment of a large diameter solid 
tumours.  
 
3.2. In vivo studies  
 
The results of the biodistribution study of 177Lu-DOTA-Bn-h-R3 in mice with SNU-C2B tumours xenograft, 
previously reported [15], showed significant uptake in blood, liver, kidneys, tumours and the skin connected to 
tumours. The maximum and the average uptake of the radioimmunoconjugate for the SNU-C2B tumours were 
10.0 ± 1.9 % ID/g. In this study, tumours uptake of 177Lu-DOTA-Bn-h-R3 was higher than reported by Alejo 
Morales-Morales et al. [16], Velikyan et al.[17] , S.-Y.Lee et al. [18] and similar as reported by D. E. Milenic et 
al. [19].  
   The biodistribution studies of 177Lu-(DOTA-Bn)n-h-R3, n = 4-5 were conducted in A431 human epidermal 
carcinoma xenografts in Balb/c nude mice. Tumor uptake reached maximum value of 22.4 ± 3.1 %ID/g at 72 h. 
From 72 to 216 hours the average tumor uptake was 18.3 ± 0.3 %ID/g. Bone uptake was low with maximum 
value of 2.7 ± 1.1 %ID/g at 24h and an average of 1.6 ± 0.5 from 72 to 264 h. Tumor to non tumours tissues 
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ratios reached maximum values of 2.6, 2.4, 6.1, 6.6, 23.5 and 17.5 for blood, liver, spleen, kidneys, muscle and 
bone, respectively. When 177Lu-(DOTA-Bn)n-h-R3, n = 4-5 conjugate was applied locoregionally to A431 
xenografts in Balc/c nude mice, tumour uptake was significantly higher at 24 and 72 h than those observed for 
intravenous application (P < 0.001). Tumour uptake peaked 32.7 ± 2.9 %ID/g at 72 h. Locoregional application 
of the 177Lu-DOTA-Bn-h-R3 conjugate showed T/nT ratios 4.6, 9.8, 10.5, 9.8 and 11.7 times higher for blood, 
liver, spleen, lungs and kidneys, respectively than those calculated for i.v. application. At 72 h the T/nT ratios 
mentioned above were two times higher for LR than IV application. In this study, the tumour uptake values and 
tumour/non tumour ratios are higher than those previously reported for h-R3 and the parental murine mAb 
labelled with 99mTc and 90Y.[20, 21].  
 
4. Conclusions 
 
   Radioimmunoconjugates with high radiolabeling yield, radiochemical purity and specific activity were 
obtained without significant loss in its biological activity. Cytotoxicity studies showed the potential of the 
radioimmunoconjugates over unmodified monoclonal antibodies to inhibit cell proliferation in cell lines with 
intermediate to high EGFR/HER-2 expression. 177Lu/90Y-DOTA-h-R3/Trastuzumab may have a potential for 
further evaluations as a radiopharmaceutical for RIT of EGFR overexpressing tumours. 
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Abstract. The major work carried-out in Hungary focused on in vivo testing of radiopharmaceutical applicant 
molecules. Elements of a complete biological evaluation system were published in earlier IAEA-coordinated 
projects. In this present period beyond the known normal and pathological animal distribution-, and 
radiotoxicological studies we established several double xenografted Nude mice models that are available to 
image and quantify the specific and non-specific binding of tumor-seeking radioligands. Spontaneously 
occurring canine tumors (eg.: canine insulinomas and B-cell lymphomas) were also selected and their usefulness 
proved in therapeutical radiopharmaceutical research.  Selection of the referred animal patients based on 
PET/CT or SPECT/CT whole body hybrid images (68Ga-DOTA-TATE, 99mTc-HYNIC-TATE, and FDG 
PET/CT) and immunohistochemical evaluation of biopsy specimens were carried-out. We also performed pilot 
studies for enhancing the radiopharmaceutical uptake in tumor xenografts by the use of locoregional 
electromagnetic hyperthermia (Oncothermia®). This complete animal testing method is capable to provide  
important preclinical data including safety-, kinetic-, excretion-, internal dosimetry-, and efficacy results that are 
assisting the decision making process for investigators. Hungary still offers its animal testing capacities for all 
other interesting participating countries.  
 
 
1. Introduction 
 
   Numerous regulatory peptide receptors are overexpressed in some specific cancers. The specific receptor 
binding property of peptides can be exploited by their labelling with a radionuclide and their use as carriers to 
guide the radioactivity to the tissues expressing their specific receptors. During the past decade, radiolabelled 
receptor-binding peptides have emerged as an important class of radiopharmaceuticals for tumour diagnosis and 
therapy. The first and most successful imaging agents to date are somatostatin analogues, which are routinely 
used for somatostatin receptor scintigraphy. Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTA-
octreotide and 177Lu-DOTA-octreotate in neuroendocrine tumours (NETs) results in symptomatic 
improvement, prolonged survival, and enhanced quality of life. The results in terms of tumour regression are 
very encouraging with few and mostly mild side effects when patients are carefully selected and kidney 
protective agents are given. Nevertheless much profit can be gained from improving the available   strategies and 
developing new strategies. Peptides such as minigastrin, glucagon-like peptide-1 (GLP-1), cholecystokinin 
(CCK), bombesin (BN)/gastrin-releasing peptide (GRP), substance P, neurotensin (NT), neuropeptide Y (NPY) 
and RGD peptides are promising for PRRT and currently under preclinical and clinical development [7]. 
   Radioimmunotherapy (RIT) combines the targeting advantage of a monoclonal antibody with the 
radiosensitivity of non-Hodgkin lymphoma (NHL) cells. The unlabeled antibodies have indeed added efficacy, 
but many patients still relapse. One method of enhancing the cytotoxic potential of monoclonal antibodies is to 
attach them to a radionuclide to form a radioimmunoconjugate (RIC). The use of an RIC has the advantage of 
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targeting not only the cell to which the antibody is bound but also the surrounding tumor cells and 
microenvironment. 
   The similarities between dog and human cancers are increasingly being recognized and utilized by biomedical 
researchers and pharma-, equipment industry. The publicly available canine genome has initiated comparative 
genomics studies too. Pet owners are highly motivated to seek novel options for management of cancer in their 
pets, especially if conventional treatments do not meet their expectations. A pet owner's decision to pursue an 
investigational treatment is often influenced by the risks associated with this therapy compared to conventional 
therapy, as well as their expectations for outcomes and reduced costs for care provided by an investigational 
trial. Additionally, many pet owners are motivated by the opportunity to contribute to the advancement of cancer 
treatment for future human and canine patients. Experience of investigators using these tumors has shown that 
animal owners and referring veterinarians are most cooperative in reasonable, humane approaches to 
experimental cancer therapy. From the researcher’s point of view the advantages of spontaneous animal tumors 
in larger animals include the relatively large tumor volumes and correspondingly larger sizes of treatment fields. 
Longer follow-up times are also generally possible. Clinical data obtained through serial monitoring can be 
obtained in addition to the data of local tumor control and normal tissue response. Animals with spontaneous 
tumors often have concomitant diseases similar to those encountered in humans, which may or may not 
complicate the management of the tumor.  In these dogs, cancers develop naturally in the context of an intact 
immune system and with a syngeneic host and tumor microenvironment. Similar environmental, nutrition, age, 
sex, and reproductive factors lead to tumor development and progression in human and canine cancers. They 
share similar features such as histological appearance, tumour genetics, biological behavior, molecular targets, 
therapeutic response, and unfortunately, acquired resistance, recurrence, and metastasis. Thus all the above listed 
facts make the referred, spontaneously occurring canine tumors maybe the best model of human malignancies.  
Similarly to several other neuro-endocrine malignancies canine insulinoma shows very relevant similarities 
human insulinoma including the overexpression of somatostatin (especially SSR-2a subgroup) receptors. B-cell 
originated malignant canine lymphomas proved to be the best model of human non-Hodgkin lymphomas in 
several studies. As human B-cell lymphomas also in dogs malignant cells overexpress CD-20 antigen in the cell 
membrane presebting a convenient target for immuno- imaging and therapy in both species.  
 
2.   Preliminary results     
 
2.1. Results on double-xenografted nude mice 
 
   More recently we realized that several advantages are provided if the same immunosupressed animal being 
inoculated with two different tumor cell lines. The main advantage is that it is available to compare, image and 
quantify the differencies between specific and non-specific tumor uptakes within the same living organism. 
Other characteristics e.g., blood-flow, glucose metabolism, hypoxic-, apoptotic regions of tumors could be also 
evaluated in the different xenografts which could provide also usefull data to understand unawaited results.  
 
TABLE 1. Summary of characteristics of several double-xenografted nude mouse models 
 
No Left thigh Right thigh Tested radiocompounds 
1 INS-1 (SSR2 +++ but folate -) 
HeDe 
(SSR2a - but folate +++) 
68Ga-DOTA-TATE 
99mTc-HYNIC-TATE 
177Lu-DOTA-TATE 
68Ga-folate targeting colloid 
99mTc-folate targeting colloid 
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2 INS-1 (SSR2 +++ but folate -) 
NRIRR/ca/09 
(SSR2a +++ but folate-) 
68Ga-DOTA-TATE 
99mTc-HYNIC-TATE 
177Lu-DOTA-TATE 
3 Raji (CD20+++ but) 
HeDe 
(SSR2a - but folate +++) 
177Lu-Rituximab 
68Ga-folate targeting colloid 
99mTc-folate targeting colloid 
4 A431 EGFR+++ but SSR2-) 
INS-1 
(SSR2 +++ but folate -) 
177Lu-hR3 
177Lu-hR3 
68Ga-DOTA-TATE 
99mTc-HYNIC-TATE 
177Lu-DOTA-TATE 
5 WRO (TSHR+++ but SSR2-) 
INS-1 
(SSR2 +++ but folate -) 
99mTc-super TSH analogue 
68Ga-DOTA-TATE 
99mTc-HYNIC-TATE 
177Lu-DOTA-TATE 
 
 
   In preliminary tests we found that radiopharmaceutical uptake in xenografts that overexpress the specific target 
could be 1.5 -18 times higher than in contralateral negative tumors.  
   If the Nude mice is inoculated with two same cell lines the model is available to measure the effects of 
different locoregional treatments. In our pilot studies locoregional electromagnetic hyperthermia (Oncothermia®) 
increased the blood-flow with 10-15% and the specific uptake upto 30% in the treated tumor compared to the 
other contralateral, non-treated xenograft. More studies are needed to prove the significance of this above 
observation.  
 
2.2.1.  Results on the referred spontaneously occurring insulinomas 
 
   Spontaneously occurring dog patients with a suspection of insulinoma were referred to our Institute for final 
diagnosis and treatment if possible. Suspection was made on hypoglycaemia and hyperinsulinoma measured in 
blood and serum samples. The diagnosis was made by blood hematology, biochemical panel, repeated glucose 
and insulin measurements and whole body hybrid imaging was also carried-out for localizing the tumors, 
stadium based diagnosis and proving the in vivo presence of target (SSR2).  Dogs were injected either by 99mTc-
HYNIC- TATE (SPECT/CT) or 68Ga-DOTA-TATE (PET/CT) and inclusion criteria were the clear focal 
localisation of radioligands in at least 1 pancreas laesion and more than one hepatic lesions. Altogether 14 dogs 
fullfilled the criterias but only 9 owners choosed the offered systemic radioimmunotherapy. 
   The included dogs were hospitalized and treated by a single injection of 177Lu-DOTA-TATE peptide at a dose 
of 100 MBq/ bwkgs. Hematological and biochemical parameters and clinical signs (especially lymph node sizes) 
were monitored weekly at the first month, then at 3, 6, 9 and 12 month after therapy. 
 
 
TABLE 2. Efficacy results of 9 referred dogs with insulinoma treated by a single injection of 177LuDOTA-TATE 
in a dose of 100 MBq/ bwkgs. 
  
No Dog Diagnostic 3ms FU 6ms FU 9ms FU 12ms FU 
1 7ys, intact male,36 kg 
99mTc HYNIC-  
TATE,SPECT/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
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2 9ys, castrated male, 39 kg 
99mTc HYNIC-  
TATE,SPECT/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
3 11 ys , spayed female, 42 kg 
99mTc HYNIC-  
TATE,SPECT/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
4 12 ys spayed female, 8 kg 
99mTc HYNIC-  
TATE,SPECT/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
5 8 ys , intact female, 22 kg 
99mTc HYNIC-  
TATE,SPECT/CT 
Symptom 
free 
Symptom 
free 
Recurrent 
disease Euthanasia 
6 9ys, intact male,13 kg 
99mTc HYNIC-  
TATE,SPECT/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
7 10 ys , spayed female, 31 kg 
68GaDOTA-TATE 
PET/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Recurrent 
disease 
8 12 ys , spayed female, 51 kg 
68GaDOTA-TATE 
PET/CT 
Symptom 
free 
but  
cardiac 
failure 
Symptom 
free 
but  cardiac 
failure 
Died 
because of 
cardiac/ 
renal 
failure 
NA 
9 
8 ys, spayed 
female , 
17 kg 
68GaDOTA-TATE 
PET/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
 
 
   Eigth out of 9 dogs tolerated well the treatment no side effects were observed. The only dog we lost 7 months 
after completing the therapy was a large sized, elderly, obes dog having a subclinical cardiac insufficiency that 
was only detected 8 days after initiating the treatment. This particular dog started to loose weight, developed 
renal- and liver insufficiency and was euthanized on the owner’s request because of progressing cardiac failure 
and renal/liver problems.  Autopsy revealed severe cardiac enlargement, cardiomyopathy, renal atrophy, 
hepatomegalia, intra- and perilobal fattic hepatodystrophia. 
   In all the 9 treated dogs we realized a fast normalization of glucose and insuline levels, 5-10 days after 
radiopharmaceutical application the glucose and insuline concentrations were found within the normal ranges. 
The symptoms (hypoglycaemia and hyperinsulinoma) recurred in one dog 9 months and in another dog 12 
months after completing the treatment but 6 out of 9 dogs were symptom free even 12 month after the treatment.  
 
This preliminary data are very promising especially because the disease in this stage is inoperable in dogs as well 
and because that conventional chemotharapy known to provide only questionable results in dogs too.  
 
2.2.2. Results on the referred spontaneously occurring malignant canine lymphomas 
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   Spontaneously occurring dog patients with a suspection of malignant lymphoma were referred to our Institute 
for final diagnosis and treatment if possible. Suspection was made on chronicly enlarged lymph nodes with no 
known intermittant infections or parasitic diseases. The diagnosis was made by blood hematology, biochemical 
panel, and cytology (immunohistochemistry on CD-20 antigen) and whole body FDG PET/CT imaging was also 
carried-out for localizing the tumors, and give the stadium-based diagnosis. The inclusion criteria were : the 
involvement of more than 10 lymph nodes, liver and spleen but not the bone marrrow in the entire body (Stage 
4a) and the immunohistochemical prove of CD20 antigen presence from a removed lymph node.  Altogether 6 
dogs fullfilled the criterias and 4 owners choosed the offered systemic radioimmunotherapy. 
   The included dogs were hospitalized and treated by a single injection of 90Y-anti CD20 (Zevalin) antibody at a 
dose of 15 MBq/ bwkgs. Hematological and biochemical parameters and clinical signs (especially lymph node 
sizes) were monitored weekly at the first month, then at 3, 6, 9 and 12 month after therapy. 
 
 
TABLE 3. Efficacy results of 4 referred dogs with stage 4a B-cell lymphoma treated by a single injection of 
90Y-anti CD20 (Zevalin®) in a dose of 15 MBq/ bwkgs. 
 
No Dog Diagnostic 3ms FU 6ms FU 9ms FU 12ms FU 
1 7ys, intact female,30 kg 
FDG, 
PET/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Recurrent 
disease 
2 9ys, castrated male, 31 kg 
FDG, 
PET/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
3 11 ys , spayed female, 27 kg 
FDG, 
PET/CT 
Symptom 
free 
Symptom 
free 
Symptom 
free 
Symptom 
free 
4 12 ys intact male, 8 kg 
FDG, 
PET/CT 
Symptom 
free 
Symptom 
free 
Recurrent 
disease 
Recurrent 
disease 
 
 
   All the 4 dogs tolerated well the treatment no severe side effects occured. Between 3-10 days postapplication 
an intermittant increase of renal parameters (carbamid, creatinine, phosphore) in each dogs were observed but 
they were normalized without treatment. 
   In all the 4 treated dogs we realized a fast decrease in lymph node sizes, 5-10 days after radiopharmaceutical 
application the lymp node sizes normalized. The symptoms recurred in one dog 9 months and in another dog 12 
months after completing the treatment but 2 out of 4 dogs were symptom free even 12 month after the treatment.  
   Collected  data of 90Y-anti CD20 (Zevalin) monoclonal antibody will be available for later 177Lu-conjugated-
Rituximab comparison.  
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1. Introduction 
 
   The objective of the present Coordinated Research Program (CRP) is to develop target-specific therapeutic 
radiopharmaceuticals based on 177Lu- and 90Y-labeled monoclonal antibodies and peptides. 
Radioimmunotherapy (RIT) or treatment of cancerous lesions over-expressing tumor-specific antigens by 
radiolabeled antibodies is an effective modality to combat a wide variety of cancers. Two radiolabeled 
monoclonal antibodies, namely 90Y-labeled anti-CD20 antibody (Zevalin®) and 131I-labeled anti-CD20 antibody 
(Bexxar®) are regularly used to treat non-Hodgkin’s lymphoma [1,2]. Several other monoclonal antibodies 
labeled with a variety of β- and ∝-emitting radionuclides are presently undergoing different stages of clinical 
trials [3,4]. Similarly, peptides labeled with suitable therapeutic radionuclides could be effectively used to treat 
cancers over-expressing specific type of receptors. Towards this, the utilization of 177Lu-labeled DOTA-TATE to 
treat the patients suffering from neuro-endocrine cancers over-expressing somatostatin receptors needs special 
mention [5,6]. Apart from these, other peptides, such as VIP, bombesin, gastrin releasing peptides, minigastrin, 
substance P, RGD have been labeled with different therapeutic radionuclides for developing agents for targeted 
tumor therapy [7,8]. 
   Although several β- and a few ∝-emitting radionuclides have been used for the development of targeted 
therapy agents based on antibodies and peptides, 177Lu and 90Y could be the two best possible isotopes for 
developing such agents [9]. Multi-Curie levels of 177Lu, with adequately high specific activity, could be 
produced by simple direct neutron capture route using enriched (in 176Lu) Lu2O3 target in medium flux research 
reactors and supplied without much decay loss owing to its comparatively longer half-life [9,10]. On the other 
hand, availability of 90Sr/90Y radionuclide generator system capable of producing clinical grade 90Y in a hospital 
radiopharmacy will ensure the uninterrupted supply of 90Y-based radiopharmaceuticals over a long period [9,11]. 
The work carried out in the Radiopharmaceuticals Division (RPhD), Bhabha Atomic Research Centre (BARC) 
following RCM-1 of this CRP is outlined in the present report. Herein, we discuss our efforts toward production 
of multi-Curie levels of 177Lu and development of suitable 90Sr/90Y radionuclide generator, preparation of 
antibody-bifunctional chelating agent (BFCA) conjugate and subsequent optimization of the labeling protocols 
for the preparation of 177Lu and 90Y-labeld antibodies, such as, MabThera® and Reditux®. The report also 
describes our effort towards the development of a DOTA-TATE cold kit, suitable for the preparation of 
therapeutic doses of 177Lu-DOTA-TATE for human administration. 
 
2. Production of 177Lu 
 
   Radiopharmaceuticals Division, Bhabha Atomic Research Centre has initiated research on the development of 
177Lu-based therapeutic agents as early as 2000 and started supplying this radionuclide for clinical applications 
from 2007. With the introduction of 177Lu-DOTA-TATE therapy in India in 2007 for the treatment of patients 
suffering from various types of neuro-endocrine cancers; the demand for adequately high specific activity 177Lu 
[T1/2 = 6.73 d, Eβ(max) = 497 keV, Eγ = 208 keV (11%), 113 keV (6.4%], suitable for the preparation of receptor-
based therapeutic agents, has shown constant and steady increase [12]. In order to cater this increased 
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requirement, production facilities at the Radiopharmaceuticals Division have recently been augmented. At 
present, high specific activity clinical grade (sterile and pyrogen free) 177Lu is being regularly produced at our 
Institute and supplied to several nuclear medicine centres across our country for the preparation of therapeutic 
radiopharmaceuticals. Starting from a modest production of ~6.5 Ci (~241 GBq) and supplying ~2.7 Ci (~100 
GBq) (11 consignments) of 177Lu in 2007, we have produced and supplied more than 100 Ci (3.7 TBq) and 50 Ci 
(1.85 GBq) (75 consignments) of 177Lu, respectively to various nuclear medicine centres of our country till the 
end of August, 2012 (Figure 1). The frequency of production has also been augmented from once in a month to 
thrice in a month to cater the need of the nuclear medicine centres. 
   At present, high specific activity clinical grade 177Lu is produced by irradiating enriched (82% in 176Lu) Lu2O3 
target at a thermal neutron flux of 9 × 1013-1 × 1014 n/cm-2.s-1 in DHRUVA reactor of our Institute for a period of 
3-4 weeks. Following irradiation, the target is dissolved in supra-pure 0.01 M HCl by gentle warming inside a 
lead-shielded plant. The resultant solution thus obtained is evaporated to near-dryness and subsequently 
reconstituted in ultra-pure water. The evaporation and reconstitution steps are repeated a few times. 
Subsequently, the preparation is allowed to pass through the Millipore® filter and dispensed as per the need of the 
customers. 
   Assay of total activity produced was primarily done by using a pre-calibrated ion-chamber and subsequently 
reconfirmed by gamma-ray spectrometry carried out using a HPGe detector coupled with a 4 K multichannel 
analyzer (MCA). The specific activity of 177Lu produced at the end-of-bombardment (EOB) is observed to be 
between 814-1295 GBq.mg-1 (22-35 Ci.mg-1). The radionuclidic purity of 177Lu is determined by analyzing the 
gamma-ray spectrum of the appropriately diluted samples of radiochemically processed 177LuCl3. The average 
level of radionuclidic impurity burden in 177Lu due to 177mLu was found to be 3.7-5.5 kBq of 177mLu / 37 MBq of 
177Lu (100-150 nCi / 1 mCi) at EOB, which indicates that 177Lu has a radionuclidic purity of ~99.98% at the time 
of supply [10,12]. The radiochemical purity of 177LuCl3 is determined by employing paper chromatography 
technique using normal saline as the eluting solvent and found to be more than 98% at the time of supply. 
   The chemical purity of 177Lu is another important criterion, particularly when the radionuclide is to be used for 
the preparation of target-specific agents. It has been documented that presence of chemical impurities such as, 
Ca, Zn, Fe, Pb, Al, Cu adversely affects the radiolabeling yield of such agents and therefore the level of these 
impurities should be as low as possible in the processed 177Lu [12]. The levels of chemical impurities present in 
the 177Lu supplied from our Institute is determined by employing inductively coupled plasma - atomic emission 
spectroscopy (ICP-AES) and found to be below acceptable limits of such impurities [12]. 
We have also developed suitable method for the production of no-carrier-added (NCA) 177Lu [theoretical specific 
activity 4.07 TBq/mg (110 Ci/mg)] which can be produced following the indirect production route involving the 
neutron irradiation of enriched (99% in 176Yb) Yb2O3 target (σ = 2.4 b). This leads to the production of 177Yb (T½ 
= 1.9 h), which subsequently undergoes β- particle emission to produce 177Lu. A novel two-step electrochemical 
pathway for the separation of NCA 177Lu from irradiated Yb target has been developed at our end [13]. The 
method is based on two subsequent electrolysis processes wherein the first separates 177Lu from the bulk of 
irradiated Yb target and the second one purifies 177Lu by removing the trace level of Yb impurities present in the 
separated 177Lu. This process provides NCA 177Lu with >99.99% radionuclidic purity and an overall separation 
yield of ~99% within 3-4 h. The Hg content in the product was determined to be <1 ppm thus making it suitable 
for various kinds of biomedical applications [13]. A suitable method was also developed to recover the Yb from 
the ytterbium amalgam to make this production route economically more viable. The method is scaled up to 
produce 37 GBq (1 Ci) of 177Lu activity and has the potential to be utilized for regular production of NCA 177Lu. 
Lu-177 obtained via the indirect route being NCA in nature has very high specific activity and is free from 
177mLu (T½ = 160.5 d), whose presence as radionuclidic impurity, is inevitable in 177Lu produced via the direct 
neutron capture route. However, the production of 177Lu through indirect route is comparatively tedious, less 
economic and difficult to scale up without high degree of automation [12]. Therefore, this method has not been 
adopted for regular production of 177Lu in India. On the contrary, as 177Lu with sufficiently high specific activity 
and in adequate quantity could be easily produced by employing direct neutron capture route, regular production 
and supply of 177Lu from BARC to nuclear medicine centres is based on this route of production. 
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FIG. 1. Growth of 177Lu production and supply in India (updated August 2012). 
 
 
3. Production of 90Y 
 
   Yttrium-90 [T1/2 = 64.1 h, Eβ(max) = 2.27 MeV, no γ] is a pure β- emitter, which has well-established applications 
in targeted radiotherapy. Yttrium-90 could be obtained either by direct neutron irradiation of natural yttrium 
target i.e. 89Y(n,γ)90Y or from a 90Sr/90Y radionuclide generator system. However, as the cross-section of 
89Y(n,γ)90Y is very low (σ = 1.28 mb), only low specific activity 90Y could be obtained by this method and 
hence, it has a limited interest [9]. Therefore, for obtaining large quantities of 90Y for therapeutic applications 
90Sr/90Y radionuclide generator is preferred. It is reported that, a few thousand Curies of 90Y could be obtained 
from only 1 Ci (37 GBq) of 90Sr over several years and such a generator can be eluted twice in a week to obtain 
450-500 mCi (16.65-18.5 GBq) with each elution [14]. It is also documented that supplementing the parent 
radionuclide activity by adding about 10% of 90Sr i.e. with 100 mCi (3.7 GBq) in every 4-5 years will be 
adequate to keep the 90Y supply constant over a very long period [14]. Therefore, effort was directed to develop 
a 90Sr/90Y radionuclide generator system suitable of producing clinical grade 90Y for radiotherapeutic 
applications. 
   Working in this direction, we have developed a novel electrochemical method for the separation of 90Y from 
the bulk of 90Sr [14]. This methodology has been transferred to Isotope Technologies, Dresden, Germany 
through International Atomic Energy Agency (IAEA) for the development of commercial 90Sr/90Y generator. 
The effort has culminated in the construction of ‘Kamadhenu’, a fully computer controlled automated 90Sr/90Y 
generator system, capable of producing 90Y suitable for radiotherapeutic applications [14,15]. The generator is 
based on two-step electrochemical process and capable of separating clinical grade 90Y from the bulk of 
90Sr(NO3)2 feed solution. The first electrolysis is performed for 90 min at pH 2-3 at a potential of -2.5 V with 
100-200 mA current using platinum electrodes while the second electrolysis is performed for 45 minutes in 0.01 
N HNO3 medium at a potential of -2.5 V with 100 mA current. In the second step, the cathode from the first 
electrolysis containing 90Y is used as the anode along with a fresh circular platinum electrode as the cathode. The 
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90Y deposited on the circular cathode after the completion of second electrolysis step is dissolved in 0.1 N HCl to 
obtain 90Y chloride which is suitable for the preparation of 90Y-labeled agents for biomedical applications. The 
recovered 90Y had a high radionuclidic purity with only 30.2±15.2 kBq (817±411 nCi) of 90Sr per 37 GBq (1 Ci) 
of 90Y (0.817±0.411 ppm) is detected [14]. Some of the major advantages of this generator system are the low 
operational cost, generation of very low volume of radioactive wastes, lesser possibilities of metallic 
contamination in the eluted 90Y and the possibility of using the 90Sr repeatedly. This generator is presently being 
used in a few countries. Though ‘Kamadhenu’ is not acquired in RPhD, the above-mentioned methodology is 
used for the regular production of 90Y, which is used for the preparation of 90Y-labeled radiopharmaceuticals. 
 
4. Preparation of 177Lu-labeled Rituximab 
 
   Non Hodgkin’s lymphoma is a type of malignancy of the lymphoid system and is mainly derived from B-
lymphocytes. Most B-cell lymphomas express CD20, making it a suitable target antigen for the preparation of 
radiolabeled monoclonal antibodies. By linking anti-CD20 monoclonal antibodies to an appropriate therapeutic 
radioisotope, sites of disseminated disease can be targeted effectively. Rituximab is a chimeric antiCD20 B-cell 
specific monoclonal antibody which is an approved drug for the treatment of low-grade non Hodgkin’s 
lymphoma. Therefore, rituximab labeled with a therapeutic radionuclide could be envisaged as a suitable agent 
for radioimmunitherapy. 
   At the time of initiation of this work, we have the accessibility to very limited quantity of Mabthera®, which 
prompted us to standardize the protocol of preparation of radiolabeled antibodies by using immunoglobulin-G 
(IgG). The experience gained from the preparation of 177Lu-labeled IgG is directly utilized for the preparation of 
177Lu-labeled Mabthera® (commercially available from Roche, Switzerland) and Reditux® (commercially 
available from Dr. Reddy’s Laboratory, India) which are described below. 
 
4.1. Preparation and characterization of 177Lu-labeled IgG 
 
Lu-177 labeled IgG was prepared by a two step process involving coupling of IgG with a suitable bifunctional 
chelating agent (BFCA) followed by radiolabeling of the BFCA-IgG conjugate. The process followed is 
described below in brief. 
 
4.1.1. Preparation and purification of p-NCS-benzyl-DOTA-IgG conjugate 
 
   In order to facilitate labeling of IgG with 177Lu, it is necessary to couple it with a suitable BFCA. As decided in 
the previous meeting, p-NCS-benzyl-DOTA (p-NCS-benzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid) was chosen as the BFCA of choice for the present study owing to its ability to form complexes with 
lanthanides with high thermodynamic stability and superior kinetic inertness [16]. The condition for BFCA-IgG 
labeling was standardized by preparing the conjugate using different molar ratios of IgG and BFCA and labeling 
the conjugates, thus obtained, with 177Lu. The radiolabeling yield of the 177Lu-labeled conjugates were 
determined by the protein precipitation method which involves precipitation of the protein in the reaction 
mixture by trichloroacetic acid followed by the separation of precipitate and supernatant by centrifugation and 
subsequently counting the activity associated with these layers. It was observed that maximum complexation 
yield was achieved when minimum ratio of IgG to BFCA was maintained at 1:10. Therefore, for subsequent 
studies IgG-BFCA conjugate was prepared by incubating 5 mg of IgG (concentration 20 mg.mL-1) with 230 µg 
of p-NCS-benzyl-DOTA (corresponding to molar ratio of 1:10) in Na2CO3 buffer (pH=9.5) at 37°C for a period 
of ~17 h. The conjugate thus obtained was purified by removing free p-NCS-benzyl-DOTA present in the 
reaction mixture by using a pre-packed PD10 column. Purification procedure involved loading of ~2.5 mL of the 
crude BFCA-IgG conjugate on the column followed by fractional elution using NH4Oac buffer (pH=5.5). 
 
4.1.2. Preparation and characterization of 177Lu-labeled p-NCS-benzyl-DOTA-IgG conjugate 
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   Radiolabeling of purified p-NCS-benzyl-DOTA-IgG conjugate with 177Lu was carried out by incubating 200 
µg of the conjugate with 177LuCl3 (525 MBq, 14.2 mCi, 0.71 µg Lu) at 37°C for a period of 1 h. Characterization 
of 177Lu-labeled p-NCS-benzyl-DOTA-IgG was carried out using HPLC with silica gel column. The elution 
profile was monitored by detecting the radioactivity signal using a NaI(Tl) detector coupled with the HPLC 
system. An isocratic system consisting of 0.05 M phosphate buffer with 0.05% NaN3 as the eluting solvent was 
used. It was observed that 177Lu-labeled p-NCS-benzyl-DOTA-IgG conjugate eluted with a retention time of 14 
min whereas 177Lu-labeled p-NCS-Benzyl-DOTA eluted with a retention time of 21 min. A typical HPLC profile 
showing the elution of 177Lu-labeled p-NCS-benzyl-DOTA-IgG conjugate is shown in Figure 2. Under the above 
mentioned optimized reaction conditions, 177Lu-labeled p-NCS-benzyl-DOTA-IgG was obtained with >95% 
radiochemical purity. 
 
 
 
 
FIG.2.  Typical HPLC pattern of 177Lu-labeled IgG. 
 
 
4.2. Preparation and characterization of 177Lu-labeled MabThera® 
 
   Conjugation of MabThera® and p-NCS-benzyl-DOTA and subsequent 177Lu-labeling of the coupled product 
was done by following the protocol developed for the preparation of 177Lu-labeled IgG mentioned above. Lu-
177-labeled MabThera® was prepared following a two-step process described below. 
 
4.2.1. Preparation and purification of p-NCS-benzyl-DOTA-MabThera® conjugate 
 
p-NCS-benzyl-DOTA-MabThera® conjugate was prepared by incubating MabThera® with p-NCS-Benzyl-DOTA 
corresponding to molar ratio of 1:10 in Na2CO3 buffer (pH=9.5) at 37°C for a period of about 17 h. The 
conjugate was purified by removing excess BFCA from the reaction mixture using pre-packed PD10 columns. 
This was achieved by loading the conjugate in the column followed by the elution with NH4Oac buffer 
(pH=5.5). Eluants were collected into 1 mL fractions and the fractions containing maximum concentration of p-
NCS-benzyl-DOTA-MabThera® conjugate [Identified by protein estimation using Lowry (Folin-Ciocalteau) 
method] were pooled together. The purified conjugate thus obtained was utilized for the preparation of 177Lu-
labeled MabThera®. 
 
4.2.2. Preparation and characterization of 177Lu-labeled MabThera® 
 
Lu-177 labeling of p-NCS-benzyl-DOTA-MabThera® conjugate was achieved by incubating the conjugate with 
177LuCl3 (525 MBq, 14.2 mCi, 0.71 µg Lu) at 37°C for 90 min using NH4Oac buffer (pH~5.5). Characterization 
of 177Lu-labeled p-NCS-benzyl-DOTA-MabThera® conjugate was done by employing HPLC equipped with a gel 
column and tracking the eluant with NaI(Tl) detector. An isocratic system consisting 0.05 M phosphate buffer 
with 0.05% NaN3 was used as the mobile phase. The peak corresponding to 177Lu-labeled antibody-BFCA 
conjugate was observed at 14 min while uncomplexed 177LuCl3 eluted within the void volume. A typical HPLC 
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profile of 177Lu-labeled p-NCS-Benzyl-DOTA-MabThera® is shown in Figure 3. Lu-177-labeled p-NCS-benzyl-
DOTA-MabThera® conjugate was prepared with >95% radiochemical purity under the optimized reaction 
conditions. 
 
 
 
 
FIG. 3. Typical HPLC pattern of 177Lu-labeled MabThera®. 
 
 
4.2.3. Determination of average number of BFCAs per MabThera® molecule  
 
   Attempt was made to determine the average number of BFCAs attached per MabThera® molecule in p-NCS-
Benzyl-DOTA-MabThera® conjugate following the reported method [17]. For this, the conjugate (100 µg) was 
incubated with 177Lu (74 MBq, 2 mCi) containing excess 176Lu (1.17 µg, 10 times molar excess of antibody-
BFCA conjugate) at 37°C for 1 h and then subsequently allowed to react with DTPA 
(diethylenetriaminepentaacetic acid, taken in equimolar ratio with 176Lu i.e. 2.6 µg) for a period of 30 min at 
room temperature. Reaction mixture thus obtained was injected into HPLC column and the areas under peaks 
corresponding to 177Lu-labeled p-NCS-benzyl-DOTA-MabThera® conjugate as well as 177Lu-labeled DTPA were 
determined. The average number of BFCAs attached per MabThera® molecule was determined from these data 
and was found to be 6. 
 
4.2.4. Stability of 177Lu-labeled MabThera® 
 
   The in-vitro stability of 177Lu-labeled MabThera® was checked by incubating the radiolabeled antibody at room 
temperature and determining its radiochemical purity at different time intervals by employing the quality control 
techniques mentioned above. It was observed that 177Lu-labeled MabThera® retained its radiochemical purity 
>95% till 3 d, upto which the study was continued.  
 
4.2.5. Biological evaluation of 177Lu-labeled MabThera® 
 
   Raji cells (Burkitt’s lymphoma), which express CD20 antigen on their surface, were used for in-vitro binding 
studies of 177Lu-labeled MabThera®. Cells were grown to confluence in RPMI-1640 medium containing 10% 
fetal calf serum. After harvesting, 1×106 cells were incubated with 177Lu-labeled MabThera® for 2 h at 37°C and 
4°C. After incubation, the cells were washed thrice with 5 mL of Dulbecco phosphate buffer (DPBS) and 
centrifuged at 2000 rpm for 6 min at room temperature. The supernatant was decanted and the pellet was 
measured for radioactivity. Cell binding studies were performed with 1.25, 7.45 and 14 ng of 177Lu-labeled 
MabThera® and a maximum of ~30% and ~37% binding were recorded when 1.25 ng of radiolabeled antibody 
were incubated at 37°C and 4°C temperature, respectively. Inhibition studies were carried out to confirm the 
specificity of binding by incubation of same number of cells with 7.45 ng of 177Lu-labeled MabThera® along with 
1 µg of cold MabThera® under similar experimental conditions. Significant inhibition of bindings was observed 
at both the incubation temperatures which show the specificity of the radiolabeled antibody towards the CD20 
antigen. The results of the cell binding studies are shown in Figure 4 (a) and (b). 
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FIG. 4.  Results of cell binding studies carried out with 177Lu-labeled MabThera® in Raji cell line at (a) 37°C and 
(b) 4°C temperature. 
 
4.3. Preparation and characterization of 177Lu-labeled Reditux® 
 
   Recently we have started a collaborative work with Tata Memorial Centre (TMH), a premier super speciality 
cancer hospital in India, towards the development of patient doses of 177Lu-labeled rituximab for the treatment of 
patients suffering from non-Hodgkins’s lymphoma. Towards this we have received the bulk supply of Reditux®, 
which is commercially available rituximab available from Dr. Reddy’s Laboratory, India and attempt was made 
to standardize the protocol to prepare 177Lu-labeled Reditux®. 
177Lu-labeled Reditux® was prepared and characterized following the same method employed for the preparation 
of 177Lu-labeled MabThera®. Under the optimized reaction condition, 177Lu-labeled Reditux® could be prepared 
with >95% radiochemical purity. A typical HPLC profile of 177Lu-labeled Reditux® is shown in Figure 5. 
 
 
 
 
FIG. 5. Typical HPLC pattern of 177Lu-labeled Reditux®. 
 
 
4.4. Preparation of 90Y-labeled Reditux® 
 
   For the preparation of 90Y-labeled Reditux®, p-NCS-Bz-DOTA-Reditux® conjugate was prepared and purified 
following the same procedure used for the preparation of 177Lu-labeled Reditux®. Subsequently, 90Y-labeling of 
p-NCS-benzyl-DOTA-Reditux® conjugate was achieved by incubating 200 µg of the conjugate with 90YCl3 (185 
MBq, 5 mCi) at 37°C for 90 min using NH4OAc buffer (pH~5.5). Characterization of 90Y-labeled p-NCS-
benzyl-DOTA- Reditux® conjugate was done by employing the HPLC technique mentioned above. A typical 
HPLC profile of 90Y-labeled p-NCS-benzyl-DOTA-Reditux® is shown in Figure 6. Y-90-labeled p-NCS-Benzyl-
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DOTA-Reditux® conjugate was prepared with >95% radiochemical purity under the optimized reaction 
conditions. 
 
 
 
 
FIG. 6. Typical HPLC pattern of 90Y-labeled Reditux®. 
 
 
5. Development of DOTA-TATE cold kit for the preparation of 177Lu-DOTA-TATE for clinical 
applications 
 
   In India the use of 177Lu-DOTA-TATE, prepared using indigenously produced 177Lu, for the treatment of 
patients suffering from inoperable neuroendocrine cancers over-expressing somatostatin receptors was started in 
2007 and at present this treatment is provided at eight nuclear medicine centres across the country. In all these 
centres, 177Lu-labeled DOTA-TATE is prepared at the hospital radiopharmacy based on the method developed at 
our centre [18]. This method enables preparation of therapeutic dose of 177Lu-DOTA-TATE with highest 
possible specific activity at the time of administration to the patients as the composition of the ingredients is 
decided based on the specific activity of 177Lu available during the preparation of the agent. However, the 
preparation requires careful adjustment of the pH of the radioactive reaction mixture prior to incubation, as the 
complexation yield of 177Lu-DOTA-TATE achievable is highly dependent on the pH. This increases the 
possibility of batch failure leading to significant wastage of expensive radioactivity and peptides. To overcome 
this, we have recently developed a cold kit which can be utilized for the preparation of patient doses of 177Lu-
DOTA-TATE by a simple and single step at the hospital radiopharmacy. 
DOTA-TATE cold kit was prepared by adding DOTA-TATE dissolved in supra-pure water to a solution of 0.1 
M ammonium acetate (pH ~5) containing gentisic acid and subsequently freeze-drying the mixture after 
adjusting its pH to 5. Each kit comprises of a lyophilized mixture of 200 µg of DOTA-TATE, 80 mg of gentisic 
acid and 15.6 mg of ammonium acetate. Therapeutic dose of 177Lu-DOTA-TATE could be prepared by adding 
the required volume of 177LuCl3 with the kit material dissolved in 1 mL of water for injection and subsequently 
incubating the reaction mixture at 85-90°C for a period of 45 min-1 h. Quality control of the 177Lu-DOTA-TATE 
was performed by paper chromatography (PC) and HPLC. In PC using 50% aqueous acetonitrile (v/v) as the 
eluting solvent, it was observed that the activity corresponding to 177Lu-DOTA-TATE moved towards the 
solvent front (Rf = 0.5 - 0.8), while uncomplexed 177Lu remained at the point of spotting (Rf = 0 - 0.1) under 
identical conditions. HPLC was performed by reported gradient elution technique using acetonitrile and water 
mixed with 0.1% trifluoro acetic acid was used as the mobile phase [19]. It was observed that upto 7.4 GBq (200 
mCi) of 177Lu-DOTA-TATE could be prepared in near-quantitative yield using this kit when the 177Lu used is 
having a minimum specific activity of 740 GBq.mg-1 (20 Ci.mg-1). The stability of 177Lu-DOTA-TATE prepared 
using the cold kit was checked by storing the preparation at room temperature and determining its radiochemical 
purity at different time intervals following the quality control procedures mentioned above. It was observed that 
the preparation is stable upto 4 d as it retained its radiochemical purity >98% when stored at room temperature. 
Figure 7 (a) and (b) represent the typical HPLC patterns of 177Lu-DOTA-TATE after preparation and 4 d post-
preparation, respectively. 
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                 (a) 
 
 
                 (b) 
 
FIG. 7. Typical HPLC patterns of 177Lu-DOTA-TATE complex (a) after preparation and (b) 4 d post-
preparation. 
 
 
6. Future plans 
 
(1) Preparation of rituximab cold kit suitable for the preparation of patient dose of 177Lu-rituximab and 90Y-
rituximab. 
(2) Standardization of protocol for the preparation of 177Lu- and 90Y-labeled trastuzumab. 
(3) Standardization of protocol for the preparation of 177Lu- and 90Y-labeled nimotuzumab. 
(4) Standardization of protocol for the preparation of 177Lu-labeled DOTA-Substance-P. 
(5) Starting clinical studies with 177Lu-DOTA-TATE prepared using the DOTA-TATE cold kit. 
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Abstract. In the first part of this CRP we focus on the optimization of the conjugation of different bifunctional 
chelating agents (BFC) to a monoclonal antibody (Moab), which the IAEA has identified of scientific relevance 
to the member states. The implemented procedures were: (a) conjugation of the monoclonal antibodies with 
three different bifunctional chelating agents at different molar ratios, (b) purification of the conjugated molecules 
using PD-10 desalting columns, (c) 111In- Radiolabeling of immunoconjugates, (d) quality control analysis to 
calculate the radiochemical purity and also determination of the average number of chelates per antibody, and (e) 
determination of stability of labelled products using an excess of DTPA.   
 
1. Introduction 
 
   Within the scope of this CRP, ur contribution was focusing on the development of procedures for conjugation 
of BFC to Rituximab, radiolabeling and quality control analysis towards optimization of the 
radiopharmaceuticals preparation. 
 
2.Materials  
 
   The MoAb hR3 (5 mg/mL), used has work horse in order to optimize all the procedures of conjugation and 
labelling of the other antibody, was provided by Cuba. The MoAb Rituximab(10 mg/mL) was provided by IAEA 
(10 mg/mL). 
   Three different bifunctional chelating agents(BFC) were used: 
 
1. p-SCN-Bn-DOTA, supplied by IAEA from Macrocyclics, 
2.  p-SCN-Bn-DTPA, supplied by IAEA from Mycrocyclics, 
3. 1B4M-DTPA, supplied by IAEA from Dr. M. W. Brechbiel. 
 
   Ultrapure water (Fluka) was used for all the procedures. Phosphate buffer 0.1 M (pH 8.5) was used for the 
Conjugation while Ammonium acetate 0.01 M (pH 7.0) for purification and radiolabeling procedures. 
   The precursor 111InCl3 was purchased from Covidien. The PD-10 desalting columns were purchased from GE-
Healthcare.  
 
3. Methods 
 
3.1. Conjugation of hR3 with BFC 
 
   The hR3 solutions (5mg/mL) were concentrated by membrane filtration using a Millipore MWCO-10000 filter 
for 5 min at 5300 rpm to obtain a final concentration of 10mg/mL. Then, 10 mg of the resulting hR3, were mixed 
with either 50- or 100-fold molar excess of BFC, previously dissolved in phosphate buffer (pH, 7.2). Then these 
mixtures were vortexed and adjusted to the final pH of 8.5 with NaOH (1 mol/L). The reaction mixture was 
incubated overnight at 4°C with gentle shaking. 
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3.2. Purification 
 
   The immunoconjugates were purified by size-exclusion chromatography on PD-10 desalting columns, pre-
equilibrated with 25 mL of ammonium acetate 0.01 M (pH, 7.0) and then eluted with the same ammonium 
acetate. Four central fractions were collected (0.5 mL each), mixed together and concentrated to 5 mg/mL by 
membrane filtration. 
 
3.3. 111In-Radiolabeling studies 
 
   100 µCi of 111InCl3 were added to each purified conjugates, previously dissolved in ammonium acetate buffer 
0.01 M (pH 7.0), at different molar ratios and with a radiolabeling specific actvity of 0.6 mCi/mg. The solutions 
were incubated at 42 °C for 3 hours. 
   After incubation a small amount of DTPA was added in order to chelate free indium ions, and the mixture was 
then incubated for 15 minutes at room temperature. 
 
3.4. Quality Control 
 
   Radiochemical purity was determined on SG-ITLC strips, and using saline as mobile phase. Radioactivity on 
the strip was detected with a phosphor imager (Phosphor Screen Cyclone). 
 
3.5. Determination of the average number of chelates per antibody 
 
   The average number of chelates per antibody was determined using two different methods, which differ from 
the use of a conjugation mixture before and after purification and from the use of In3+ as a carrier. 
   The first method, described by Hnatowich, consists of the addition of 111InCl3 to a small aliquot of the 
conjugated solution before purification. After incubation for 5 min at room temperature, ITLC analysis using 
saline as mobile phase was performed. Only labeled free chelates migrate whereas the labelled immunoconjugate 
remains at the origin. The average number of chelates groups attached per antibody molecule is calculated from 
the coupling efficiency. For example, assuming a 20% coupling efficiency, a 10:1 molar ratio results in an 
average of 2 groups per molecule [(20/100) × 10 = 2]. 
   The second method, described by D.R. Beckford Vera, consists of the following steps: 
 
1. addition of 0.4 nmol of purified conjugated molecules to NH4OAc 0.5 mol/L (pH 7.0), 
2. addition of 8.0 nmol of In3+ in a standardizied solution spiked with 111InCl3, 
3. incubation of the reaction mixture at 42°C for 3 hours, 
4. addition of DTPA followed by quality control with radio-ITLC using saline as mobile phase. 
 
   The number of chelates per antibody molecule was calculated from the ratio of counts remaining at the origin 
to the total number of counts multiplied by the molar metal ratio (In3+/mol) of the conjugate. 
 
3.5. Stability 
 
   Stability of 111In-radioimmunoconjugates was performed by incubation in DTPA excess at room temperature 
and samples were analyzed by ITLC after 24 and 48 hours. 
 
4. Results 
 
4.1. Radiochemical purity (RCP) 
91 
The radiochemical purity of the purified immunocojugates was greater than 95% using both 1:50 and 1:100 
molar ratios with p-SCN-Bn-DOTA as chelating agent, whereas for the other immunoconjugates was about 70%, 
as shown in Table 1 below. 
 
 
TABLE 1. Radiochemical purity 
 
Radioconjugated molecules % RCP 111In-Radiolabelling 
hR3 : p-SCN-Bn-DOTA =  1 : 50 98.4 % 
hR3 : p-SCN-Bn-DOTA =  1 : 100 99.6 % 
hR3 : p-SCN-Bn-DTPA =  1 : 50 66 % 
hR3 : p-SCN-Bn-DTPA =  1 : 100 71.2 % 
hR3 : 1B4M-DTPA =  1 : 50 68.1 % 
hR3 : 1B4M-DTPA =  1 : 100 75 % 
 
 
4.2. Conjugation 
 
   The results of conjugation are shown in Table 2, which reports the number of chelating groups (NoG) linked to 
the antibody as measured by the two different methods. The two methods gave different results. However, 
Beckford’s method proved to be more accurate as it gave results closely comparable with published data (Table 
3). 
 
 
TABLE 2. Conjugation 
 
Radioconjugated molecules NoG (Hnatowich’s method) 
NoG 
(B. Vera’s method) 
hR3 : p-SCN-Bn-DOTA =  1 : 50 6.85 11.26 
hR3 : p-SCN-Bn-DOTA =  1 : 100 9.7 12.38 
hR3 : p-SCN-Bn-DTPA =  1 : 50 3.7 10.68 
hR3 : p-SCN-Bn-DTPA =  1 : 100 6.8 16.02 
hR3 : 1B4M-DTPA =  1 : 50 3.05 11.06 
hR3 : 1B4M-DTPA =  1 : 100 8.5 12.0 
 
 
 
TABLE 3. Comparison of results with published data 
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(Published results) (L/P) NoG (Present work) 
D.R. Beckford Vera (50:1) 9 
D.R. Beckford Vera (100:1) 13 
M. Moreau (20:1) 2.6 
 
 
4.2. Stability 
 
   The results of stability measurements performed at room temperature using an excess of DTPA are shown in 
the Table 4 below. 
 
 
TABLE 5. Stability studies 
 
111In-radiolabelled conjugates 0 hours 24 hours 48 hours 
hR3 : p-SCN-Bn-DOTA =  1 : 50 99.1 97.9 94.7 
hR3 : p-SCN-Bn-DTPA =  1 : 50 68.2 66.4 61.1 
hR3 : 1B4M-DTPA =  1 : 50 55.0 45.2 41.4 
 
 
5. Preliminary experiments with Rituximab 
 
   Preliminary experiments using Rituximab as MoAb were also performed following the same procedures. In 
particular, the followig steps were accomplished. 
  
- Conjugation of Rituximab with p-SCN-Bn-DOTA as chelating agent at two different molar ratios: 1:50 and 
1:100. 
- Purification of the immunoconjugates by size exclusion chromatography,  
- 111In-Radiolabeling of purified immunoconjugates(specific activity 0.6 mCi/mg); 
- Quality control analysis by ITLC. 
- Determionation of the average number of chelates per antibody using Beckford method. 
 
   The results are summarized in Tables 6 and 7 below. 
 
 
TABLE 6. Preliminary results on the radiolabelling of Rituximab 
 
Radioconjugated molecole % RCP 111In-Radiolabeling 
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Rituximab : p-SCN-Bn-DOTA =  1 : 50 93.5 
Rituximab : p-SCN-Bn-DOTA =  1 : 100 99.5 
 
 
 
TABLE 7. Preliminary results on the conjugation of Rituximab 
 
Immunoconjugate (L/P) NoG (Beckford Vera’s method) 
Rituximab : p-SCN-Bn-DOTA =  1 : 50 18.7 
Rituximab : p-SCN-Bn-DOTA =  1 : 100 19.9 
 
 
6. Future Developments 
 
   Future steps will be devoted to further conduct the following studies. 
 
- Measurement of the conjugation yield by MALDI-TOF mass spectrometry. 
- Labeling of Rituximab with 177Lu at increasing specific activity. 
- Stability studies at 37°C in human serum. 
- Evaluation of biological activity both in vitro, using antiCD-20 expressing cells, and in vivo, using 
lymphoma-bearing animal models (NHL). 
 
7. Conclusions 
 
   We have (a) developed a standard conjugation procedure, (b) optimized the quality control of the 
immunoconjugates by checking the number of BFC per molecule of antibody, (c) performed an efficient 
labelling of the immunoconjugate with 111In and (c) checked the stability of the labeled products using excess of 
a challenging agent. These basic techniques will be further utilized for further studies aimed at developing an 
instant kit formulation for efficient labelling immunoconjugates. 
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Abstract. In the frame work of the CRP “Therapeutic radiopharmaceuticals based on 177Lu and 90Y labeled 
monoclonal antibodies and peptides: Development and preclinical evaluations” we proposed to participate as a 
specialized center for pre-clinical in vitro screening of kit formulations of 177Lu-labelled-mAb/peptides 
synthesized by other laboratories participating in this IAEA coordinated project. During this year we tested in 
vitro biological properties of DTPA- and HYNIC-conjugated Rituximab on CD20+ve cells. Furthermore, we 
continued our studies on labeled superagonist rhTSH analogues testing in vitro properties and in vivo 
biodistribution and targeting possibilities. We developed a know-how on studying candidate radiopharmaceutical 
performing routinely different in vitro quality controls and binding assays. We therefore continue to offer to this 
CRP our skill and know-how to test the immunoreactivity and binding properties of newly developed products. 
 
1. Introduction 
 
   The CRP in which we are participating is a co-operative effort between many laboratories with the main goal 
to promote the clinical application of radioimmunotherapy and peptide receptor-based radionuclide therapy for 
the most important cancers in developing countries. Most importantly we aim to develop an easy-to-use 
technology to radiolabel anti-cancer antibodies and peptides with 177Lu for receptor –targeted therapy. To 
accomplish such an important goal, we believe that all the participant should share their best experiences in order 
to play their best role in this project. Our current projects are focused on the development of kit formulation to 
radiolabel an anti-CD20 antibody (Rituximab) and a superagonist rhTSH analogue with 177Lu to treat non-
Hodgkin lymphoma and non-iodine up-taking metastatic thyroid cancer, respectively. We already successfully 
labelled these compounds for diagnostic purposes with 99mTc using different labeling procedures. Therefore, we 
performed pilot experiments on 99mTc labeled DTPA- and HYNIC-Rituximab to acquire information on the 
binding properties of the mAb, in order to plan experiments for 177Lu-labelled molecules.  Furthermore, we will 
continue to offer our expertise, in the preliminary evaluation of kits provided by all participants, for testing all 
kits both in vitro and in vivo. 
 
2. Scenario 
 
   Non-Hodgkin lymphoma (NHL) is one of the most commonly occurring hematologic malignancy and 85% of 
NHLs are B cell lymphomas [1]. It is common in the elderly and it is characterized by advanced stage at 
presentation and an indolent clinical course with a median survival of 8 to 10 years. While patients might 
initially respond to therapy, the disease is characterized by multiple episodes of recurrence leading ultimately to 
death due to refractary disease, transformation to an aggressive large B cell pathology or complications of 
therapy. Most patients with follicular NHL who transform to an aggressive NHL are very difficult to treat 
successfully. Chemiotherapy (CHT) has not a significant impact on survival, but recently, radioimmunotherapy 
(RIT), which uses a radiolabelled monoclonal antibody (with 131I or 90Y) to deliver radiation to the sites of 
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disease, has been extensively studied in this population with promising results. Thus RIT offers several 
advantages over other therapeutic modalities and in association with CHT [2]. It delivers the radiation dose 
specifically to the target with limited exposure of non-target issues. It is normally very well tolerated. The uptake 
of the radiopharmaceutical is not necessarily required by all tumour cells. Penetration of beta rays in living 
tissues is of several millimetres, and the therapeutic effect is obtained also in cells that do not take up the 
radiopharmaceutical if they are adjacent to up-taking cells by the so called cross-fire effect.  
   If it is possible to find a well characterized cell surface antigen over-expressed on the tumor cells, it could be 
possible to develop a powerful radiopharmaceutical using mAb as vehicles for radiations [3]. RIT can be an 
adjuvant treatment in patients where the administration of unlabelled antibody is not successful. CD20 is a 
preferential target for RIT of lymphomas, since it is over-expressed on malignant B cells (4). Anti-CD20 
antibodies such Rituximab (Mabthera) have been developed and recently ibritumomab tiuxetan (Zevalin) labeled 
with 90Y has been approved by FDA as a radiopharmaceutical for NHL treatment [5]. 90Y is a β-emitter used for 
RIT, since its radiation is cytotoxic. β-particles are cytotoxic over a spherical volume with a radius that extends 
from a few millimeters to several centimeters. Despite initial enthusiasm, Zevalin® is now criticized by most 
because its poor long term efficacy, its high cost and because 90Y is characterized by a systemic toxicity due to 
its high energy. 
   We therefore believe that developing an easy kit for the labeling of anti-CD20 with a more suitable isotope, 
such as 177Lu, would provide a more suitable therapeutic tool for NHL [6]. 177Lu is a short-range β emitter (Eβmax 
= 497 keV, 670µm) and this makes it ideal for treating micro-metastatic disease reducing systemic toxicity. 
Moreover, it emits also γ rays (208keV, 11% abundance) and could be used for dosimetric purposes. Therefore, 
we believe that it may have a great clinical impact the development of a kit for the rapid preparation of anti-
CD20 labelled with 177Lu.  
   In parallel, we propose to investigate also the preparation of other 177Lu-labelled peptides/antibodies. In 
particular we initiated a project on the labelling of a newly developed TSH super-analogue that shows higher 
affinity and efficacy respect to the available rhTSH [7]. From our preliminary data, it appears that the 177Lu-
DOTA-rhTSH analogue is indeed a promising radiopharmaceutical for the treatment of non-iodine-up-taking 
metastases that retain the TSH receptor expression [8].  
   Over the years we developed an excellent know-how on mAb and peptide labelling for diagnostic and 
therapeutic purposes. We have a fully equipped radiochemistry analytical and semi-preparative lab with facilities 
for cell tissue cultures, HPLC and ITLC with detectors for gamma and beta emitting isotopes, a Ligand Tracer 
for automatic binding assays, autoradiography, SDS-PAGE, etc. and an animal facility equipped for animal 
experiments with radiopharmaceuticals, micro-SPECT, micro-PET and micro-CT. That allows us to easily 
screen several peptides and mAbs directed to different surface antigens expressed on tumor cells. 
 
3. Results 
 
   Before rushing to 177Lu labelling we wanted to test the biological properties of conjugated Rituximab. We 
compared our previous experiment on directly labelled mAb with DTPA- and HYNIC- conjugated Rituximab. 
Because of the lower cost and higher availability, we selected 99mTc as the isotope of choice for preliminary 
studies. 
 
3.1. 99mTc-HYNIC-Rituximab 
 
   Despite the wide range of groups where HYNIC could bind on the target molecule, we have chosen to use this 
coligand first, because of our experience on HYNIC-conjugated molecules and the possibility to label 
conjugated molecules with a low cost isotope like 99mTc for preliminary studies on the biological properties of 
the conjugated mAb. As a first step, the bifunctional chelator was conjugated to native Rituximab in a specific 
modification buffer. Unbound HYNIC molecules were removed through purification with a fast and high 
recovery chromatographic column. The labelling was performed using tricine as a coligand and SnCl2 as a 
reducing agent for 99mTc reduction. A titration of each reagent was performed in order to optimize the labelling 
96 
protocol. Labelling efficiency and colloid formation were measured through instant thin layer chromatography 
with silica gel strips as stationary phase and 0.9% NaCl solution and H2O:EtOH:NH3 (5:3:1) as mobile phases. 
Eventually, we could efficiently radiolabel HYNIC-Rituximab with a labelling efficiency of 97% and negligible 
amount of colloids, without the need of a further purification step. The labelled antibody was stable in both 
saline and human serum solution up to 24 h (37°C) and in a solution containing a physiological concentration of 
cysteine as well. Kd, kon and koff were calculated performing an in vitro binding assay using the LigandTracer. 
107 of Raji cells (CD20+ve) were let to attach to the bottom of a tilted petri plate and the dish was placed in the 
rotor of the machine with 3.9 nM solution of 99mTc-HYNIC-Rituximab. When the binding reached a plateau a 
1000-fold molar excess of unlabelled antibody was added for displacement and retention studies. Eventually the 
medium was replaced with a fresh one to measure the signal from internalized molecules. Kd was measured 
fitting the data with the Graph Pad software and was found to be 1.77 nM. 
 
3.2. 99mTc-DTPA-Rituximab 
 
   We started to investigate the biological properties of DTPA conjugated Rituximab labelling the molecules with 
99mTc. The mAb was conjugated with DTPA in a carbonate buffer (pH, 8.6) and the unbound chelator was 
removed after a purification step with a chromatographic column. The labelling was performed using SnCl2 as a 
reducing agent and a titration was performed in order to find the best labelling conditions. The best we could 
reach is a labelling efficiency of 92% with marked colloid formation (23%) and a further purification step was 
necessary in order to achieve a high labelling efficiency (97%) with low amount of colloids (4%). The labelled 
mAb was stable in saline and serum solution up to 24 h (37°C) and in a solution containing a physiological 
concentration of cysteine as well. Kd, kon and koff were calculated performing an in vitro binding assay using the 
LigandTracer. 107 of Raji cells (CD20+ve) were let to attach to the bottom of a tilted petri plate and the dish was 
placed in the rotor of the machine with 3.9 nM solution of 99mTc-HYNIC-Rituximab. When the binding reached 
a plateau a 1000-fold molar excess of unlabelled antibody was added for displacement and retention studies. 
Eventually the medium was replaced with a fresh one to measure the signal from internalized molecules. 
Eventually the medium was replaced with a fresh one to measure the signal from internalized molecules. Kd was 
measured fitting the data with the Graph Pad software and was found to be 6 nM (native Rituximab has Kd of 
approximately 5 nM) 
 
3.3. 99mTc-HYNIC-TR1401 
 
   We carried on our studies on labelled superagonist rhTSH analogue TR1401. We tested the biological 
properties of the labelled hormone in vitro and in vivo. LigandTracer experiments were performed on ML-1 
(human thyroid carcinoma cells, TSHR+ve) cells. Briefly, 106 cells were grown in the lower part of a petri dish 
for 24 hours, then the plate was placed in the LigandTracer adding different nM concentrations of 99mTc-
HYNIC-TR1401 and was allowed to rotate until the signal reached a plateau. Afterwards, an excess of 
unlabelled TR1401 was added for displacement studies. The data fitting was performed with the Graph Pad 
sotware measuring the Kd that was found to be 3 nM (the value of the native TR1401 Kd is approximately 1 nM). 
In vivo studies were performed in normal Balc/c mice injecting ~100 µCi in the tail vein and acquiring images 
with a high-resolution portable mini-gamma camera at 1, 3, 6 and 20h. The images show a high signal from the 
kidneys, presumably the excretion route of the radiopharmaceutical. At each time point 3 mice were sacrificed, 
the major organs were collected, weighted and counted in order to calculate the %ID/g. The highest value was 
found to be in the thyroid, whereas the signal from other organs decreased over time. Ex-vivo counts confirmed 
the high kidney uptake. In vivo tumor targeting experiments were performed in a mouse bearing a JP09 
(TSHR+ve) tumor. Images were acquired and the target-to-background ratio was calculated with the data 
obtained from the .txt matrix. Highest value was reached at 6 h p.i. (3.5). The same experiment was performed in 
two groups of nude athymic mice. The first group was injected in the right thigh with a pellet of JP09 cells 
(THSR+ve) and the second group was injected with JP02 cells (TSHR-ve). After 1 hour ~100 µCi of labelled 
97 
TR1401 were injected in the tail vein and the images were acquired at 1, 3, 6 and 24 h showing a focal uptake in 
the right thigh of the mice injected with TSHR+ve cells. Mice injected with TSHR-ve cells showed no uptake. 
 
3.4. Images in cats with 99mTc-HYNIC-TR1401 in collaboration with Dr Lajos Balogh 
 
   In collaboration with Hungary, we performed in vivo studies in cats in order to image the thyroid that we could 
not see in scans performed in mice because of its small size and relatively low uptake respect to other organs. 
Both cats had a tumor, which we believed to be TSHR-ve, an osteosarcoma and a head and neck tumor. In the 
former we were able to visualize the thyroid and the tumor was completely negative, but with surprise, the latter 
presented a high uptake of labelled TR1401 at the tumor site. According to data from protein bank 
(www.proteinatlas.org) we found out that head and nect tumors express TSHR, justifying the uptake seen in the 
second cat. Therefore, we plan to study more intensively our radiopharmaceutical in animals bearing different 
kind of tumors in order to confirm our findings. 
   In conclusion, HYNIC- and DTPA-conugated Rituximab has shown high affinity for the CD20 antigen and we 
will now proceed to study the properties of 177Lu-labelled molecule repeating the same experimental protocol 
used for 99mTc-HYNIC- and 99mTc-DTPA-Rituximab. At the same time, we renew our proposal to  help in this 
CRP by offering our skill and know-how to test the immunoreactivity and binding properties of other products 
developed by collaborating laboratories. We remind that we can also perform biodistribution and targeting 
studies in MICO-luc autofluorescent mice. Finally, in collaboration with Dr Balogh, we will continue our studies 
on labeled superagonist rhTSH analogue with 99mTc and 177Lu for diagnostic and therapeutic applications in 
patients with non-iodine up-taking differentiated thyroid cancer 
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1. Introduction  
 
   The purpose of this investigation was to introduce a technology for the production of ready-to-use cold kit 
formulations for labeling DOTA-Rituximab and peptide-based (Substance P) conjugates with Lu-177 and Y-90, 
and to firmly establish and standardize the resulting methods for synthesis and conjugation.  
Concomitantly, the biological properties and pharmacokinetic behaviour of  radiolabelled 177Lu-DOTA-
Rituximab and 177Lu-Substance P were investigated using experimental systems comprising both isolated cell 
cultures and animal models.  
 
2. Labelling of Substance P  
 
   Endogenous Substance P [1] is an undeca- neuropeptide that functions as a neurotransmitter and 
neuromodulator. It belongs to the tachykinin neuropeptide family. Substance P and its closely related analogue 
neurokinin A (NKA) are produced from a polyprotein precursor after differential splicing of the 
preprotachykinin A gene. 
   Owing to the ideal nuclear properties and richer chemistry of Tc-99m, and of its theranostic counterpart Re-
188, it was first considered convenient to start a preliminary labelling study using these radionuclides with the 
purpose to evaluate the bioditribution behaviour of the radiolabelled peptide before investigating a peptide 
derivative suitable for binding to Lu-177. Thus, a modified peptide sequence, suitable for labelling Substance P 
with Tc-99m and Re-188, was synthesized and its biological characteristics examined by in vivo biodistribution 
studies in normal mice. 
 
 
FIG.1. Chemical structure of the peptide Substance P (aminoacid sequence: Arg Pro Lys Pro Gln Gln Phe Phe 
Gly Leu Met). 
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2.1. Syntesys of modified Substance P  
 
   A peptide with the sequence Cys-Cys-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met (Cys-Cys-SP), where 
the groupment of two terminal cysteine residues served as chelating site for the metal, was synthesized for 99mTc-
labelling. Additional ligands utilized for the preparation of the corresponding 99mTc-complex were tris-
cyanoethyl phosphine [PCN = P(CH2CH2CN)3] as ancillary ligand, succinic dihydrazide [SDH = H2N-NH-
C(=O)-CH2-CH2-C(=O)-NH-NH2] as donor of nitrogen atoms to form the 99mTc-nitrido core, and tin chloride as 
reducing agent. Similarly, a peptide characterized by the sequence IsoCys-Cys-Arg-Pro-Lys-Pro-Gln-Gln-Phe-
Phe-Gly-Leu-Met (IsoCys-Cys-SP), where IsoCys represents isocysteine, was obtained for labelling with Re-
188, while keeping the other additional ingredients exactly as employed with Tc-99m [2]. 
 
2.2. Preparation of the conjugate complex [99mTc(N)(Cys-Cys-SP)PCN] 
 
   A solution containing 0.9 mL of Na[99mTcO4] (100MBq) containing 5.0 mg of SDH and 0.10 mg of SnCl2 was 
added to a vial. The mixture was kept at room temperature for 15 min. To the resulting mixture, 0.5-0.05 mg of 
Cys-Cys-SP (dissolved in 0.5 mL of saline) and 0. 5 mg of PCN (dissolved in 0.5 mL of saline containing 2.0 
mg of gamma-hydroxypropylcyclodextrin) were simultaneously added. The vial was heated at 100° C for 30 
minutes. The radiochemical yield was determined by HPLC chromatography. The final pH was 6-7. A pictorial 
illustration of the molecular stucture of the resulting Tc-99m peptide conjugate complex is reported below. 
 
 
 
 
FIG. 2. Drawing of the molecular structure of the 99mTc-Substance P conjugate complex. 
 
 
2.3. HPLC chromatography 
 
   Radiochemical purity (RCP) was checked by HPLC (Beckman System) using the following chromatographic 
conditions. Column, Zorbax 300SB-C18, 300Anst., 5 micron (4.6 × 250 mm) with a guard column; detector, UV 
and radiometric, mobile phase, A (0.1 % TFA in water), B (0.1 % TFA in CH3CN); flow rate, 1 ml/min; 
gradient, 0-30 min, %B 0-100,  30-32 min, %B, 100, 32-34 min, %B, 100-0. Retention time was 15.8 min. 
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FIG. 3.  HPLC chromatogram of [99mTc(N)(Cys-Cys-SP)PCN]. 
 
 
2.3. Stability 
 
   To evaluate inertness of the 99mTc-peptide conjugate towards transchelation by potential endogenous ligands, it 
was incubated in solutions containing increasing amounts of cysteine and glutathione. Determination of 
radiochemical purity (RCP) after incubation revealed that the radiocompound was highly resistant to substitution 
by competing ligands. Similarly, incubation was performed to evaluate the stability of the 99mTc-complex in both 
mouse, rat and human serum. It was found that the complex was not stable in rat serum and started to decompose 
after 30 min of incubation. Surprisingly, this decomposition was not observed in mouse serum and slowed down 
in human serum starting only after 60 min of incubation. This result provides another example of the strong 
dependence of the biological properties of some radiolabelled molecule on the specific animal species. 
 
2.4. Preparation of the conjugate complex [188Re(N)(IsoCys-Cys-SP)PCN] 
 
   A solution containing 1.5 mL of Na[188ReO4] (100 MBq) containing 5.0 mg of SDH and 0.10 mg of SnCl2, 1.5 
mg of ascorbic acid, 28 mg of sodium oxalate and 0.1 mL of glacial acetic acid, was added to a vial. The mixture 
was kept at room temperature for 15 min. To the resulting mixture, 0.5-0.05 mg of IsoCys-Cys-SP (dissolved in 
0.2 mL of saline) and 0. 5 mg of PCN (dissolved in 0.3 mL of saline containing 2.0 mg of gamma-
hydroxypropylcyclodextrin) were simultaneously added. The vial was heated at 100° C for 1 hour. The 
radiochemical yield was determined by HPLC chromatography using the same conditions as detailed for the Tc-
99m preparation. The final pH was 4.5. Retention time was 16.1 min. 
 
3. Biodistribution studies with a YAP(S)PET small-animal tomograph 
  
   Biodistribution of the Tc-99m conjugate complex with Substance P was carried out in a normal mouse using a 
multimodality YAP(S)PET-CT small-animal scanner [3]. Though this animal model is the most commonly 
employed for this type of imaging, in the present study, it was also the most advantageous since the 99mTc-
Substance P conjugate exhibited high stability in this animal species. 
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3.1. SPECT data acquisition  
 
   SPECT-CT studies were performed on anesthetized normal mouse (~ 25 g) injected with 75 MBq (2 mCi) of 
99mTc-Substance P to study the tracer whole-body distribution. The mouse was scanned starting from 20 min 
after injection . The SPECT acquisition consisted of 3 bed position, 3 cm apart, 20-min acquisition time for each 
position, 128 views over 360°. The second acquisition starts at 90 min after the injection with the same 
modalities. The energy window was 140-250 keV and the images were reconstructed using the iterative EM-ML 
algorithm including the collimator response. 
 
3.2. X-ray data acquisition  
 
   The radiographic images have been acquired using a digital X-ray imaging system integrated with the 
YAP(S)PET scanner. The acquisition parameters for X-ray projections were: X-ray-tube voltage 35 kV, anode 
current 1 mA, exposure 1 s, 8 views over 360° and magnification factor 1.2. Each final image was obtained by 
subtracting dark noise contributions and performing flat field corrections. 
 
 
          
(a)                                                                         (b)  
 
FIG. 4. SPECT mouse coronal sections at (a) 20 min and (b) 90 min post injection of 99mTc-Substance P. 
 
 
 
FIG.5. X-ray mouse transparent whole-body images. 
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FIG. 6. Comparison of non-superimposed SPECT and CT (transparent) mouse coronal sections showing uptake 
in target and not-target organs for 99mTc-labelled Substance-P. 
 
 
3.3. Results 
 
   Imaging studies with small-animal scanners are particularly useful for obtaining a whole in vivo picture of the 
pharmacokinetic behavior of a tracer. SPECT whole-body images at different acquisition times showed that the 
radiocompound was eliminated through the kidneys into urine as expected for a peptide-based compound. Liver 
uptake was almost negligible and yielded also some uptake into the gatsrointenstinal tract. Signature of the 
specific receptor interaction characteristic of the peptide Substance P was demonstrated by the high uptake in 
thymus, which is a receptor-rich organ for this peptide. At earlier times post injection, prolonged persistence of 
activity into the blood stream was observed, which allowed imaging of the cardiac area. Although, blood 
washout occurred at later times points, this did not prevent the clear visualization of the thymus gland, thus 
indicating high tracer uptake in this organ according to its high receptor density. This observation was also 
supported by ex-vivo experiments (not shown here) that measured uptaked activity after removal of the gland. It 
is worthy to note that the analogous Re-188 peptidic complex showed almost identical biosditribution behaviour 
(not reported here) as evidenced on images collected by exploiting the gamma emission associated with the beta 
decay of this radionuclide. This result further supports the principle that a couple of Tc-99m and Re-188 
radiocompounds having exactly the same ligand arrangement and molecular structure always constitutes a true 
example of theranostic (diagnostic/therapeutic) pair. 
 
4. Studies on the development of a suitable freeze-drying protocol for antibodies 
 
   The other part of our work was aimed at establishing a convenient procedure for freeze-drying antibody’s 
solutions without compromising immunoreactivity and ensuring sterile and pyrogen-free conditions. This 
preliminary achievement is essential to support the purpose of obtaining suitable ready-to-use instant kit 
formulation for labeling antibodies with Lu-177 and Y-90. 
   The procedure for freeze-drying should provide a stable kit formulation giving identical labelling results as the 
freshly prepared liquid formulation while preserving immunoreactivity of the conjugated antibody. This 
condition has to be tested both before conjugation of the antibody to some chelating ligand for the metal, and 
after conjugation. For this reason, the most important parameters to be primarily evaluated are the freeze-drying 
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time required in each phase, namely (a) prefreezing, (b) primary drying and (c) secondary drying, and freezing 
temperature. Successively, the following properties have to be tested: 
 
− Appearance, 
− Specific surface area, 
− Sublimation rate, 
− Residual moisture and recon time, 
− Physical state of protein and excipients in the lyophilized cake, 
− Crystallinity, 
− Protein aggregation, changes in conformation and bioactivity, 
− Stability over time. 
 
4.1. Representative freeze-drying procedure for proteins 
 
As an example of freeze-drying protocol for proteins, the following standard procedure was investigated as 
applied to human serum albumin (HSA), immunoglobulins (IgGs), and antibodies (Mabthera). Specific 
conditions and parameters were as detailed below. 
 
− Volumne of solution: 1mL 
− Filled into 2-mL glass vial (fill depth = 0.75 cm) 
− Freeze drier model LABCONCO 
 
4.1.1. Procedure 
 
− Ramp from room temperature to - 45 0C , (ramp rate 1 0C/min). 
− Hold for 2 hours, then ramp to -20 0C (10C/min). 
− Hold for 1 hours, then return to -45 0C . 
− Maintain shelf temperature for 2 hours. 
− Primary drying conducted at chamber pressure (Pc) of 57 mTorr and shelf temperature of -25 0C and +25 0C. 
− Keep chamber pressure (Pc) was constant for primary and secondary drying. 
− Prymary drying was carried out 4 min for HSA and 3 min for IgG and mAb. 
− Perform secondary drying. 
− Shelf temperature at 40 0C for 10 hours (increase interval 15-20 hours, ramp rate 1 0C/min) 
 
4.1.2. Results 
 
   The stability of the resulting freeze-dried formulations have been measured at different times (6 months for 
IgG, 10 months for HSA and 3 months for Mabthera) and Figure 5 reports the radiochemical purity after labeling 
of lyophilized HSA with I-125. 
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FIG.7. Freeze-dried HSA radiolabelled with I-125 after 10-month storage as checked by radiometric HPLC. 
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Abstract. DTPA- or DOTA-chelated antibodies have been proved to be efficient in radioimmunotherapy of 
cancer after radiolabelling with beta-emitting radiometals. The standardization of methodology for conjugation 
of suitable chelators to monoclonal antibodies and their further pharmaceutical development were planned in the 
framework of IAEA coordinated research project on the development of radiopharmaceuticals labeled with 90Y 
or 177Lu. Therefore, our study was focused on the development of dry kit based on DOTA-anti-CD20 for 177Lu 
labeling as potential radiopharmaceutical for radionuclide therapy. 
 
1. Introduction 
 
   The development of new target-specific radiopharmaceuticals for diagnosis and therapy of different disease 
remains a challenge for the scientific community. Monoclonal antibodies (mAb) are attractive molecules in the 
field of molecular imaging agent development, partly because of the development of personalized medicine. This 
field of research is in constant evolution in order to develop and improve labeling techniques suitable to 
antibodies half-life for both preclinical biodistribution studies and further possible applications in diagnosis and 
treatments. Rituximab (trade names Rituxan and MabThera) is a chimeric monoclonal antibody against the 
protein CD20, which is primarily found on the surface of B cells. Rituximab destroys B cells, and is therefore 
used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or 
dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and some autoimmune 
disorders. 
   Lu-177 (T1/2 = 6.7 days, Eγ = 0 .208 MeV, Eβmax = 0.497 MeV, max tissue penetration = 2.0 mm) is being 
strongly considered for RIT mainly because of its availability, the convenient energy of its beta particles and the 
ability to form stable complexes with macrocyclic and acyclic ligand. Its half-life is appropriate for preparation, 
transportation and successful delivery of therapeutic doses to the tumor by radioimmunoconjugates (mAb). 
   In the first 18 months of the CRP we focused on the conjugation of Rituximab with macrocyclic bifunctional 
chelating agents, the optimization of 177Lu labeling of the conjugates DOTA(SCN)-Rituximab and 
DOTA(NHS)-Rituximab and on the freeze-dried kit formulation for both conjugates. 
 
2. Optimization of conditions for antibody conjugation and labelling of the DOTA-conjugates with Lu-177 
 
2.1. Materials 
 
   Chimeric anti-CD20 monoclonal antibody Rituximab (MabThera 100 mg/10 ml) was provided by Roche. Lu-
177 c.a. (specific activity above 555 GBq/mg Lu) as chloride solution, was provided by National Centre for 
Nuclear Research, Radioisotope Centre POLATOM. Isothiocyanate-benzyl-DOTA (p-SCN-BZ-DOTA) and 
DOTA-(N-hydroxysuccinimide ester) were purchased from Macrocyclics. Ultrafilter: Amicon® Ultra- 2ml, 10K: 
MWCO 10 000; Millipore. PD-10 column for purification of DOTA-mAb: PD-10 Desalting Column, GE 
Healthcare. Kit for determination of protein concentration: BCATM Protein Assay Kit, Pierce, Il, USA, no. 
23225. 
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   To reduce metal contamination, all the solutions used in conjugation and radiolabeling reactions were passed 
through a Chelex 100 column in a following procedure: 5 g of Chelex 100 was dissolved in 15 ml of deionized 
water and transferre slowly to Agilent Bond Elut Reservoir column then the column washed at the flow rate of 
around 1 ml/min with 5 ml 0.1M HCl followed by deionized water until pH of effluent was ~ 7.0.  Such prepared 
column could be used for purification of around 20 ml of buffer solution. Columns for filling with Chelex resin: 
Agilent Bond Elut Reservoir, 6 ml capacity, Agilent Technologies.  
 
2.2. Antibody conjugation 
 
   Two different chelators p-SCN-DOTA  and DOTA-NHS-ester were conjugated to anti-CD20 antibody with 
appropriate molar excess of chelator over antibody (mAb:DOTA) respectively of 1:5; 1:10 for p-SCN-DOTA 
and 1:33, 1:75, 1:100 for DOTA-NHS-ester. 
 
2.2.1.  Preparation of antibody solution for conjugation 
 
   The solution of MabThera containing 20 mg of antibody was purified by double filtration using Amicon Ultra-
2 ml centrifuge filter (30 min, 5000 rpm). The final volume was reduced to < 0.5 ml (40 mg/ml). 
 
2.2.2. Conjugation of anti-CD-20 with p-SCN-Bn-DOTA 
 
The concentrated mAb solution was incubated with p-SCN-DOTA in 250 µl of 0.2 M carbonate buffer, pH 9.5 
at 37 0C for 90 min in molar ratios of 1:5 or 1:10. 
 
2.2.3.  Conjugation of anti-CD-20 with DOTA-NHS-ester 
 
   The concentrated mAb solution was incubated with 1ml of 40-mM DTPA at 4 0C for 40 min following by 
purification on PD-10 using 0.1-M sodium phosphate as a mobile phase. Then the purified mAb was incubated 
with 1:33, 1:75 and 1:100 excess of DOTA-NHS-ester at 4 0C for 48 h. 
 
2.3. Purification of DOTA-Rituximab conjugates 
 
   To remove the non-reacted chelators the immunoconjugates were purified by size-exclusion chromatography 
on PD-10 desalting columns pre-conditioned with 0.25-M ammonium acetate, pH 7.0. Fractions of 0.5 ml were 
collected. Concentration of antibody in the collected eluates was determined by BCA method. Number of 
coupled DOTA molecules was determined using Pb:Arsenazo III reaction. 
 
2.4. Determination of antibody concentration 
 
   Antibody concentration in the eluates obtained in 2.2.1. and 2.3. was determined by BCA method using the kit 
provided by Pierce and according to the instructions delivered with the kit. When using the microplate procedure 
the samples from the collected fractions should be used after 5-fold dilution in 0.25 M ammonium acetate, pH 
7.0. For the fractions containing the highest concentration of antibody (usually fractions 6-9) the purity of 
obtained conjugate was assessed by HPLC. Fractions having the purity confirmed by HPLC were collected in 
one vial. 
 
2.5. Quality control 
 
The radiochemical purity of the labeled conjugates and their stability were determined using SE-HPLC and TLC. 
 
2.5.1. SE-HPLC  
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   Column, BioSep-SEC-s2000 (300 × 7.5 mm (Phenomenex); flow rate, 1ml/min; isocratic elution, eluent 0.1-M 
phosphate buffer, pH 5.8, UV detection at 220 and 280 nm, analysis time ca. 20 min, sample volume, 20 µl.  
   In this system the retention time for DOTA-Rituximab conjugates was ca. 6.6 min. 
 
2.5.2. TLC 
 
   TLC- Silica Gel (ITLC-SG) strips (Pall Life Science, USA) using 0.1 M sodium acetate buffer pH 5.0 as 
developing solvent. 
 
2.6. Determination of number of conjugated DOTA molecules 
 
Color reaction is based on the formation of Arsenazo III complexes with metal cations. The method was 
described in: E. Dadachowa, L. L. Chapell and M. W. Brechbiel, Nucl. Med. Biol, Vol 26, 977-982, 1999. 
 
2.6.1. Procedure 
 
   Solution of Arsenazo III (AAIII) – Pb: 5-µM Pb(II), 10-µM AAIII  in  0.25-M ammonium acetate pH 7. 
   Tested sample: to 980 µl of AAIII-Pb solution add 20 µl of 5-fold diluted conjugate. After 10-min incubation, 
measure the absorbance at 656 nm in the UV-VIS spectrophotometer against 0.25-M ammonium acetate.  
   Blank sample: to 980µl of AAIII-Pb solution add 20µl of 0.25M ammonium acetate pH7. After 10 min 
incubation measure the absorbance at 656 nm in the UV-VIS spectrophotometer against 025M ammonium 
acetate.  
   The number of conjugated DOTA molecules was calculated according to Lambert-Beer equation, 
 
 
∈
⋅⋅−
=
20/10005)( 0AAC PDOTA
, 
 
 
where A0 = absorbance of blank, AP = absorbance of tested sample and ∊ = absorbance coefficient given by the 
relation, 
 
cb
A
⋅
∈= 0
, 
 
 
where ∊ = absorbance coefficient, b = length of optical pathway and c = concentration of Pb in the AAIII-Pb 
solution. 
   It is highly recommended to assay the number of DOTA molecules from at least 3 independent samples.  
 
2.7. Storage 
 
   The purified conjugates of DOTA(SCN)-Rituximab and DOTA(NHS)-Rituximab were divided into portions 
containing 1-1.5 mg mAb in about 100-150µl and were stored at -20 0C. 
   The immunoconjugate of DOTA(NHS)-Rituximab (1 ml, 2.4 mg/ml) was also prepared in the kit form by 
lyophilization with 5 mg of mannitol and was stored at 2-8 0C. 
  
2.8. 177Lu radiolabelling of DOTA-Rituximab 
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   To around 1.0 mg of DOTA-Rituximab in 100 µl volume 50 µl of 0.5 M ammonium acetate pH 7.0 and 
[177Lu]LuCl3 (LutaPol) with radioactivity about of 250-2200 MBq were added. Afterwards, the reaction mixture 
was incubated at 380C from 30 min to 2 h. An aliquot of 10-20 µl was then used for the analysis by HPLC as 
described below. 
 
2.8.1. HPLC analysis 
 
   To around 20 µl of radiolabelled conjugate 10 µl of 10 mM DTPA solution was added in order to bind non-
reacted 177Lu. HPLC analysis was performed 5 min after DTPA addition with method described in 2.5., and 
using UV detection at 220 nm, 280 nm and radiometric detection. 177Lu-DOTA-Rituximab, retention time ∼ 6.6 
min, 177Lu in the DTPA complex, retention time ∼ 9.7min. 
 
2.9. Stability studies 
 
The stabilities of radiolabelled conjugates were evaluated after storage preparations at room temperature and 
after incubation in human serum albumin (HSA). SE-HPLC method as described above was used for 
radiochemical purity determination. 
 
2. Results 
 
   The conjugation of DOTA(SCN) to mAb was performed using five and tenfold excess of p-SCN-Bn-DOTA, 
resulting in a DOTA-rituximab conjugate with an average ratio of 3 and 5 DOTA molecules per antibody 
respectively, see Table 1. The table presents also the results of stability of 177Lu-DOTA(SCN)-mAb. 
 
 
TABLE 1. Stability of 177Lu-DOTA(SCN)-Rituximab 
 
Molar excess of 
chelator 
DOTA:Ab 
Average numer of 
conjugated DOTA(SCN) 
Radiochemical purity, % 
0.5 h 2.0 h 24.0 h 
5:1 (n=2) 3:1 89.3±9.6 87.1±10.6 79.4±9.2 
10:1 (n=3) 5:1 96.6±5.0 92.2±6.1 90.9±5.1 
 
   An example of HPLC profile of 177Lu-DOTA(SCN)-Rituximab with UV and radiometric detection is presented 
in Fig. 1 and 2. 
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FIG. 1. HPLC-UV profile of the DOTA(SCN)-Rituximab. 
 
 
 
FIG. 2. HPLC-radiometric profile of 177Lu-DOTA(SCN)-Rituximab. 
 
 
   Fig. 3 presents the results of 177Lu-DOTA(SCN)-Rituximab in 1% HSA indicating that the radiochemical 
purity of 177Lu-DOTA(SCN)-Rituximab was higher than 90% up to 24 hours. 
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FIG. 3. Stability of 177Lu-DOTA(SCN)-Rituximab in HSA. 
 
 
   The conjugation of DOTA(NHS)-ester to rituximab was performed using 33, 75 and 100-fold excess of 
DOTA-NHS-ester, resulting in a DOTA-rituximab conjugate with an average ratio of  9 and 10 DOTA 
molecules per antibody respectively, see Table 2.  
 
 
TABLE 2. Stability of 177Lu-DOTA-Rituximab at RT 
 
Initially molar ratio 
DOTA:Ab 
Average numer of 
conjugated DOTA 
Radiochemical purity, % 
0.5 h 2.0 h 24.0 h 
33:1 (n=1) 7:1 19.0 20.5 - 
75:1 (n=2) 9:1 92.7±3 87.5±1.5 - 
100:1 (n=3) 10:1 98.1±0.4 97.6±1.1 95.6±3.0 
 
 
   Representative HPLC profiles of 177Lu-DOTA-Rituximab with UV and radiometric detection are presented in 
Figs. 4 and 5. 
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FIG. 4. HPLC-UV profile of the DOTA-Rituximab. 
 
 
 
FIG. 5. HPLC-radiometric profile of  177Lu-DOTA-Rituximab. 
 
 
   The stability of 177Lu-DOTA-Rituximab prepared in the wet labelling procedure and using the freeze–dried 
conjugate are compared in Fig. 6. No significant differences were observed between the two preparations 
stability. 
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Freeze-dried  „wet” labelling 
 
 
FIG. 6. Comparison of stability of 177Lu-DOTA(NHS)-Rituximab using freeze-dried conjugate and the conjugate 
stored in 0.5 M ammonium acetate buffer, pH 7.0 at -200C. 
 
3. Conclusions on antibodies  
 
   The aim of our study was to prepare the DOTA- conjugates with mAb and to prepare such conjugate in the 
form of dry kit which would allow rapid and reporducible labelling of the DOTA-mAb. 
   Optimized conditions of radiolabelling at pH 7.0 (1.2 mg of DOTA(SCN)-Rituximab, 177LuCl3 up to 1.4 GBq 
in 50 µl of 0.5 M ammonium acetate pH 7.0, 2 hours incubation at 380C) resulted in 177Lu-DOTA-Rituximab 
with specific activity of 1.1 GBq/mg (158 GBq/µmol). The labeling yield was found to be 92-94% at 30 min and 
increased to > 97 % at 2 hours incubation. High radiochemical yields above 95% were obtained for mAb 
conjugated at 1:10 molar ratio. 177Lu-DOTA(SCN)-Rituximab was stable up to 24 h in HSA at RT.  
   High radiochemical yield above 98%were obtained for DOTA-NHS conjugated mAb at 1:100 molar ratio. 
Freeze-dried conjugate containing 2.4 mg mAb, 5 mg mannitol, 3.32 mg sodium acetate was prepared. 
Radiolabelled conjugates (both wet and freeze-dried conjugates) were stable up to 120 h at RT. 
 
4. 177Lu-DOTA-Substance P 
 
   Gliomas, WHO grades II-IV, have been shown to consistently overexpress the transmembrane neurokinin type 
I receptor (NK-1). NK-1 receptors have also been detected on tumour cells infiltrating the intra- and peritumoral 
vasculature. The physiological ligand for NK-1 receptor is Substance P. This peptide can be labelled with 
various radionuclides for diagnostic and therapeutic applications using the chelators. Recently the successful 
appliaction of targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-
[Thi8, Met(O2)11]-substance P has been published by Cordier et al., 2010 [6]. These authors used 111In-DOTA-
[Thi8, Met(O2)11]-substance P for evaluation of receptor expression and dose distribution with 3-D data set 
(SPECT and low-dose CT) immediately after injection and at later time points. The aim of our work was to use 
68Ga DOTA-[Thi8, Met(O2)11]-substance P PET imaging for the possible pre-therapeutic assessment of receptor 
expression and therapeutic dose distribution. The first dose of 213Bi/68Ga- DOTA-[Thi8, Met(O2)11]-substance P 
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was administered to the patient. Therapeutic application of 177Lu-DOTA-[Thi8, Met(O2)11]-substance P is 
planned. 
 
5. Methods 
 
5.1. Labelling of DOTA-[Thi8, Met(O2)11]-Substance P 
 
5.1.1. Labelling of DOTA-[Thi8, Met(O2)11]-substance P with 177Lu 
 
   For radiolabelling, to 1.0 mL of a 5% ascorbic acid solution (pH = 4.5) 50 µg DOTA-[Thi8,Met(O2)11]-
substance P (piChem, Austria) and 1.85 GBq of 177LuCl3 (S.A. > 555 GBq/mg Lu) were added. The reaction 
mixture was incubated at 95°C for 25 min. 
 
5.1.2. Labelling of DOTA-[Thi8, Met(O2)11]-substance P with 68Ga 
 
   For radiolabelling, first 3 mL of eluate of the 68Ge/68Ga generator (iThembaLABS) with radioactivity of 350 – 
780 MBq of 68Ga was added of 100 µg DOTA-[Thi8,Met(O2)11]-substance P dissolved in 2.4 mL 1.25 M 
AcONa, giving final pH of about 3.7. Incubation was carried out at 95oC for 15 min using heating oven. 
 
5.2. Quality control 
 
   For determination radiochemical purity of the labelled preparations several methods were used. 
 
5.2.1. HPLC 
 
   A solvent module (Shimadzu LC20A) with UV detector and online γ-ray detector (Raytest, Gabi) was used for 
HPLC analysis. Reversed phase HPLC was performed with JupiterProteo 4u 90A column (4.6 x 150 mm, 
Phenomenex) at the gradient or isocratic condition. The flow rate was 0.6 ml/min and UV detection at 220 nm. 
Solvent system for gradient elution: solvent A – 0.1 % TFA in Acetonitrile, solvent B – 0.1 % TFA in water was 
used. Gradient: 0-9 min. from 18% to 60% A; 9-13 min. 60 0% A; 13-18 min. from 60 to 18% A, 18-23 min 18 
% A; 20-25 min 95% B. Before injection to the 25 µl of tested sample the 25 ml solution containing 1.0 mg/ml 
DTPA were added to bind free radionuclide. In these conditions the retention time of 177Lu-DTPA is 3.0 min, 
and that of 177Lu and 68Ga- DOTA-[Thi8,Met(O2)11]-substance P is 9.3 min. For isocratic elution solution 
containing 25% of 0.1 % TFA in Acetonitrile and 75% of 0.1 % TFA in water was used. In these case the 
retention time of 177Lu-DTPA is 2.5 min, and that of 177Lu and 68Ga- DOTA-[Thi8,Met(O2)11]-substance P is 5.9 
min. 
 
5.2.2. TLC 
 
   For determination of the content of the unbound 177Lu or 68Ga the thin layer chromatography analysis was 
performed in the following systems: 
- ITLC-SA plates, 0.05 M sodium citrate (pH=5.5). Under these conditions the unbound lutetium or gallium 
migrate with the solvent front while the other components remains at the origin. 
- ITLC-SA plates, MeOH : 1 M ammonium acetate (1:1 v:v). Under these conditions the unbound lutetium or 
gallium remains at the origin while the other components migrate with the solvent front. 
 
5.3. In vitro stability  
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   The radiolabelled preparation was stored at room temperature in 5 ascorbic acid solution up to 19 hours for 
177Lu- DOTA-[Thi8,Met(O2)11]-substance P. The stability of preparations (described as the radiochemical purity, 
RCP) was determined by HPLC and SepPack separation. 
 
6. Results 
 
   DOTA-[Thi8,Met(O2)11]-substance P was stable in the applied radiolabelling conditions. No product 
degradation was observed in HPLC (Fig 7 and 8). The radiolabelling yield for 177Lu- DOTA-[Thi8,Met(O2)11]-
substance P was higher then 98 % with specific activity around 17 GBq/mg of peptide. The 177Lu- DOTA-
[Thi8,Met(O2)11]-substance P was stable (RCP higher than 95%) at RT up to 19 h (Fig. 9). 
 
 
 
FIG. 7. HPLC-UV profile of DOTA-[Thi8, Met(O2)11]-substance P before labeling. 
 
 
 
 
FIG. 8. HPLC-UV profile of DOTA-[Thi8, Met(O2)11]-substance P after labeling 
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FIG. 9. The Stability of 177Lu-DOTA-[Thi8, Met(O2)11]-substance P at RT 0, 3.5 and 19 hour after labeling. 
 
 
   Radiochemical purity of 68Ga-DOTA-[Thi8, Met(O2)11]--substance P determined by HPLC was in the range 
from 80.5 to 98.2% (average 90.6%) in 6 consecutive labeling runs in the labeling procedure lasting 20-25 min. 
Fig.4 presents typical radiochromatogram. In case of TLC methods similar results were obtained. From 81.1 to 
98.3% (average 90.9%) for 0.05M sodium citrate and from 83.2 to 99.7% (average 92.2%) for MeOH : 1M 
ammonium acetate (1:1 v:v). Fig.5 presents the distribution of radioactivity on TLC strips. 
   High labeling yields and high radiochemical purity of 68Ga-DOTA-[Thi8, Met(O2)11]-substance P allowed its 
use in patients. Figure 6 presents the PET images acquired directly after administration of therpeutic dose. 
 
RCP 99,7 % 
RCP 98,9 % 
RCP 96,5 % 
116 
 
 
FIG. 10. HPLC chromatogram of 68Ga-DOTA-[Thi8, Met(O2)11]-substance P. 
 
 
 
FIG. 11. TLC of 68Ga- DOTA-[Thi8, Met(O2)11]-substance P, (left) ITLCSG and 0.05M sodium citrate, (right) 
ITLC-SG and MeOH : 1M ammonium acetate (1:1 v:v). 
 
 
 
 
FIG. 12. Post-therpeutic PET images of 68Ga-DOTA-[Thi8, Met(O2)11]-substance P co-injected with 213Bi- 
DOTA-[Thi8, Met(O2)11]-substance P. 
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TABLE 3. Summary of radiochemical purity results of 68Ga-DOTA-[Thi8, Met(O2)11]-substance P 
 
Labelling HPLC TLC 
  
ITLC-SG, 
MeOH/1M 
ammonium acetate 
ITLC-SG, 0.05M 
sodium citrate 
1 87,5 88,1 91,2 
2 80,5 81,1 83,2 
3 98,2 98,3 99,7 
4 95,7 95,6 97,1 
5 92,5 92,9 93,3 
6 89,4 89,2 91,3 
Mean 90,6 90,9 92,6 
 
 
Conclusions on DOTA-Substance-P 
 
   This study is performed in collaboration with Medical University of Warsaw in the therapy of glioma patients. 
Study extension to 177Lu-DOTA-[Thi8, Met(O2)11]-substance-P is planned.  
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Abstract. The main purpose of this research project was to develop 90Y and 177Lu-labeled bioactive compounds 
(antibodies and peptides) for targeting of human cancers. A number of peptides have been prepared by solid-
phase peptide synthesis according to Fmoc/HBTU chemistry. After radiolabeling with 177Lu radionuclide, these 
compounds will be evaluated for their potential as radiotherapeutic agents. The results of these evaluations will 
be discussed. 
 
1. Introduction 
 
   Conventional chemotherapy is restricted by intrinsic multidrug resistance of cancerous cells, and the toxic 
side-effects resulting from high therapeutic doses necessary for efficacy. With the advent of the 21st century, a 
deeper understanding of cancer turned the focus of cancer research toward a more selective, targeted approach 
that would eventually produce anticancer therapies with fewer side-effects and improved therapeutic efficacy 
[1]. One of the various approaches for targeted cancer therapy is based on findings that receptors for certain 
peptides are overexpressed on a variety of human cancers. These receptors serve as potential molecular targets 
for cancer diagnosis and therapy with radiolabeled peptides. Peptide-based radiopharmaceuticals, which bind to 
tumor receptors with high affinity and specificity, hold great promise in nuclear oncology [1-3].  
   Tumor targeting with radiolabeled peptides is gaining enormous acceptance in nuclear oncology [2, 3]. This is 
because of the favorable pharmacokinetics and specific tumor targeting characteristics, together with the 
overexpression of their receptors on tumor cells, makes these receptor binding peptides powerful biological tools 
for the diagnostic imaging and targeted radiotherapy [2]. Among the most clinically-relevant peptide receptor 
systems, bombesin (BN) peptide receptors are of great interest, because of the overexpression of their receptors 
on various important and frequently occurring human cancers including prostate, breast and small cell lung 
cancer. The high expression in cancer cells and low expression in normal tissues makes BN peptides attractive 
agents for targeting BN receptor-expressing cancers [2, 3]. These features also provide the possibility to use BN-
like peptides for therapy when labeled with therapeutic radionuclides. Additionally, upon conjugation with 
cytotoxic drugs, they can be utilized as vehicles for site-specific delivery of cytotoxic drugs into receptor-
specific tumor cells [1]. In addition to BN peptides, we will prepare and evaluate HER2 (human epidermal 
growth factor receptor type 2) also called HER2/neu, a tumor-specific antigen that is amplified and/or 
overexpressed on several human cancers including breast and ovarian cancer. It was assumed that the synthetic 
peptides derived from tumor-associated antigens and retaining most or all of the original affinity and specificity 
to tumor-related antigens can be useful for tumor targeting. The overexpression of HER2/neu in various tumors 
and relatively low expression on normal tissues makes it an attractive target for tumor targeting with HER2/neu-
derived synthetic peptides [4]. Also, s synthetic peptide derived from alpha-fetoprotein, a naturally-occurring 
human protein produced during pregnancy, which itself has anti-estrogenic and anti-breast cancer activity [5], 
have been synthesized.  
   Monoclonal antibodies (MoAbs), designed against various antigens or receptors associated with specific tumor 
types can be used as targeted carriers of radionuclides to malignant tumors overexpressing either respective 
antigens or receptors. Since Rituximab will be available soon as a generic product, this coordinated research 
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project is designed to focus on the development of 177Lu/90Y-labeled DOTA-Rituximab as a therapeutic 
radiopharmaceutical for the treatment of lymphomas. Formulation of DOTA-Rituximab in a kit form would 
make it feasible for the routine preparation of 177Lu/90Y- DOTA-Rituximab for radiotherapy. 
   Radionuclides emitting β-radiations (e.g., 90Y and 177Lu) have shown great therapeutic potential since the 
emitted particle range exceeds the cell diameter thus more effective killing of tumor cells can be achieved. The 
radiolanthanides, 177Lu is particularly attractive for use in radiotherapeutic application due to its attractive 
physical characteristics (T1/2 = 6.65 days, Eβmax = 0.497 MeV) and ready availability. With a longer half-life (6.65 
days), 177Lu emits not only medium energy β-particles (497 keV), but also a low-abundant γ-photon (208 keV), 
which enables γ-scintigraphy, tumor dosimetry, disease staging as well as external evaluation of the in vivo 
targeting efficacy of the administered 177Lu-labeled radiopharmaceuticals [2].  
   The development of 177Lu-labeled compounds expected to improve antitumor effect by killing peptide 
receptor-expressing tumor cells more effectively for the better control of the disease. Tumor receptor binding 
peptides and MoAbs labeled with 90Y or 177Lu have become an important and emerging class of therapeutic 
radiopharmaceuticals in clinical nuclear oncology. Several 90Y or 177Lu-labeled peptides are currently in clinical 
trials to determine their therapeutic potential. On the other hand, a number of MoAbs have been already 
approved by the FDA for immunotherapy of several human cancers. 
 
2. Work plan (work already initiated or in progress) 
 
   Within the defined objectives of the current CRP, we see our major contribution towards the design and 
development of novel peptide-based radiopharmaceuticals for the diagnosis and treatment of human cancers. In 
addition, we will be focusing our interest in developing DOTA-coupled Rituximab antibody for targeting 
lymphoma. The main experimental procedures pertaining to this project is outlined below: 
 
1. Preparation of peptide molecules by solid-phase synthesis procedure 
2. Coupling of DOTA chelator to the targeting molecules (peptides/Rituximab) 
3. Purification and characterization of synthesized molecules 
4. Radiolabeling of biomolecules with 177Lu 
5. Quality control and HPLC purification procedures of 177Lu-compounds 
6. Determination of in vitro stability of radioconjugates in human plasma 
7. In vitro binding studies of radiolabeled compounds with tumor cells 
8. In vivo animal biodistribution studies in normal mice to determine pharmacokinetics 
9. In vivo tumor targeting in nude mice bearing human tumor xenografts 
 
2.1. Synthesis of peptides  
 
   All the peptides were prepared by solid-phase peptide synthetic technique on a CS036 peptide synthesizer (CS 
Bio Co., San Carlos, CA, USA), following standard Fmoc (9-fluorenylmethoxycarbonyl) chemistry on a 0.2 
mmol scale. To incorporate the C-terminal amino acids, each Fmoc-protected amino acid (4-fold molar excess 
compared with the resin) was activated at its α-carboxylic function with an activating reagent, HBTU (O-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), in the presence of DIEA 
(diisopropylethylamine), and allowed to react for 60-min with the resin-bound amino acid to form a new 
peptide-bond. The Fmoc-protecting group was removed using a solution of 20% (v/v) piperidine in DMF (N,N-
dimethylformamide). The remaining Fmoc-amino acids were assembled on the derivatized-resin by repeated 
cycles of deprotection (with 20% piperidine in DMF), activation (reaction of 4-fold molar excess of Fmoc-amino 
acids with HBTU and DIEA to form active ester in situ) and coupling of the activated amino acids with the 
peptide-resin. After stepwise incorporating all the desired amino acids to the sequence, the last N-terminal 
Fmoc-protecting group was removed and the peptide-resin washed to prepare for condensation with DOTA 
(Macrocyclics, Dallas, TX, USA). 
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   For conjugation of peptides to DOTA, NHS-DOTA active ester was prepared first by reacting DOTA ligand 
with NHS (N-hydroxysuccinimide) in the presence of DCC (dicyclohexylcarbodiimide) and then condensed with 
peptide-resin to produce DOTA-coupled peptides (Scheme 1). The peptide-resin was washed thoroughly and 
dried. Each peptide was then cleaved from the resin, and the other side-chain protecting groups were removed by 
treating with a cleavage mixture (~5 mL) of trifluoroacetic acid (TFA)/water/dithiothreitol (95:2.5:2.5) for 2 h at 
room temperature. The resin was removed by filtration and TFA was evaporated under reduced pressure. The 
fully deprotected crude peptides were obtained by precipitation with cold diethyl ether. The structures of the 
synthesized peptides were confirmed by mass spectrometry (Waters Micromass Quattro Premier XE, 
Manchester, UK). 
 
2.2. Conjugation of Rituximab antibody to DTPA 
 
   In our initial experiment, Rituximab antibody was conjugated to p-SCN-Bn-DTPA (Macrocyclis) using the 
molar ratios of BFCA to antibody 15:1. The concentration of the antibody for the conjugation reaction is ~5 
mg/mL reconstituted in distilled water. The conjugation was performed at pH 8.5-9.0 for 90 min at 37°C. After 
conjugation, the purification of bioconjugate was done by PD-10 column. Because of the poor conjugation yield, 
there is a need to optimize the reaction parameters in order to maximize the conjugation yield. 
 
Fmoc-NH  
20% piperidine/DMF
Fmoc-Nle-OH
Sequential addition of the amino acids using
standard Fmoc/HBTU methodology
HBTU/DIEA
           
           
          
           
NH2
Fmoc-Nle-NH
Resin
Resin
Resin
HBTU/NMM
    Scheme 1. An example of the preparation of DOTA-coupled universal BN peptide ligand  
    by solid-phase peptide synthesis method (X= Glu).
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N
N
N
N
COOHHOOC
HOOC CO-NH- Phe Gln Trp Val βAla
Phe His
Ala
NleCONH2
Asp
N
N
N
N
COOHHOOC
HOOC CO-NH- Ile Ile Ser Val Val
Ile Gly
Ala
LeuCONH2
Asp
DOTA-Asp-BNU
DOTA-HER2/neu
N
N
N
N
COOHHOOC
HOOC CO-NH- Phe Gln Trp Val βAla
Phe His
Ala
NleCONH2
Glu
DOTA-Glu-BNU
Figure 1: Structures of DOTA-coupled peptides.  
 
 
2.3. Radiolabeling of biomolecules with Ga-68 and Lu-177 
 
   For labeling with Ga-68, ~0.1 mg of each DOTA-conjugate (1 mg/mL in CH3CN:H2O) was mixed with 0.4 
mL with 0.5 M ammonium acetate buffer followed by 1-2 mCi of Ga-68 (obtained from 68Ge/68Ga generator). 
The pH of the labeling mixture was adjusted to 4.5. The reaction mixture was then heated at 90°C for 35 min. 
The preparation w filtered through a 0.2-µm pore syringe filter prior to HPLC analysis (Figure 2). 
   For radiolabeling with Lu-177, 0.5–1.0 mg of DOTA-coupled compounds (1 mg/mL solution in CH3CN/H2O) 
will be labeled with 177LuCl3 (~2 µL, 2 mCi), dissolved in 0.1 M HCl. The final pH will be adjusted to 7 with 1.0 
M ammonium acetate buffer. The labeling mixture will be incubated at 40°C for 90-min. Labeling conditions, 
such as incubation time, incubation temperature, and the amount of the ligand to be used will be optimized in 
order to maximize the labeling yield while reduces the reaction time. Purification and labeling efficiency will 
then be determined by radio-HPLC analysis. 
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FIG. 2. Radio-HPLC elution profile of 68Ga-DOTA-BN. 
 
 
2.4. HPLC purification and analysis 
 
   HPLC analysis and purification of radiolabeled compounds were accomplished on a Shimadzu HPLC system. 
Peak separations/isolations were achieved using a C18 reversed-phase column (10 µm, 4.6 x 250 mm).  
   Radiochemical purity was estimated by evaluating radioactivity peaks eluted for each compound from the 
HPLC column and calculating the area under the peak (ROI). The main peak for each radioconjugate was 
isolated and dried under a stream of nitrogen. The HPLC-purified  compounds  were  reconstituted  in  sterile  
saline  for  in  vitro  and  in  vivo studies. 
 
2.5. In vitro metabolic stability of radiolabeled peptides   
 
   The in vitro metabolic stability was determined by incubating the HPLC-purified radiolabeled compounds with 
human plasma in duplicate for 1 h at 37°C. Following incubation, the plasma proteins were precipitated with a 
mixture of CH3CN/EtOH (1:1) and the sample was centrifuged at a speed of 4000 rpm for 7 min.  The su 
pernatant layer was filtered through a 0.2-µm pore filter and analyzed by HPLC in order to determine the 
percentage of intact radioconjugate and its potential metabolites (Figure 3). 
 
 
 
FIG. 3. Radio-HPLC elution profile of 68Ga-DOTA-BN after incubation with human plasma for 60 min at 37°C. 
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3. Future Work plan 
 
(a) Radiolabeling of biomolecules with Lu-177 will be performed and the reaction conditions will be optimized 
to achieve high labeling efficiency 
(b) Radio-HPLC analysis of radiolabeled compounds will be carried out to obtain carrier-free purified product 
for in vitro and in vivo studies. 
(c) In vitro stability studies will be performed 
(d) In vitro cell binding studies using different cancer cell lines 
(e) In vivo biodistribution in healthy mice to determine biokinetics 
(f) In vivo tumor targeting in nude mice. 
 
4. Research outputs 
 
   The expected outputs of this project will be the formulation of protocols for routine preparation and quality 
control procedures of 177Lu-labeled bioactive molecules, (177Lu-DOTA-BN analogs, 177Lu-DOTA-HER2/neu and 
177Lu-DOTA-α-fetoprotein, etc.) for the management and treatment of various cancers in Saudi Arabia as well as 
settings of the guidelines on quality standardization in the preparation of 177Lu-radiopharmaceuticals for possible 
human use. In addition, the development and preclinical evaluation of new 177Lu-labeled peptides for the 
management of cancers, such as breast, ovarian and prostate will be predicted as an outcome of this CRP. 
 
5. Conclusions 
 
   The results obtained with these preclinical evaluations will be beneficial in providing useful information for its 
application in clinical settings, which is the ultimate goal of this project. It is expected that these findings, 
combined with the availability of the corresponding kit formulation, will favor the subsequent clinical 
investigation in humans of the new therapeutic radiopharmaceuticals. 
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Abstract. The general scope of CRP project is the development of peptides and antibody based 
radiopharmaceuticals labelled with 177Lu and 90Y to be applied in tumor treatment.  We defined many specific 
objectives such as preparation of 177Lu- or 90Y-labeled DOTA-Rituximab® as therapeutic radiopharmaceutical 
for the treatment of non-Hodgkin’s lymphomas using two different conjugation of the bifunctional chelating 
agents BFCA such as SCN-Bz-DTPA and SCN-Bz-DOTA for optimization of labelling technique (incubation 
time, optimal pH, temp., S.A.) of conjugated-MoAb´s  and  optimize  protocols for kit formulation of 
Rituximab® for radiolabelling with 177Lu and 90Y Rituximab.                          
   Clinical application of peptide receptor radionuclide therapy (PRRT) using Substance P-DOTA for 
glioblastoma and preparation of 177Lu- or 90Y- labelled DOTA-Substance P for optimization of labelling 
technique (incubation time, optimal pH, temp, S.A.) of conjugated SP. 
 
1. Radiolabelling of the peptide Substance P with Y-90 
 
   Substance P (SP) is an 11-amino acid peptide, which has an important role in modulating pain transmission 
through neurokinin-1 and -2 receptors (NKr), overexpressed in malignant gliomas. The aim of the present work 
was to produce a SP analog (DOTA-SP) to be radiolabelled with Y-90, in order to determine the best 
radiolabeling methodology. The radionuclide Y-90 (half-life, 64 hours) decays exclusively through β-emission 
suitable for radiotherapy. A high radiochemical purity (> 99%) and high specific activity of DOTA-SP was 
achieved. Labelling was carried out with 15 µg of SP and 1 mCi (37 MBq) where the mixture was heated at 90 
°C for 30 min. The labelling yield was more than 99% and the final labelled product was stable for more than 
144 hours in saline and human plasma at temperatures 4° C and -20 °C in saline and HSP, while both at 25°C, 
the product started to decompose after 72 hrs in both media. The above mentioned condition were used for 
further labelling procedures.When the reaction time was 30 minutes, the temperature was 90 oC, the mass of 
DOTA-SP was 10-15 µg and 90Y activity was 37 MBq (1 mCi) and the radiochemical purity achieved was more 
than 98%. 
 
2. Material and methods 
 
2.1. Reagents 
 
   DOTA-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (DOTA-Substance P, PiChem) was provided 
by IEO-Milan, Italy, and BFCA such as SCN-Bz-DTPA, Rituximab® was provided through IAEA. The 
precursor 90YCl3 was locally obtained from a solvent extraction generator produced in our laboratory. All other 
chemicals and reagents required for experiments were of analytical grade and purchased from Sigma Aldrich 
Chemical Co. 
 
2.2. Optimization of radiolabeling conditions 
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   Several studies were carried out to establish the labelling conditions for obtaining the highest yield of labelled 
DOTA-SP. Conditions were 0.75 - 75 mg od DOTA-SP, 0.2 mol/L sodium acetate buffer (0.3 mL, pH 4.5) and 
~100 MBq of 90YCl3 [in 0.01N HCl, 37MBq (1 mci), specific activity (0.1mCi/µg] were heated at different 
temperatures (60 – 95°C) for different times (10 - 35 minutes) and different pH (4-5.5). All reagents of these 
experiments were prepared with Chelex 100 treated free metal. 
 
2.3. Radiochemical purity determination 
 
   Thin layer chromatography (ITLC) was applied to determine free yttrium, with citrate/citric acid buffer pH 5.0 
as development solvent (Rf  of labelled SP-DOTA was 0.1-0.3 and Rf of free yttrium was 0.9-1.0).  
 
 
3. Stability of radiolabelled SP 
 
3.1 In vivo and in vitro stability 
 
   To determine the in vitro stability of 90Y-DOTA-SP the prepared product was stored at 4-20- 25 °C for 
different times (1 to 9 days) or human plasma samples were spiked with 90Y-DOTA-SP (SA = 0.1 mCi/µg) and 
incubated for 1, 4 and 24 hours, followed by ITLC analysis. All experiments were performed in triplicate. 
 
 
 
 
 
 
FIG. 1. In vitro stability of radiolabelled SP-DOTA for different times. 
 
 
 0 day (1day) (3days) (4days) (5days) (6days) (9days) 
saline at -20° C 99.6 98.7 98.5 99.9 99.6 100.0 99.6 
human plasma at 25°C 99.4 99.5 90.3 70.6 57.1 69.2 40.1 
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3.2. Animals (in vivo) 
 
   4 to 6 week old male rat were injected in the lateral tail vein. and  blood samples were taken , centrifuged to 
get plasma samples, for different times (1,3,8,16,20,24  hours), and  followed by ITLC analysis. All experiments 
were performed in triplicate. 
 
3.3. Human plasma (in vitro) 
 
   To determine the stability of 90Y-DOTA-SP the preparation was stored (at 37 )°C  using incubator for 
different times (1, 3, 8, 16, 20, 24 hours), human plasma samples were spiked with 90Y-DOTA-SP 
(SA=0.1mci/µg) and  followed by ITLC analysis. All experiments were performed in triplicate. 
 
 
 
 
FIG. 2. Radiolabelling purity of Sp-DOTA-90Yin vivo and vitro. 
 
4. Results 
 
   Different Substance P masses (0.2-0.75 µg) were radiolabel using 37 MBq (1 mCi) of radionuclide and the 
results are shown in FIG. 1. High radiolabeling yields (> 95%) were achieved when 0.74, 1.5, 2, 10, and 15 µg of 
DOTA-SP reacted with 1-mCi Y-90. When the mass of DOTA-SP reduced to 0.3 µg the radiochemical purity 
decreased to 25 and no radiolabel reaction occurred using 0.2and 0.15 µg of the peptide. 
human plasma at -20°C 98.7 99.5 99.9 99.9 99.4 99.4 97.3 
saline at 4 c٥ 99.1 99.9 99.2 100.0 99.2 99.2 99.4 
saline at 25°C 99.2 99.7 91.1 91.7 80.2 80.2 63.5 
human plasma at 4°C 99.8 99.6 98.9 99.9 99.4 99.4 99.6 
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Ratio (mci/µg) SA (mCi/µg) RCP% 
(mci/0.15µg) 0.15 0 
(mci/0.2 µg ) 0.2 5.5 
(mci/0.25 µg ) 0.25 10.5 
(mci/0.3 µg) 0.3 25 
(mci/0.5 µg ) 0.5 80.5 
(mci/0.74 µg ) 0.74 98 
(mci/1.5 µg ) 1.5 99 
(mci/2 µg ) 2 99.8 
(mci/10 µg ) 10 99.6 
(mci/15 µg ) 15 99.5 
 
FIG. 3. Radiochemical purity at different conditions using different 90Y/SP ratios (mCi/µg). The reactions were 
performed at 90°C for 30 minutes. At 1 mCi/15 µg a radiochemical purity of 99.5 was obtained. 
 
 
4.1. Study of radiolabelling conditions 
 
   Several studies were done to establish the labeling conditions for obtaining the highest yield of labelled 
DOTA-SP (0.2 - 15 µg), 0.2 mol/L sodium acetate  buffer (0.3 mL, pH 4.5) and ~37 MBq of 90YCl3 (in 0.01N 
HCl, 37MBq (1 mCi), specific activity 0.5-15 mci/µg ) were heated at different temperatures (60 – 95°C) for 
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different times (10 - 35 minutes). All reagents of these experiments were prepared with Chelex 100 treated free 
metal. 
 
4.2. Effect of incubation time  
 
   The effect of incubation time on radiochemical purity of 90Y-DOTA-SP was investigated. Radiochemical 
purity (%) at different times (10, 20, 25, 30 and 35 minutes) was measured  and the results are shown in Fig. 3. 
High radiolabeling yields (> 95%) were achieved when the incubation temperature was between 20 -35 °C .  
 
 
 
 
FIG. 4. Effect of the incubation time on radiochemical purity of 90Y-DOTA-SP. 
 
 
TABLE 1. Effect of the incubation time on radiochemical purity of 90Y-DOTA-SP. 
 
Radiolabiling time (min) Radiochemical purity % 
10 69 
20 97.6 
25 98.2 
30 99.9 
35 99.7 
 
 
4.3. Effect of different temperatures  
 
   The labelling conditions for obtaining high yield of labelled substance P, when the temperature between (70-
95° C). 
 
 
TABLE 2. Effect of temperature on radiochemical purity of 90Y-DOTA-SP 
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FIG. 5. Effects of the radiolabelling at different temperatures on the radiochemical purity. 
 
 
4.4. Effect of pH 
 
   Labelling conditions  showed high yield of labelled substance P, at  Ph values  between 4,5-5,5 
 
 
 
 
 
 
 
 
Temperature (°C ) RCP % 
60 80.4 
70 95.9 
80 99.5 
90 99.9 
95 99.5 
Final (pH) RCP% 
4 79 
4.5 99.1 
5 98 
5.5 98.5 
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FIG. 6. Effect of the radiolabelling at different pH on radiochemical purity. 
 
 
5. 90Y-monoclonal antibodies 
 
   Anti-CD20 monoclonal antibody (Rituximab®) has become a standard treatment for relapsed or refractory 
CD20-positive low-gradenon-Hodgkin’s lymphoma (NHL), along with Chemotherapy. (Rituximab®) is a 
chimerical antibody, discovered in 1990 by IDEC Pharmaceuticals (San Diego, CA). It possesses a high binding 
affinity to the CD20 antigen. The CD20 antigen is expressed on the surface of normal and malignant B 
lymphocytes but not on stem cells or other healthy tissues. Rituximab® kills CD20-positive B-lymphocytes via a 
mechanism involving antibody-dependent cytotoxicity. 
   Over recent years, radio immunotherapy has been used in the treatment of CD20+lymphoma, specifically low-
grade NHL that has relapsed or refractory. 
   Standard therapy is treated. Radio immunotherapy is used alone or in combination with other therapies with 
the goal of improving efficacy. For this purpose beta-emitting radioisotopes are coupled to anti-CD20 antibodies. 
Lymphocytes and lymphoma cells are highly radiosensitive. 
 
5.1. Preparation and characterization of 90Y-Rituximab 
 
5.1.1. Material and methods 
 
   Chimeric anti-CD20 rituximab monoclonal antibodies were provided by Roche (Roche Pharma Schweiz, 
Basel,Switzerland). The p-SCN-benzyl-DOTA (Back-DOTA) and The 2-(4-isothiocyanatobenzyl)-6-methyl-
diethylenetriamine pent acetic acid (1B4M-DTPA, also known as MX-DTPA) from IAEA, Austria. 
   The radionuclide 90Y was obtained from 90Sr/90Y generator in our Lab consisting of Sr-Spec Resin(crown 
ether) packed  in three columns for separation and purification of 90Sr/90Y. 
   All other reagents were purchased from Aldrich or Sigma, The centrifuge filter devices Amicon Ultra-15filter 
(Millipore, MWCO 30, 000). 
  
 5.1.2. Preparation of Rituximab+MX-DTPA and Rituximab+DOTA-NCS. 
 
1-Buffer sodium carbonate (0.2 M) pH = 9.0. 
2-Buffer ammonium acetate (0.25 M), pH = 5.53; buffer ammonium acetate (0.25 M), pH = 7.5. 
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   Two different kind of chelating agents were available for coupling reaction: a) MX-DTPA and DOTA-SCN. 
Both conjugations have been carried out at a molar ratio chelating/antibody of (10:1). Different specific activity 
(10 , 20 , 25 mci /mg ) have been studied. 
  Commercially available Rituximab monoclonal antibody and DOTA-NCS were used. 428 µl containing 
(3.0mg) mAb after removing the essential buffer using centrifuge with condition (4000 rpm at 4oC) was divided 
in two equal aliquots.Then these have been dissolved in carbonate buffer 0.2M at pH = 9.0 using sodium 
carbonate( 0.2M) as buffer solution pH=9.  The reaction was allowed to proceed over night at room temperature 
under vigorous stirring, then the buffer was changed to sodium acetate buffer 0.5M at pH = 7, which is more 
suitable and the final buffer filtered to obtain 1ml. Inject the sample on the HPLC. 
 
 
 
 
FIG. 7. Conjunction of Rituximab with 2(-4isothiocyanatobenzyl)-6-methyl-diethylenetriamine penta acetic acid 
(1B4M-DTPA, also known as MX-DTPA) on HPLC. 
 
 
 
 
 
FIG. 8. Conjugation of Rituximab with p-isothiocyanato benzeyl DOTA(p-NCS-Bz-DOTA) Rituximab+DOTA-
NCS 
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   The 90Y was obtained from 90Sr/90Y generator in our lab consisting of Sr-Spec Resin(crown ether) packed  in 
three columns for separation and purification of 90Sr/90Y  . The generator was loaded with about 50 mci of 90Sr 
and the yield of 90Y was about 45 mci which means more than 90% elution efficiency. 
Each labeling was carried to reach different specific activity (SA) as detailed below. 
 
(1) SA: 10 mCi/1mg 
88 µl of Y90 activity 3mCi, pH = 5. 
100 µl of Rituximab-DOTA in acetate (0.3mg/100µl), pH = 7.5. 
100 µl of (0.01 µl DTPA, pH = 7.5). 
Incubate at 42◦C (for 1hr). 
 
(2) SA: 20 mCi/1mg. 
105 µl of Y90 activity 6 mCi, pH = 5. 
100 µl of Rituximab-DOTA in acetate (0.3 mg/100µl), pH = 7.5. 
100 µl of (0.01 µl DTPA, pH=7.5). 
Incubate at 42◦C (for 1 hr). 
 
(3) SA: 2 5mCi/1mg. 
140 µl of Y90 activity 7.5mCi, pH = 5 . 
100 µl of Rituximab-DOTA in acetate (0.3mg/100µl), pH = 7.5 
100 µl of (0.01 µl DTPA pH = 7.5). 
Incubate at 42 ◦C (for 1hr). 
 
 
 
 
SA (mCi/1mg) RCP% RCP% 
 RIT-DOTA-90Y RIT-DTPA-90Y 
10 93.60% 90% 
20 95.30% 98% 
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FIG 9. Different SA of RIT-DOTA-90Y, RIT-DTPA -90Y 
 
 
5.3. Quality control 
 
5.3.1. High Pressure liquid Chromatography 
 
   Quality control of radio pharmaceutical is carried out by high performance liquid chromatography column: 
(2.1*200 mm) Hypersil AA-ODS – 5 micron, Flow: 0.4 m/min, λ = 254nm Mobile phase : 95% NaCl, 5% 
ACN)-20 min. The analysis (HPLC) showed an overall radiochemical purity of RCP ≥  95-98%. 
 
5.3.2. Thin Layer Chromatography 
 
   ITLC-SG (instant Thin Layer Chromatography-Gelman Sciences) paper using with several mobile phases 
(Saline 0.1 M  pH=7 , Methanol: ammonia 3:2 , Methanol: ammonium acetate 1:1). ITLC radioactivity was 
analyzed by cutting the strips in two segments and the radioactivity was measured by LS counter (Beckmam, 
USA) the results were calculated and the radio chemical purity was Showed that both reactions were at ( SA  10, 
20,25 mci /mg)  successful thus obtaining labeling yield of 99.885% and 99.5%. 
 
5.4. Stability studies 
 
5.4.1. Stability of conjunction of RIT-DOTA- and RIT-DTPA 
 
   The stability of conjugates of monocular antibody with two different chelating agents and after storage at 1, 25, 
42, 60, 75, 90 days was evaluated by ITLC after injecting each sample on HPLC. Table below showed the radio 
labeling with 90Y for 3 months storage of these conjugates. 
 
 
 
 
 
 
25 96.50% 97% 
134 
Time(days) RCP% RCP% 
1 RIT-DOTA RIT-DTPA 
25 99% 97% 
42 98% 96% 
60 98% 98% 
75 96% 96% 
90 94% 95% 
   
 
FIG. 10. Stability of conjugates of RIT-DOTA- and RIT-DTPA during 90 days. 
 
 
5.4.2 In vitro 
 
   The stability of labeled monoclonal antibody was evaluated by ITLC after storage at +4ºC,-20ºC and incubate 
at room temperature in saline and human plasma for 9 days for both Rituximab+ MX-DTPA, 
Rituximab+DOTA-NCS. 
 
 
 
 
 
 
 (0 day) (1 day) (3 days) (4 days) (5 days) (6 days) (9 days) 
saline at 25° C 99.9 99.3 99.0 94.9 94.3 88.9 81.2 
saline at 4 c٥ 99.6 99.3 99.5 99.6 99.9 99.8 98.9 
saline at-20° C 99.5 99.4 99.5 99.4 99.9 99.8 99.7 
human plasma at 25° C 99.4 97.5 98.5 95.0 85.6 88.2 34.9 
human plasma at 4 c٥ 99.4 99.1 95.8 99.2 99.8 99.9 99.3 
human plasma at-20° C 99.3 99.8 96.4 90.4 99.7 99.9 99.5 
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FIG. 11. Stability of radiolabelled Rit-DOTA-NCS. 
 
 
 
 
 
 
 
 
FIG. 12. Stability of radiolabelled Rit-DOTA-NCS. 
 
 
5.4.3. Animals (in vivo) 
 
   4 to 6 week old male rat were injected in the lateral tail vein. and  blood samples were taken , centrifuge to get 
plasma samples. The stability of labeled monoclonal antibody for both was evaluated by ITLC different times. 
The radiochemical purity was not less than 98 % during 24 day. 
 
 
0 day (1day) (3days) (4days) (5days) (6days) (9days) 
99.9 99.3 99.0 94.9 94.3 88.9 81.2 
99.6 99.3 99.5 99.6 99.9 99.8 98.9 
99.5 99.4 99.5 99.4 99.9 99.8 99.7 
99.4 97.5 98.5 95.0 85.6 88.2 34.9 
99.4 99.1 95.8 99.2 99.8 99.9 99.3 
99.3 99.8 96.4 90.4 99.7 99.9 99.5 
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       FIG. 13. Stability of RIT-DOTA-90Y and RIT-DTPA-90Y. 
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